sorafenib has been researched along with Kidney Neoplasms in 875 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 234 (26.74) | 29.6817 |
| 2010's | 589 (67.31) | 24.3611 |
| 2020's | 52 (5.94) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, JH; Deng, YL; Kania, RS; McTigue, M; Murray, BW; Solowiej, J | 1 |
| Song, M | 1 |
| Li, J; Lin, X; Liu, Y; Luo, X; Tao, H; Wang, J; Yang, B; Zhou, X | 1 |
| Chen, Y; Fang, W; Fenical, W; Li, K; Liang, Z; Liao, S; Liu, S; Liu, Y; Luo, X; Tang, L; Tian, Y; Zhan, Z; Zhang, T; Zhou, X | 1 |
| DiPaola, RS; Dutcher, JP; Flaherty, KT; Haas, NB; Jewett, MAS; Kane, C; Karam, JA; Kim, SE; Matin, SF; Pins, MR; Puligandla, M; Uzzo, RG; Wood, CG | 1 |
| He, Y; Huang, L; Li, H; Li, Q; Liang, S; Lu, W; Luo, Y; Wang, X; Xiong, L; Zhang, D; Zhang, P | 1 |
| Carbasse, C; Jacot, W; Leenhardt, F; Perrier, C; Pinguet, F; Viala, M | 1 |
| Albiges, L; Bellmunt, J; Bex, A; Davis, ID; Eisen, T; Escudier, B; Frangou, E; Hancock, B; Hermann, GG; Joniau, S; Kaplan, R; Larkin, J; Meade, A; Oza, B; Parmar, MKB; Ritchie, AWS; Royston, P; Smith, B; Stewart, GD; Stockler, MR | 1 |
| Antonuzzo, L; Basso, U; Bersanelli, M; Bimbatti, D; Buti, S; Carella, C; Conca, R; De Giorgi, U; Doni, L; Fornarini, G; Galli, L; Gambale, E; Giorgione, R; Naglieri, E; Nesi, G; Pignata, S; Procopio, G; Rebuzzi, SE; Roviello, G; Santini, D; Sbrana, A; Stellato, M | 1 |
| Imai, T; Kaneko, S; Okayama, Y; Oya, M; Sunaya, T; Tsujino, T | 1 |
| Chen, C; Deng, Q; Li, J; Shao, C; Shi, Z; Sun, H; Tang, W; Xiao, J; Xuan, Z; Ye, S; Yue, J; Zhang, L; Zhao, Y; Zheng, J; Zhu, F | 1 |
| Caterino, M; Ciardiello, F; Facchini, S; Fasano, M; Lo Giudice, G; Pirozzi, M; Rauso, R; Sica, A; Varriale, E; Zotta, A | 1 |
| Cao, D; Chi, Z; Cui, C; Guo, J; Kong, Y; Li, J; Li, S; Liu, Y; Mo, J; Sheng, X; Si, L; Wu, X; Xu, H; Yan, X; Zhou, L | 1 |
| Ito, H; Kubota, Y; Kumada, N; Nagai, S; Teramoto, S | 1 |
| Atkins, MB; Escudier, B; Hutson, TE; Kasturi, V; McDermott, DF; Pal, SK; Porta, C; Rini, B; Verzoni, E; Zengin, ZB | 1 |
| Górka, J; Hoffman, RM; Jura, J; Kwapisz, O; Marona, P; Miekus, K; Rys, J | 1 |
| Chen, L; Li, M; Li, S; Lu, C; Nie, L; Qing, H; Wang, Y; Wang, Z; Wu, S | 1 |
| Bi, X; Cao, C; Jiang, W; Shang, B; Shi, H; Shou, J; Wu, J; Xie, R; Zhou, A | 1 |
| Atkins, MB; Escudier, B; Hutson, TE; Kasturi, V; McDermott, DF; Meza, L; Pal, SK; Porta, C; Rini, B; Verzoni, E | 1 |
| Lee, JL; Lee, JY; Lee, N | 1 |
| Liu, D; Xu, M; Zhou, G | 1 |
| Bottinor, WJ; Cella, D; DiPaola, RS; Flamand, Y; Haas, NB; Hundley, WG; Ky, B; ONeill, AM; Salsman, JM; Subramanian, P; Wagner, LI | 1 |
| Chen, B; Li, Q; Liu, B; Luo, M; Miao, J; Song, G; Zeng, K | 1 |
| Foegh, M; Frykman, G; Hansen, A; Jia, L; Knudsen, S; Martin, V; Mekonnen, H; Petersen, S; Pili, R; Shah, P | 1 |
| Cheng, C; Gu, P; Li, D; Li, W; Wan, S; Xu, L | 1 |
| Chang, K; Chen, Y; Dai, B; Feng, T; Wang, C; Wang, Y; Xu, F; Xu, N; Ye, D; Zeng, B; Zhang, W; Zhang, X | 1 |
| Gao, J; Hu, D; Hu, W; Wang, W; Yang, S; Yu, G | 1 |
| Chen, Z; Hou, Y; Liu, X; Ni, X; Wang, L; Weng, X; Yang, C; Ye, C; Yu, X; Zhang, Y; Zheng, Q | 1 |
| Chen, H; Huang, C; Huang, J; Lin, Y; Yang, J; Zhong, W | 1 |
| Cheng, Q; Gao, X; Guo, M; Jiang, P; Jiang, S; Liu, L; Liu, Q; Yao, H; Zhang, Q; Zheng, J | 1 |
| Atkins, MB; Bhatt, RS; Bullock, AJ; DiPaola, RS; Dutcher, JP; Flaherty, K; Haas, NB; Manola, J; McDermott, DF; Puligandla, M; Tamasauskas, D; Uzzo, RG; Xu, W | 1 |
| Budolfsen, C; Bæk Møller, N; E Magnusson, N; Grimm, D; Infanger, M; Krüger, M; Wehland, M | 1 |
| DiPaola, RS; Dutcher, JP; Flaherty, KT; Haas, NB; Jegede, OA; Jewett, MAS; Kane, CJ; Lee, Z; Manola, J; Messing, EM; Pins, MR; Uzzo, RG; Wood, CG | 1 |
| Cai, B; Cai, W; Chen, Y; Huang, J; Huang, Y; Xue, W; Zhang, J; Zhou, J | 1 |
| Ando, S; Fujimura, T; Fujisaki, A; Kameda, T; Kamei, J; Komatsubara, M; Kubo, T; Kurokawa, S; Sugihara, T; Takayama, T; Takeshima, S; Yamazaki, M | 1 |
| Cai, B; Cai, W; Chen, Y; Huang, J; Huang, Y; Kong, W; Liu, Q; Wang, Z; Xue, W; Yuan, Y; Zhang, J | 1 |
| Bex, A | 2 |
| Atkins, MB; Escudier, BJ; Hutson, TE; McDermott, DF; Needle, MN; Pal, SK; Porta, C; Rini, BI; Verzoni, E | 1 |
| Crucitta, S; Danesi, R; Del Re, M; Fogli, S; Gianfilippo, G; Porta, C; Rini, BI; Schmidinger, M | 1 |
| Chu, Q; Li, J; Liu, JY; Liu, XL; Xue, HY | 1 |
| Albersen, M; Baldewijns, M; Beuselinck, B; Bourgain, C; Debruyne, PR; Haaker, L; Laenen, A; Laguerre, B; Lerut, E; Oudard, S; Renders, I; Rioux-Leclercq, N; Roussel, E; Tryssesoone, L; Van den Bulck, H; Verbiest, A; Wynendaele, W | 1 |
| Adachi, M; Akaza, H; Azuma, H; Inamoto, T; Okayama, Y; Oya, M; Sunaya, T; Tatsugami, K | 1 |
| Kanayama, HO; Kishida, T; Kobayashi, Y; Koie, T; Kondo, T; Matsuyama, H; Naito, S; Obara, W; Oya, M; Saika, T; Sassa, N; Shinohara, N; Shiroki, R; Takahashi, A; Takahashi, M; Teishima, J; Tomita, Y; Ueda, T; Yamaguchi, K | 1 |
| Abufaraj, M; D'Andrea, D; Dahlem, R; Fisch, M; Fuehner, C; Hillemacher, T; Janisch, F; Kienapfel, C; Kimura, S; Klotzbücher, T; Meyer, CP; Rink, M; Shariat, SF; Vetterlein, MW | 1 |
| Wright, KM | 1 |
| Atkins, MB; Escudier, BJ; Hutson, TE; McDermott, DF; Needle, MN; Pal, SK; Porta, C; Powers, D; Rini, BI; Verzoni, E | 1 |
| Jiang, W; Li, C; Liu, X; Ma, J; Shi, H; Shou, J; Wang, D; Wen, L; Zhang, H; Zheng, S; Zheng, W; Zhou, A | 1 |
| Li, D; Li, W; Liu, M; Yang, D; Zhang, Y; Zhao, S | 1 |
| Albiges, L; Barber, J; Bellmunt, J; Bex, A; Brown, J; Davis, ID; Eisen, T; Escudier, B; Frangou, E; Hancock, B; Hermann, GG; Hodgkinson, E; Joniau, S; Kaplan, R; Larkin, J; McMenemin, R; Meade, A; Nathan, P; Oza, B; Parmar, MKB; Pickering, LM; Ritchie, AWS; Smith, B; Stewart, GD; Stockler, MR | 1 |
| Bex, A; Hofmann, F; Hwang, EC; Lam, TB; Ljungberg, B; Marconi, LS; Yuan, Y | 1 |
| Bhikshapathi, DVRN; Poornima, P; Sandhya, P | 1 |
| Chen, X; Guo, J; Hu, X; Wang, H; Xi, W; Xiong, Y; Yao, J; Zhu, Y | 1 |
| Atzori, F; Bearz, A; Cappelletti, V; Chiuri, VE; Claps, M; Cognetti, F; de Braud, FG; Donini, M; Guadalupi, V; Mennitto, A; Miceli, R; Milella, M; Morelli, F; Mosca, A; Ortega, C; Procopio, G; Sepe, P; Verzoni, E | 1 |
| Dahlem, R; Fisch, M; Fühner, C; Hillemacher, T; Janisch, F; Kienapfel, C; Klotzbücher, T; Marks, P; Meyer, CP; Mori, K; Mostafei, H; Rink, M; Shariat, SF; Yu, H | 1 |
| Brezinová, B; Chovanec, M; Dubovan, P; Gomolčáková, J; Jurišová, S; Mardiak, J; Mego, M; Rejlekova, K | 1 |
| Atkins, MB; Escudier, BJ; Hutson, TE; McDermott, DF; Needle, MN; Pal, SK; Rini, BI; Szarek, M | 1 |
| Cheng, F; He, W; Wang, J; Yao, Z; Zhang, T; Zhao, G; Zheng, B | 1 |
| He, Y; Huang, L; Ji, J; Liang, S; Luo, Y; Wang, X; Zhang, D | 1 |
| Liu, S; Yin, R | 1 |
| Amiri-Kordestani, L; Beaver, JA; Bhatnagar, V; Chang, E; Chen, XH; Fiero, MH; Fourie Zirkelbach, J; Goldberg, KB; Ibrahim, A; Kluetz, PG; Pazdur, R; Qiu, J; Ricks, TK; Tang, S; Weinstock, C; Yu, J; Zahalka, E; Zhang, L; Zhao, M | 1 |
| Ambert, V; Cambon-Thomsen, A; Castellano, D; Diekstra, MHM; Eisen, T; Fritsch, A; Garcia Donas, J; Guarch Troyas, R; Guchelaar, HJ; Hartmann, A; Hulsbergen-van de Kaa, C; Jaehde, U; Junker, K; Kiemeney, LALM; Martinez-Cardus, A; Masson, G; Maurits, JSF; Oosterwijk, E; Oosterwijk-Wakka, J; Oskarsdottir, A; Radu, MT; Rafnar, T; Rodriguez-Antona, C; Roessler, M; Ruijtenbeek, R; Stefansson, K; van der Zanden, LFM; Vermeulen, SH; Warren, A; Wessels, L | 1 |
| Baracos, V; Becher, H; Kazemi-Bajestani, SMR; North, S; Venner, P | 1 |
| Bergmann, L; Doehn, C; Gschwend, J; Keilholz, U; Miller, K | 1 |
| Go, ML; Huynh, H; Sim, MY; Yuen, JSP | 1 |
| Ishihara, H; Kondo, T; Tanabe, K | 1 |
| Fujimoto, N; Kamba, T; Kitada, S; Komohara, Y; Ma, C; Motoshima, T; Nakayama, T; Pan, C; Takeya, M; Yamada, S; Yano, H | 1 |
| Choueiri, TK; Kaymakcalan, MD; Lalani, AA; Lin, X; McKay, RR; Simantov, R | 1 |
| Gao, Q; Lin, H; Song, Y; Yang, Y; Zhao, L | 1 |
| Bortlicek, Z; Buchler, T; Chloupková, R; Dusek, L; Fiala, O; Finek, J; Hornova, J; Kiss, I; Kopeckova, K; Kopecky, J; Lakomy, R; Melichar, B; Poprach, A; Slaby, O; Studentova, H; Svoboda, M; Vyzula, R; Zemanova, M | 1 |
| DiPaola, RS; Haas, NB; Heng, DYC; Kane, CJ; Manola, J; Messing, EM; Ristau, BT; Uzzo, RG; Wood, CG | 1 |
| Fujii, Y; Ishioka, J; Kawamura, N; Kihara, K; Matsuoka, Y; Okuno, T; Saito, K; Uehara, S; Yamamoto, S; Yasuda, Y; Yokoyama, M; Yonese, J; Yuasa, T | 1 |
| Durand-Zaleski, I; Fleury, L; Maroun, R; Maunoury, F; Nachbaur, G; Vanhille, JL | 1 |
| Amzal, B; Fu, S; Karcher, H; Lister, J; Meng, J | 1 |
| Gandhi, S; George, S; Jain, RK | 1 |
| Cai, W; Chen, Y; Dong, B; Huang, J; Huang, Y; Kong, W; Xue, W; Zhang, J; Zhong, H; Zhou, L | 1 |
| Bersanelli, M; Buti, S; DiPaola, RS; Haas, NB; Manola, J; Puligandla, M; Taguchi, S | 1 |
| Adeniran, A; Boeke, M; Camp, RL; DiPaola, RS; Flaherty, KT; Haas, NB; Jilaveanu, LB; Kluger, HM; Manola, J; Neumeister, V; Pins, M; Puligandla, M; Wang, XV; Weiss, SA; Zito, C | 1 |
| Akiyama, M; Chen, KR; Hioki, T; Makita, S; Takama, H; Watanabe, D | 1 |
| Fukuda, H; Iizuka, J; Ishihara, H; Kobayashi, H; Kondo, T; Omae, K; Takagi, T; Tanabe, K; Yoshida, K | 1 |
| Blinman, PL; Coskinas, X; Davis, ID; Eisen, T; Hovey, E; Kaplan, R; Martin, A; Meade, A; Ritchie, A; Sengupta, S; Stockler, MR; Troon, S | 1 |
| Cella, D; DiPaola, RS; Haas, NSB; Manola, J; Wagner, LI; Zhao, F | 1 |
| Chen, X; Guo, J; Lin, Z; Liu, L; Qu, Y; Wang, J; Wang, Z; Xiong, Y; Xu, J; Yang, Y | 1 |
| Golinelli, G; Pia, F; Rosa, MS; Toso, A; Valletti, PA | 1 |
| Che, X; Li, Q; Tang, Q; Wang, Q; Wu, G; Zhang, Z | 1 |
| Eisen, T; Hutson, TE; Lipatov, O; Molina, AM; Motzer, R; Nosov, D; Sternberg, CN; Tomczak, P | 1 |
| Cao, YW; Dong, Z; Guo, L; Kang, EH; Liu, Y; Niu, HT; Wang, YH; Zhang, W | 1 |
| An, L; Chen, L; Dai, Z; Feng, Y; Gan, H; Gong, C; Haydon, RC; He, F; He, TC; Huang, B; Huang, S; Ji, X; Lei, J; Liu, B; Liu, F; Liu, W; Luu, HH; Shu, Y; Wang, X; Wu, K; Wu, X; Wu, Y; Yan, S; Yang, C; Yu, X; Yuan, C; Zeng, L; Zeng, Z; Zhang, B; Zhang, L; Zhang, R; Zhang, W; Zhao, C | 1 |
| Cai, W; Chen, YH; Dong, BJ; Huang, JW; Huang, YR; Kong, W; Li, MY; Xue, W; Yuan, YC; Zhang, J; Zhou, LX | 1 |
| Deng, XB; Liang, YY; Lin, XT; Mo, ZW; Shao, XF; Wang, B; Yuan, YW; Zeng, LS | 1 |
| Akaza, H; Kabu, K; Oya, M; Tatsugami, K | 1 |
| Feng, G; Feng, Y; Liu, L; Pang, X; Shang, W; Xie, H | 1 |
| Chen, LJ; Li, BT; Mai, HX; Mei, GH; Tang, YY; Xu, XJ; Zhang, B; Zhao, FL | 1 |
| Bao, Y; Liu, B; Qu, L; Sun, S; Wang, L; Xiong, Y; Xu, Z; Yang, F; Zhao, T | 1 |
| Belandia, B; Cimas, FJ; Fernandez-Aroca, DM; García-Cano, J; Giménez-Bachs, JM; Ortega-Muelas, M; Pascual-Serra, R; Roche, O; Ruiz-Hidalgo, MJ; Salinas, AS; Sanchez-Prieto, R; Serrano-Oviedo, L; Valero, ML | 1 |
| Bi, F; Cheng, Y; Guo, J; Jiang, M; Ren, X; Rosbrook, B; Sheng, X; Wang, J | 1 |
| Belsey, J; Eisen, T; Escudier, B; Gibson, D; Morgan, J; Motzer, R; Porta, C | 1 |
| DiPaola, RS; Haas, NB; Narayan, V; Puligandla, M; Subramanian, P; Uzzo, R | 1 |
| Dong, P; Gao, X; Lu, X; Park, SH; Ren, H; Shi, G; Xue, M | 1 |
| Fujita, M; Kuroda, T; Mukai, M; Nakai, Y; Nishimura, K; Oka, T; Shioyama, W; Takada, M; Yasui, T | 1 |
| Alsaab, HO; Alzhrani, RM; Cheriyan, VT; Iyer, AK; Polin, LA; Rishi, AK; Sau, S; Vaishampayan, U | 1 |
| Cai, W; Chen, Y; Guo, J; Hu, X; Huang, J; Huang, Y; Kong, W; Li, M; Yuan, Y; Zhang, J | 1 |
| Boorjian, SA; Cheville, JC; Costello, BA; Gershman, B; Leibovich, BC; Lohse, CM; Lyon, TD; Shah, PH; Thompson, RH | 1 |
| Kim, J; Kim, S; Nam, CM | 1 |
| Ma, CG; Shi, GH; Wang, HK; Xu, WH; Ye, DW; Zhang, HL; Zhou, LP | 1 |
| Aravantinos, G; Bamias, A; Dimopoulos, MA; Fountzilas, G; Gavalas, N; Gkerzelis, I; Karavasilis, V; Kostouros, E; Koutras, A; Koutsoukos, K; Samantas, E; Tzannis, K; Zagouri, F | 1 |
| Alitalo, KK; Crona, DJ; Etheridge, AS; Glubb, DM; Hilliard, E; Innocenti, F; Klauber-DeMore, N; Leppänen, VM; Peña, CE; Peterson, YK; Skol, AD | 1 |
| Laguna, MP | 1 |
| Fan, XR; Huang, HF; Ji, ZG | 1 |
| Ravaud, A | 2 |
| Arondekar, B; Bushmakin, AG; Cappelleri, JC; Cella, D; Hariharan, S; Motzer, RJ; Ramaswamy, K; Rini, BI | 1 |
| Bedke, J; Beeker, A; Bögemann, M; Bokemeyer, C; Bolenz, C; De Santis, M; Frank, M; Grimm, MO; Gschwend, JE; Indorf, M; Lehmann, J; Leiber, C; Müller, L; Retz, M; Teber, D; van Alphen, R; Wirth, M; Zimmermann, U | 1 |
| Hu, D; Hu, Y; Li, J; Wang, X | 1 |
| Escudier, B; Kudo, M; Worden, F | 1 |
| Wang, HT; Xia, M | 1 |
| DiPaola, RS; Dutcher, JP; Epperson, CN; Gyawali, B; Haas, NB; Mamtani, R; Wang, XV | 1 |
| Cao, F; Guo, Z; Liu, C; Si, T; Xing, W; Yang, X; Yu, H | 1 |
| Chen, F; Chen, P; He, D; Lu, J; Wang, H; Wang, Y; Wang, Z; Wei, D; Wu, G; Ye, Y; Yuan, J; Zheng, Y; Zhu, Z | 1 |
| Fuja, D; Green, YS; Jonasch, E; Koh, MY; Reichert, EC; Rudasi, E; Sargis, T | 1 |
| Ito, T; Matsushita, Y; Miyake, H; Motoyama, D; Otsuka, A; Sugiyama, T; Tamura, K; Watanabe, H | 1 |
| Chen, X; Guo, J; Hu, X; Liu, L; Wang, H; Yao, J; Zheng, W; Zhu, Y | 1 |
| Fukuda, H; Iizuka, J; Ishida, H; Ishihara, H; Kobayashi, H; Kondo, T; Okumi, M; Takagi, T; Tanabe, K; Yoshida, K | 1 |
| Eto, M; Kishida, T; Kondo, T; Matsuyama, H; Mikami, S; Mizuno, R; Nonomura, N; Oya, M; Ozono, S; Shinohara, N; Takayama, T; Tatsugami, K | 1 |
| Bamias, A; Bracarda, S; Casper, J; Escudier, B; Felici, A; Jardinaud-Lopez, M; Negrier, S; Rosbrook, B; Sella, A; Staehler, M; Tarazi, J | 1 |
| Guan, H; He, J; He, Y; Min, L; Peng, X; Wang, J | 1 |
| Cui, P; Huang, S; Lin, S; Ren, Y; Wang, X; Weng, G; Yao, X | 1 |
| Altavilla, A; Attademo, L; De Giorgi, U; De Lisi, D; Pignata, S; Procopio, G; Santini, D; Verzoni, E | 1 |
| Canzano, F; Di Lella, F; Manuguerra, R; Vincenti, V | 1 |
| Bies, RR; Jin, Y; Kang, SP; Karrison, TG; Maitland, ML; Ratain, MJ; Sharma, MR; Stadler, WM; Wu, K | 1 |
| Abadie-Lacourtoisie, S; Azzouzi, AR; Bigot, P; Chautard, D; Delva, R; Hoarau, N; Latteux, G; Lebdai, S | 1 |
| Breaker, K; Flaig, IP; Flaig, TW; La Rosa, FG; Naam, M | 1 |
| de Gramont, A; Dos Santos, C; Faivre, S; Raymond, E; Riveiro, ME; Serova, M; Slimane, K; Tijeras-Raballand, A | 1 |
| Albiges, L; Di Palma, M; Escudier, B; Fizazi, K; Levy, A; Loriot, Y; Menard, J | 1 |
| Omrčen, T; Rini, B; Schmidinger, M; Sella, A; Szczylik, C; Torday, L; Vrdoljak, E | 1 |
| Bruno, R; Claret, L; Mercier, F | 1 |
| Grybäck, P; Kanter, L; Lewensohn, R; Nilsson, S; Sandström, P; Shah, CH; Sherif, A; Ullén, A; Viktorsson, K | 1 |
| Ahn, H; Ahn, JH; Ahn, S; Ahn, Y; Hong, JH; Kim, CS; Lee, DH; Lee, JL; Park, I; Park, K; Park, SJ; Song, C | 1 |
| Bhattacharyya, H; Cella, D; Chen, C; Escudier, B; Kim, S; Motzer, R; Rini, B; Rosbrook, B; Tarazi, J | 1 |
| Chen, C; Escudier, B; Gore, ME; Hariharan, S; Hutson, TE; Kim, S; Michaelson, MD; Motzer, RJ; Negrier, S; Oudard, S; Rini, BI; Rosbrook, B; Tarazi, J; Tomczak, P | 1 |
| Haraldsdottir, S; Ing, SW; Kendra, K; Li, Q; Olencki, TE; Villalona-Calero, MA | 1 |
| Calvani, N; Chiuri, V; Cinieri, S; Fedele, P; Gnoni, A; Lorusso, V; Maiello, E; Morelli, F; Orlando, L; Scavelli, C | 1 |
| Anthony Greco, F; Hainsworth, JD; Penley, WC; Shipley, DL; Thompson, DS; Waterhouse, DM; Webb, CD | 1 |
| Ammi, M; Azzouzi, AR; Baumert, H; Beauval, JB; Bensalah, K; Berger, J; Bernhard, JC; Bigot, P; Escudier, B; Fardoun, T; Grenier, N; Hétet, JF; Lagabrielle, S; Lebdai, S; Long, JA; Paparel, P; Patard, JJ; Rioux-Leclercq, N; Rouprêt, M; Soulié, M; Xylinas, E | 1 |
| Akaza, H; Chen, C; Kanayama, H; Kim, S; Naito, S; Ozono, S; Shinohara, N; Tarazi, J; Tomita, Y; Tsukamoto, T; Ueda, T; Uemura, H | 1 |
| Agerbaek, M; Donskov, F; Fode, K; Folkmar, TB; Smidt-Hansen, T | 1 |
| El Tal, AK; Ganger, LK; Mehregan, DA; Remichofsky, CJ | 1 |
| Al-Harbi, H; Choueiri, TK; Heng, DY; Knox, JJ; Kollmannsberger, C; MacKenzie, M; North, S; Rini, BI; Vickers, MM | 1 |
| Gong, R; Liu, LR; Nie, LH; Song, TR; Wang, JZ; Wazir, R; Wei, Q; Zhao, RN | 1 |
| Eisner, F; Gerger, A; Pichler, M; Samonigg, H; Schaberl-Moser, R | 1 |
| Helft, PR | 1 |
| Albiges-Sauvin, L; Antoun, S; Baracos, VE; di Palma, M; Escudier, B; Fizazi, K; Iacovelli, R; Lanoy, E; Loriot, Y; Merad-Taoufik, M | 1 |
| Itoh, K; Komai, Y; Matsubara, N; Mukai, H; Naito, Y; Sakai, Y | 1 |
| Ikehata, Y; Kitamura, H; Masumori, N; Takahashi, S; Tsukamoto, T | 1 |
| Bianco, R; Damiano, V; Formisano, L; Martignoni, G; Massari, F; Nappi, L; Rosa, R; Scarpa, A; Tortora, G | 1 |
| Abernethy, AP; Chen, C; George, DJ; Harrison, MR; Kirkendall, DT; Korytowsky, B; Stepanski, EJ; Walker, MS | 1 |
| Kobayashi, M; Komatsu, K; Kubo, T; Kurokawa, S; Morita, T; Nakano, K; Natsui, S; Nukui, A | 1 |
| Amoh, Y; Fujita, T; Ikeda, M; Iwamura, M; Matsumoto, K; Mii, S | 1 |
| Hiyama, Y; Kato, S; Matsuda, Y; Shibamori, K; Tabata, H; Takei, F; Yanase, M | 1 |
| Ichiyanagi, N; Kamata, S; Yoshinaga, A | 1 |
| Garcia-Donas, J; Jonasch, E; Rodriguez-Antona, C | 1 |
| Albiges, L; Escudier, B; Ferté, C; Fizazi, K; Iacovelli, R; Koscielny, S; Loriot, Y; Rocher, L; Soria, JC | 1 |
| Kubota, Y; Makiyama, K; Nakaigawa, N; Nakamura, M; Sakata, R; Sano, F; Tatenuma, T; Yao, M | 1 |
| Hosoya, N; Iwaba, A; Kanno, H; Kato, T; Kawazoe, H; Mashima, E; Nagaoka, A; Naito, S; Nishida, H; Sakurai, T; Tomita, Y; Yamakawa, M | 1 |
| Paglino, C; Porta, C; Vercelli, A | 1 |
| Aronson, P; Uhlenhake, EE; Watson, AC | 1 |
| Garnick, MB | 1 |
| Alekseev, BY; Alyasova, A; Berkenblit, A; Bondarenko, I; Cella, D; Eisen, T; Esteves, B; Harza, M; Hutson, TE; Ivanescu, C; Kogan, M; Krivoshik, A; Lesovoy, V; Lipatov, O; Lyulko, O; Motzer, RJ; Nosov, D; Sternberg, CN; Strahs, A; Szczylik, C; Tomczak, P | 1 |
| Broom, RJ; Dranitsaris, G; Schmitz, S | 1 |
| Bajetta, E; Bracarda, S; Miceli, R; Porta, C; Procopio, G; Ricci, S; Ridolfi, L; Sacco, C; Verzoni, E; Zilembo, N | 2 |
| Derbel Miled, O; Dionne, C; Droz, JP; Flechon, A; Negrier, S; Neidhart, EM; Segura-Ferlay, C; Terret, C | 1 |
| Alesini, D; Cascinu, S; Cortesi, E; De Marchis, L; Iacovelli, R; Naso, G; Palazzo, A; Santoni, M; Trenta, P | 1 |
| Dermeche, S; Gravis, G; Guerin, M; Salem, N; Walz, J | 1 |
| Huang, T; Song, XS; Zhang, ZW | 1 |
| Chiba, T; Fukudo, M; Hatano, E; Ito, T; Kamba, T; Matsubara, K; Mizuno, T; Ogawa, O; Seno, H; Shinsako, K; Uemoto, S; Yamasaki, T | 1 |
| Boyer, M; Davis, ID; Guo, Y; Liew, MS; Quaggiotto, M; Tafreshi, A; Thientosapol, E | 1 |
| Bastide, C; Bay, JO; Bruyere, F; Guy, L; Karsenty, G; Mahammedi, H | 1 |
| Larkin, J; Yousaf, N | 1 |
| Al-Shukri, S; Bair, AH; Chen, C; Hutson, TE; Kim, S; Lesovoy, V; Lipatov, ON; Rosbrook, B; Stus, VP; Vogelzang, NJ | 1 |
| Bamias, A; Bearz, A; Bellmunt, J; Imarisio, I; Melichar, B; Paglino, C; Porta, C; Procopio, G; Sabbatini, R; Schmidinger, M; Tinelli, C | 1 |
| Novara, G; Zustovich, F | 1 |
| Fukatsu, A; Gotoh, M; Hattori, R; Kuroda, M; Kuwahara, K; Morikawa, T; Sassa, N; Shimoyama, Y; Shiroki, R; Tsuzuki, T; Yoshino, Y | 1 |
| Bjarnason, GA; Escudier, B; Esteban, E; Hariharan, S; Hutson, TE; Lim, HY; Lu, DR; Motzer, RJ; Niethammer, A; Pittman, KB; Senico, P | 1 |
| Afsar, B; Benekli, M; Buyukberber, S; Cetin, B; Coskun, U; Deger, SM; Gonul, II; Gumusay, O; Ozet, A | 1 |
| A, M; H J, H; L, M; M, K; N, M; P J, G; S, B | 1 |
| Bortlicek, Z; Buchler, T; Dusek, L; Kiss, I; Kubackova, K; Lakomy, R; Melichar, B; Pavlik, T; Poprach, A; Svoboda, M; Vyzula, R | 1 |
| Akaza, H; Fukuyama, T | 1 |
| George, DJ; Liu, NS; Liu, Z; Qi, CZ; Signorovitch, JE; Wang, X; Wong, MK; Yang, H | 1 |
| Garcia-Roig, M; Lokeshwar, V; Ortiz, N | 1 |
| Eto, M; Kimura, G; Minami, H; Naito, S; Nonomura, N; Shinohara, N; Tokunaga, S | 1 |
| Agarwal, N; Bjarnason, GA; Choueiri, TK; Donskov, F; Heng, DY; Knox, JJ; Kollmannsberger, C; Lee, J; Mackenzie, M; North, S; Pal, SK; Rha, SY; Rini, BI; Srinivas, S; Tan, MH; Vaishampayan, UN; Wood, LA; Yuasa, T | 1 |
| Fujisawa, M; Harada, K; Kusuda, Y; Miyake, H | 1 |
| Appleman, LJ; Bass, MB; Friberg, G; Friedland, D; Gordon, MS; Hong, DS; Kurzrock, R; Mendelson, DS; Rasmussen, E; Samlowski, WE; Tannir, N; Vogelzang, NJ; Wu, BM; Zhong, ZD | 1 |
| bin-Noordin, MI; Davoudi, ET; Javar, HA; Kadivar, A; Sabeti, B | 1 |
| Boerman, OC; Boers-Sonderen, MJ; de Weijert, MC; Desar, IM; Langenhuijsen, JF; Leenders, WP; Mulders, PF; Muselaers, CH; Oosterwijk, E; Oyen, WJ; Stillebroer, AB; van Herpen, CM | 1 |
| Petrou, PK; Talias, MA | 1 |
| Arnaldi, G; Cascinu, S; Conti, A; De Giorgi, U; Iacovelli, R; Massari, F; Procopio, G; Rizzo, M; Santoni, M; Tortora, G; Trementino, L | 1 |
| Chang, H; Kim, KM; Kim, YJ; Lee, DW; Lee, HJ; Lee, JS | 1 |
| Colecchia, M; De Braud, F; Garanzini, E; Grassi, P; Iacovelli, R; Procopio, G; Testa, I; Torelli, T; Verzoni, E | 1 |
| Stadler, WM | 1 |
| De Lichtenberg, TH; Hermann, GG; Holm, ML; Højer Larsen, MJ; Mansourvar, Z; Rørth, M; Scheike, T | 1 |
| Bögemann, M; Herrmann, E; Hertle, L; Hoffmeister, I; Krabbe, LM; Moritz, R; Papavassilis, P; Thielen, B | 1 |
| Schmidinger, M | 1 |
| Bjarnason, GA; Cai, C; Davis, ID; De Giorgi, U; Escudier, B; Esteban, E; Grünwald, V; Kollmannsberger, C; Lee, JL; Marker, M; Melichar, B; Motzer, RJ; Porta, C; Rha, SY; Shi, MM; Squires, M; Sternberg, CN; Szczylik, C; Urbanowitz, G; Vogelzang, NJ; Zolnierek, J | 1 |
| Bergmann, L; Burkholder, I; Gauler, T; Grünwald, V; Kahl, C; Kube, U; Maute, L; Weikert, S | 1 |
| Atkinson, BJ; Flaherty, AL; Jonasch, E; Matrana, MR; Shetty, AV; Tannir, NM | 1 |
| Inoue, K; Kamada, M; Karashima, T; Kawada, C; Komatsu, T; Kuroda, N; Niimura, M; Shuin, T; Udaka, K | 1 |
| Brose, MS; Frenette, CT; Keefe, SM; Stein, SM | 1 |
| Grande, C; Walko, CM | 1 |
| Arruda, LS; Baum, M; Cisar, L; Kim, S; Motzer, RJ; Quinn, DI; Rini, BI; Roberts, WG; Rosbrook, B; Tarazi, J; Wood, LS | 1 |
| Bhinder, A; Carson, WE; Clinton, SK; Geyer, S; Kendra, K; Lam, E; Lesinski, GB; Mace, TA; Monk, P; Mortazavi, A; Olencki, T; Tahiri, S | 1 |
| Choueiri, TK; Heng, DY; Lin, X; McKay, RR; Perkins, JJ; Simantov, R | 1 |
| Chen, J; Guo, H; Li, S; Li, Y; Liang, X; Meng, H; Shi, B; Zhang, D; Zhu, Y | 1 |
| Banna, G; Bracarda, S; Burattini, L; Calvani, N; Ciuffreda, L; Contu, A; De Giorgi, U; Derosa, L; Felici, A; Ferrari, V; Ferraù, F; Galligioni, E; Gasparro, D; Gernone, A; Iacovelli, R; Lo Re, G; Morelli, F; Pia Brizzi, M; Porta, C; Procopio, G; Rizzo, M; Sabbatini, R; Sava, T; Taibi, E; Zustovich, F | 1 |
| Bertens, D; Desar, IM; Kessels, RP; Langenhuijsen, JF; Mulder, SF; Mulders, PF; Punt, CJ; van Herpen, CM; van Spronsen, DJ; Vissers, KC | 1 |
| Ambrosetti, D; Amiel, J; Gastaud, L; Grépin, R; Marsaud, A; Pagès, G; Pedeutour, F | 1 |
| Ahn, H; Hong, JH; Jeong, IG; Kim, CS; Kwon, T; Lee, JL; Song, C; You, D | 1 |
| de Waal, R; de Weijert, M; Desar, I; Hulsbergen-van de Kaa, C; Kats-Ugurlu, G; Leenders, W; Maass, C; Mulders, P; Muselaers, S; Oosterwijk, E; Oosterwijk-Wakka, J; van Herpen, C; van Krieken, H | 1 |
| Rexer, H | 3 |
| Biondani, P; DE Braud, F; Grassi, P; Porcu, L; Procopio, G; Testa, I; Torri, V; Verzoni, E | 1 |
| Bellmunt, J; Bracarda, S; Cerbone, L; Choueiri, TK; Fay, AP; Foreshew, A; Hutson, TE; Lampron, ME; Pons, F; Porta, C; Powles, T; Sternberg, CN | 1 |
| Bjarnason, GA; Choueiri, TK; Donskov, F; Heng, DY; Khambati, HK; Knox, JJ; Kollmannsberger, CK; MacKenzie, MJ; North, S; Rini, BI; Tan, MH; Vaishampayan, UN; Wood, L | 1 |
| Cisar, L; Clark, JI; Escudier, B; Hariharan, S; Hutson, TE; Kannourakis, G; Kim, S; Lim, HY; Michaelson, MD; Motzer, RJ; Porfiri, E; Rini, BI; Rosbrook, B; Staehler, M; Tarazi, J; Zalewski, P | 1 |
| Elledge, R; Elledge, RO; Raskauskiene, D | 1 |
| Berkers, J; Beuselinck, B; De Wever, L; Dumez, H; Joniau, S; Lerut, E; Oyen, R; Paridaens, R; Schöffski, P; Strijbos, M; Van Poppel, H; Wolter, P | 1 |
| Bozcuk, H; Coskun, HS; Gunduz, S; Mutlu, H; Uysal, M | 1 |
| Fujisawa, M; Furukawa, J; Kusuda, Y; Miyake, H | 1 |
| Blanchard, F; Di Fiore, F; Nouhaud, FX; Pfister, C; Rebibo, JD; Sabourin, JC | 1 |
| Atzori, F; Basso, U; Bracarda, S; Burattini, L; Buti, S; Cascinu, S; Cerbone, L; Conti, A; De Giorgi, U; De Vivo, R; Derosa, L; Di Lorenzo, G; Falconi, M; Iacovelli, R; Masini, C; Massari, F; Milella, M; Montironi, R; Mosca, A; Muzzonigro, G; Ortega, C; Pagano, M; Paglino, C; Porta, C; Procopio, G; Rizzo, M; Rossi, M; Santini, D; Santoni, M; Sternberg, CN; Verzoni, E | 1 |
| Batalla, A; Blay, P; Curto, JR; Menéndez, L | 1 |
| Ghimire, KB; Shah, BK | 1 |
| Gao, C; Peng, FH; Peng, LK | 1 |
| Bortlicek, Z; Buchler, T; Kubackova, K; Linke, Z; Melichar, B; Pavlik, T; Pokorna, P; Prausova, J; Vyzula, R | 1 |
| Bracarda, S; D Buono, S; Hamzaj, A; Marrocolo, F; Paglino, C; Porta, C; Sisani, M; Sternberg, CN | 1 |
| Dai, B; Lin, GW; Ma, CG; Qin, XJ; Shen, YJ; Shi, GH; Wang, HK; Xiao, WJ; Yao, XD; Ye, DW; Zhang, HL; Zhang, SL; Zhu, Y; Zhu, YP | 1 |
| Fujii, Y; Hatano, T; Horie, S; Kawata, N; Kimura, G; Kondo, T; Kume, H; Morita, M; Murakami, M; Nakajima, K; Nakazawa, H; Ohno, Y; Okegawa, T; Oya, M; Saito, K; Takahashi, S; Wakumoto, Y; Yamaguchi, R | 1 |
| Bartsch, G; Blaheta, RA; Haferkamp, A; Juengel, E; Kim, D; Makarević, J; Reiter, M; Tsaur, I | 1 |
| Ahn, H; Böckenhoff, A; Escudier, B; Guo, J; Jäger, D; Korbenfeld, E; Leonhartsberger, N; Ma, JH; Mardiak, J; Stauch, K; Ye, DW; Yu, J; Zemanova, M | 1 |
| Luo, CL; Wu, XH; Zhao, CX | 1 |
| Götze, L; Hegele, A; Hofmann, R; Keil, C; Nockher, WA; Olbert, P | 1 |
| Donskov, F; Fode, K; Geertsen, PF; Hermann, GG; Ibsen, R; Jensen, NV; Kjellberg, J; Soerensen, AV | 1 |
| Arora, J; Boonkaew, B; Callaghan, C; Chava, S; Dash, S; He, J; John, VT; Lee, BR; Liu, J; Maddox, MM; Mandava, SH | 1 |
| Hu, W; Liu, XH; Lv, SQ; Wang, XH; Yuan, Q; Zhu, HC | 1 |
| Jin, G; Liu, Y; Sun, K; Tian, Y; Wang, Y; Yang, X; Zhang, Q; Zhou, C | 1 |
| Deng, J; Ji, Z; Li, H; Li, Y; Yu, H; Zhang, Y | 1 |
| Cen, J; He, X; Hu, C; Hui, L; Li, C; Li, Y; Mu, W; Qiu, Z; Qu, Z; Ren, H; Shi, X; Zhang, H | 1 |
| Kumar, S | 1 |
| Gu, D; Pan, X; Qian, L; Shan, Y; Xue, B; Yang, D; Zheng, B; Zhou, J; Zhu, H | 1 |
| Lauer, R; Rao, A | 1 |
| Bornemann, L; Dicken, V; Moltz, JH; Peitgen, HO; Scheuring, U; Zaim, S | 1 |
| Araki, H; Gotoh, M; Hattori, R; Kimura, T; Sassa, N; Tanaka, K; Tsuzuki, T; Yamada, S; Yoshino, Y | 1 |
| English, PA; Escudier, B; Huang, X; Kim, S; Loomis, AK; Motzer, RJ; Rini, BI; Rosbrook, B; Tarazi, J; Williams, JA | 1 |
| Fishman, MN; Foreman, PK; Fulp, WJ; Tomshine, J | 1 |
| Qin, S; Zhang, S | 1 |
| Eto, M; Harada, M; Horlad, H; Kawano, Y; Komohara, Y; Maeda, Y; Motoshima, T; Takeuchi, A; Takeya, M; Tanoue, K | 1 |
| Fujisawa, M; Miyake, H; Tei, H | 1 |
| Bos, MM; De Santis, M; Eichelberg, C; Fischer von Weikersthal, L; Flörcken, A; Freier, W; Goebell, PJ; Gottstein, D; Hauswald, K; Indorf, M; Lerchenmüller, C; Los, M; Michel, MS; Pahernik, S; Schenck, M; Schirrmacher-Memmel, S; Staehler, M; van Arkel, C; Vervenne, WL; Zimmermann, U | 1 |
| Petrou, P | 1 |
| Atkins, MB; DiPaola, RS; Dutcher, JJ; Flaherty, KT; Haas, NB; Jewett, M; Kane, CJ; Ky, B; Manola, J; Uzzo, RG; Wilding, G; Wood, CG; Wood, L | 1 |
| Bensalah, K; Ouzaid, I | 1 |
| Charbit, D; Defortescu, G; Di Fiore, F; Giwerc, A; Gouerant, S; Nouhaud, FX; Pfister, C; Sabourin, JC | 1 |
| Di Bella, S; Facchetti, R; Giannattasio, C; Giganti, MO; Maloberti, A; Mancia, G; Meani, P; Moreo, A; Musca, F; Pozzi, M; Ricotta, R; Sartore-Bianchi, A; Siena, S; Stucchi, M; Vallerio, P | 1 |
| Iguchi, T; Kato, M; Nakatani, T; Ninomiya, N; Tamada, S; Yamasaki, T | 1 |
| Atkins, MB; DiPaola, RS; Dutcher, JJ; Flaherty, KT; George, DJ; Manola, JB; Margolin, KA; McDermott, DF; Pins, M | 1 |
| Cha, TL; Chang, SY; Chen, MR; Chen, YC; Chuang, MJ; Ho, JY; Hsiao, PW; Huang, SM; Lee, HJ; Lin, CC; Lin, HK; Lin, VC; Sun, GH; Tang, SH; Tsai, YT; Wu, ST; Yu, CP; Yu, DS | 1 |
| Akaza, H; Eto, M; Fujisawa, M; Hashine, K; Naito, S; Ozono, S; Sakai, H; Shinohara, N; Tomita, Y | 1 |
| Im, GH; Jeon, TY; Kim, CK; Kim, JH; Lee, JH; Park, BK | 1 |
| Hashimoto, Y; Iizuka, J; Kennoki, T; Kobayashi, H; Kondo, T; Omae, K; Takagi, T; Tanabe, K | 1 |
| Albiges, L; Escudier, B | 1 |
| Adachi, M; Akaza, H; Gemma, A; Hyodo, I; Iijima, M; Inuyama, L; Itoh, H; Okayama, Y; Oya, M; Sunaya, T | 1 |
| Blaney, SM; Fox, E; Jayaprakash, N; Kim, A; Krailo, M; Weigel, B; Widemann, BC | 1 |
| Chung, J; Hong, SH; Joo, KJ; Kim, CS; Kim, S; Kim, SH; Kim, TN; Kwak, C; Kwon, TG; Lee, SE; Nam, BH; Seo, IY; Seo, SI; Song, K | 2 |
| Fang, D; Guo, G; Huang, L; Li, X; Song, Y; Yu, X; Zhang, C; Zhang, X; Zhou, L | 1 |
| Abernethy, AP; George, DJ; Harrison, MR; Hirsch, BR; Mitchell, AP; Walker, MS | 1 |
| Fujisawa, M; Harada, K; Imai, S; Miyake, H; Miyazaki, A | 1 |
| Fujisawa, M; Harada, K; Imai, S; Miyake, H | 1 |
| Boers-Sonderen, MJ; De Geus-Oei, LF; Desar, IM; Fütterer, JJ; Mulder, SF; Mulders, PF; Oyen, WJ; Van Der Graaf, WT; Van Herpen, CM | 1 |
| Gao, ZL; Lin, CH; Liu, QZ; Men, CP; Wang, J; Wang, K; Wu, JT; Yu, SQ; Yuan, HJ | 1 |
| Atkins, MB; Barac, A; Freedman, AN; Fu, AZ; Jang, S; Minasian, L; Potosky, AL; Tsai, HT; Zheng, C | 1 |
| Arai, Y; Eto, M; Fujioka, T; Hashine, K; Hinotsu, S; Hirao, Y; Kawano, Y; Kimura, G; Matsubara, A; Mita, K; Naito, S; Shinohara, N; Tatsugami, K; Tsukamoto, T | 1 |
| Defortescu, G; Di Fiore, F; Giwerc, A; Gouerant, S; Nouhaud, FX; Pfister, C; Rebibo, JD | 1 |
| Gu, WJ; Ma, CG; Qin, XJ; Shi, GH; Wang, HK; Ye, DW; Zhang, HL; Zhou, LP | 1 |
| Akiba, J; Bae, KH; Igawa, T; Kurisawa, M; Kusano, H; Nakayama, M; Ogasawara, S; Sanada, S; Suekane, S; Sumi, A; Todoroki, K; Ueda, K; Xu, K; Yano, H | 1 |
| Deguchi, T; Horie, K; Kato, T; Kawata, K; Kikuchi, M; Miyazaki, T; Mizutani, K; Nakano, M; Seike, K; Takagi, K; Takai, M; Tsuchiya, T; Ushikoshi, H; Yasuda, M; Yokoi, S | 1 |
| Albiges, L; Choueiri, TK; De Velasco, G; Fay, AP; Heng, DY; Kaymakcalan, MD; Kollmannsberger, CK; Kroeger, N; Lee, JL; McKay, RR; North, SA; Rha, SY; Smoragiewicz, M; Wells, JC; Xie, W | 1 |
| Grünwald, V; Ivanyi, P | 1 |
| Cai, Y; Li, H; Li, Y; Wang, K; Zhang, Y | 1 |
| Jonasch, E; Li, N; Liu, Z; Pal, SK; Perez, JR; Reichmann, WM; Signorovitch, JE; Vogelzang, NJ | 1 |
| Chen, P; Li, P; Lu, J; Lu, X; Wang, F; Wang, J; Wang, Q; Wang, Y; Wang, Z; Wu, G; Yuan, J; Zhang, L; Zheng, Y | 1 |
| Ahn, H; Ahn, JH; Hong, B; Hong, JH; Jeong, IG; Koo, DH; Lee, DH; Lee, JL; Park, I; Song, C; You, D | 1 |
| Koo, V; Li, N; Liu, Z; Pal, SK; Perez, JR; Reichmann, WM; Signorovitch, JE; Vogelzang, NJ | 1 |
| Chi, Z; Cui, C; Guo, J; Kong, Y; Li, S; Lian, B; Mao, L; Sheng, X; Si, L; Tang, B; Wang, X; Yan, X | 1 |
| Balar, AV; Bangalore, S; Kang, SK; Ohmann, EL; Volodarskiy, A | 1 |
| Daido, Y; Kitamura, Y; Nishimoto, K; Shinchi, Y; Takao, M; Tokonabe, S; Yoshii, H | 1 |
| Jonasch, E; Li, N; Liu, Z; Pal, SK; Perez, JR; Reichmann, WM; Signorovitch, JE; Vogelzang, NJ; Yang, C | 1 |
| Bortlicek, Z; Buchler, T; Dusek, L; Fiala, O; Honzirkova, M; Kubackova, K; Melichar, B; Pavlik, T; Poprach, A; Slaby, O; Svoboda, M; Veskrnova, V; Vyzula, R; Zemanova, M | 1 |
| Lin, Z; Shu, M; Wang, R; Zai, X; Zhang, B | 1 |
| Aurilio, G; Cossu Rocca, M; Cullurà, D; de Cobelli, O; Iacovelli, R; Nolé, F; Santoni, M; Verri, E | 1 |
| Cai, H; Cao, Q; Chen, J; Chu, H; Cui, L; Dong, B; Huang, Y; Ji, J; Jiang, M; Ju, X; Li, P; Li, X; Liu, F; Qin, C; Shao, P; Sun, L; Sun, X; Wang, J; Wang, M; Wang, S; Wang, X; Wu, B; Ye, D; Yin, C; Zhang, H; Zhang, Z; Zhao, H; Zhou, H; Zhou, L; Zhu, J; Zou, Q | 1 |
| Diekstra, MH; Gelderblom, H; Guchelaar, HJ; Swen, JJ | 1 |
| Duprez, T; Filleul, B; Laruelle, M; Machiels, JP | 1 |
| Callaghan, C; Dash, S; Lee, BR; Liu, J; Maddox, M; Mandava, SH; Peralta, D; Tarr, MA | 1 |
| Diaz, J; Pandha, H; Sapunar, F; Sehgal, M; Takyar, S | 1 |
| Chi, Z; Cui, C; Guo, J; Li, S; Lian, B; Mao, L; Sheng, X; Si, L; Tang, B; Wang, X; Yan, X | 1 |
| Bersanelli, M; Buti, S; Castagneto, B; Di Meglio, G; Leonetti, A; Masini, C; Pellegrino, B | 1 |
| Blumenstengel, K; Busies, S; Hutzschenreuter, U; Marschner, N; Müller, L; Münch, A | 1 |
| Ahn, KS; Baek, SH; Kim, C; Shim, BS; Um, JY | 1 |
| Atkins, MB; Carducci, M; Cella, D; Choueiri, TK; Coomes, R; DiPaola, RS; Dutcher, JP; Flaherty, KT; Haas, NB; Jewett, M; Kane, C; Kohli, M; Kuzel, TM; Manola, J; Matin, S; Pili, R; Pins, M; Puzanov, I; Sexton, WJ; Stadler, W; Uzzo, RG; Wagner, L; Wilding, G; Wong, YN; Wood, CG | 1 |
| Bodnar, L; Chrom, P; Semeniuk-Wojtas, A; Spencer, NJ; Stec, R; Szczylik, C | 1 |
| Galsky, MD; Mehrazin, R; Sfakianos, J; Tsao, CK | 1 |
| Stone, L | 1 |
| Dicken, V; Felsch, M; Lehmacher, W; Scheuring, UJ; Zaim, S | 1 |
| Keck, B; Lieb, V; Lüdecke, G; Sikic, D | 1 |
| Gan, H; Gu, W; Shi, G; Wang, B; Wang, H; Ye, D; Zhang, H; Zhou, L; Zhu, Y | 1 |
| Adachi, M; Akaza, H; Ito, Y; Kabu, K; Oya, M; Tatsugami, K | 1 |
| Grünwald, V; Kalanovic, D; Lin, X; Simantov, R | 1 |
| Bai, Q; Guo, J; Liu, L; Long, Q; Qu, Y; Wang, J; Xi, W; Xia, Y; Xiong, Y; Xu, J | 1 |
| Chikui, K; Igawa, T; Matsuo, M; Nakiri, M; Nishihara, K; Ogasawara, N; Suekane, S; Suyama, S; Ueda, K | 1 |
| Apolo, AB; De Santis, M; Galsky, MD; Leibovich, BC; Milowsky, MI; Pham, MN; Pisters, LL; Siefker-Radtke, AO; Sonpavde, G; Steinberg, GD; Sternberg, CN; Tagawa, ST; Weizer, AZ; Woods, ME | 1 |
| Chagin, K; Djousse, L; Fraeman, KH; Gagnon, DR; Hall, SA; Nelson, J; Nordstrom, BL; Shantakumar, S; van Herk-Sukel, M | 1 |
| Aziz, SA; Bhat, GM; Changal, KH; Lone, AR; Mir, MH | 1 |
| Bruno, R; Chanu, P; Chen, Y; Claret, L; Mercier, F; Milligan, PA; Rosbrook, B; Yazdi, P; Zheng, J | 1 |
| Chung, J; Joo, J; Joung, JY; Kim, S; Kim, SH; Lee, KH; Seo, HK | 1 |
| Gao, Y; Guo, G; Li, H; Liu, K; Ma, X; Meng, Q; Song, Z; Wang, D; Wang, L; Zhang, X; Zhang, Y; Zhao, C | 1 |
| Al-Shukri, S; Andrews, GI; Bair, AH; Hutson, TE; Lipatov, ON; Rosbrook, B; Shparyk, Y; Stus, VP; Vogelzang, NJ | 1 |
| Fujita, T; Iwamura, M; Matsumoto, K; Nishi, M; Tabata, K; Yoshida, K | 1 |
| Iizuka, J; Ishihara, H; Kobayashi, H; Kondo, T; Omae, K; Takagi, T; Tanabe, K; Yagisawa, T | 1 |
| Dai, B; Gu, WJ; Shi, GH; Wan, FN; Wang, HK; Ye, DW; Zhang, HL; Zhu, Y | 1 |
| Calvo, E; Escudier, B; Grünwald, V; Heng, DY; Schmidinger, M | 1 |
| Bourlon, MT; Breaker, K; Clemons, JE; Flaig, TW; Gao, D; Lam, ET; Trigero, S | 1 |
| Ding, S; Gao, D; Gao, M; Liu, S; Lv, J; Niu, Z; Wang, X; Wang, Z | 1 |
| Anai, S; Fujimoto, K; Hori, S; Miyake, M; Morizawa, Y; Nakai, Y; Onishi, S; Tanaka, N; Tatsumi, Y | 1 |
| Bao, Y; Chen, C; Li, J; Liu, B; Liu, J; Qu, L; Sun, S; Tan, H; Wang, J; Wang, L; Wei, D; Wu, D; Wu, Z; Xu, Z; Yang, F | 1 |
| Albiges, L; Bensalah, K; Bex, A; Canfield, SE; Dabestani, S; Fernández-Pello, S; Giles, RH; Hofmann, F; Hora, M; Kuczyk, MA; Lam, TB; Ljungberg, B; Marconi, L; Merseburger, AS; Powles, T; Staehler, M; Tahbaz, R; Volpe, A | 1 |
| Bearz, A; Demkow, T; Gore, ME; Jones, RJ; Kuczyk, M; Porta, C; Ravaud, A; Shapiro, J; Strauss, UP | 1 |
| Arslan, A; Duensing, S; Grüllich, C; Hadaschik, B; Hallscheidt, P; Hatiboglu, G; Hohenfellner, M; Huesing, J; Pahernik, S; Radtke, JP; Roth, W; Teber, D; Tolstov, Y | 1 |
| Campitiello, M; Eid, N; Hennequin, L; Longo, R; Plastino, F; Quétin, P; Wendel, C | 1 |
| Chi, ZH; Guo, J; He, ZS; Li, XS; Sheng, XN; Wang, HK; Ye, DW; Zhang, HL | 1 |
| Brachet, PE; Chevreau, C; Dos Santos, M; Joly, F | 1 |
| Joshi, A; Kannan, RA; Kothari, R; Menon, S; Noronha, V; Patil, VM; Popat, P; Prabhash, K; Ramaswamy, A; Sable, N; Sahu, A | 1 |
| Bedke, J; Burchardt, M; Kroeger, N; Stenzl, A | 1 |
| Gallacher, D; Gallacher, J; Jones, A; Narov, K; Sampson, JR; Samsel, PA; Shen, MH; Yang, J | 1 |
| Huang, L; Luo, C; Wen, T; Xiao, H; Xiong, M | 1 |
| Chen, X; Guo, J; Lin, Z; Liu, L; Qu, Y; Wang, J; Xi, W; Xiong, Y; Xu, J; Yao, J | 1 |
| Kong, W; Liu, G; Liu, X; Qu, J; Suo, S; Wu, G; Xu, J; Zhang, J | 1 |
| Agarwal, N; Ghate, SR; Li, N; Pal, SK; Peeples, M; Perez, JR; Swallow, E; Vogelzang, NJ; Zichlin, ML | 1 |
| Afriansyah, A; Hamid, AR; Mochtar, CA; Umbas, R | 1 |
| Daniel, PT; Essmann, F; Gillissen, B; Preissner, R; Richter, A; Schulze-Osthoff, K | 1 |
| Cai, W; Chen, Y; Dong, B; Huang, J; Huang, Y; Kong, W; Xue, W; Zhang, J; Zhou, L | 1 |
| Abe, K; Iwata, T; Kakoki, K; Miyata, Y; Mochizuki, Y; Nagayasu, T; Obatake, M; Sakai, H | 1 |
| Gobe, GC; He, Y; Hooper, J; Jeffery, PL; Lourie, R; McGuckin, MA; Morais, C; Ng, CP; Oancea, I; Seim, I; Shah, ET; Sheng, Y; Wong, KY | 1 |
| Dragomir, A; Edqvist, PH; Enblad, G; Niinivirta, M; Pontén, F; Ullenhag, GJ | 1 |
| Atkins, MB; Choueiri, TK; DiPaola, RS; Dutcher, JP; Flaherty, KT; Haas, NB; Manola, J; Uzzo, RG | 1 |
| Cho, A; Choi, YD; Hwang, SH; Kang, WJ; Rha, SY; Yun, M | 1 |
| Gerami, P; Guitart, J; Lacouture, ME; Reilly, LM | 1 |
| Cohen, PR; Diwan, AH; Evans, HL; Hong, DS; Kurzrock, R; Prieto, VG; Reddy, SB; Tannir, NM; Wright, JJ | 1 |
| Chanco Turner, ML; Chevreau, C; Fojo, T; Hornyak, TJ; Kong, HH; Sibaud, V | 1 |
| Lountzis, NI; Maroon, MS | 1 |
| Andrea, A; Di Silverio, F; Panebianco, V; Parente, U; Passariello, R; Sciarra, A; Von Heland, M | 1 |
| Hakenberg, OW | 1 |
| Kuczyk, MA; Merseburger, AS | 1 |
| Bierer, S; Bolenz, C; Gerss, J; Herrmann, E; Hertle, L; Köpke, T; Wülfing, C | 1 |
| Bart, S; Billemont, B; Bitker, MO; Izzedine, H; Rixe, O; Sultan, V; Thibault, F | 1 |
| Strumberg, D | 3 |
| Bouffard, D; Joncas, V; Krasny, M; Provost, N; Sammour, R | 1 |
| Gakis, G; Kramer, MW; Kruck, S; Kuczyk, MA; Merseburger, AS; Stenzl, A | 1 |
| Bukowski, RM; Choueiri, TK; Cotta, C; Dreicer, R; Elson, P; Garcia, J; Khasawneh, MK; Mekhail, T; Rini, BI; Unnithan, J; Wood, L | 1 |
| Bhalla, IP; Bukowski, RM; Choueiri, TK; Elson, P; Ganapathi, R; Golshayan, AR; Jaeger, E; Rini, BI; Sein, N; Sercia, L; Simko, J; Small, EJ; Vaziri, SA; Waldman, FM; Weinberg, V; Wood, L; Zhou, M | 1 |
| Autier, J; Escudier, B; Robert, C; Spatz, A; Wechsler, J | 1 |
| Ardavanis, A; Doufexis, D; Kountourakis, P; Rigatos, G | 1 |
| Rini, BI; Vakkalanka, BK | 1 |
| Rübben, H | 1 |
| Amin, C; Calvo, BF; Godley, PA; Pruthi, RS; Rathmell, WK; Wallen, E | 1 |
| Culine, S; Patard, JJ; Pouessel, D | 2 |
| Chun, FK; Eichelberg, C; Heinzer, H; Heuer, R; Hinrichs, K; Huland, H; Zacharias, M | 1 |
| O'Dowd, A | 1 |
| Bierer, S; Hertle, L; Nitschmann, S | 1 |
| Bensalah, K; Cornu, JN; Oudard, S; Patard, JJ; Rouprêt, M | 1 |
| Alexandrescu, DT; Dasanu, CA; Farzanmehr, H; McClure, R | 1 |
| Amoroso, V; Ferrari, V; Grisanti, S; Marini, G; Marpicati, P; Rangoni, G; Simoncini, E; Valcamonico, F; Vassalli, L | 1 |
| Bierer, S; Gerss, J; Herrmann, E; Hertle, L; Köpke, T; Wülfing, C | 1 |
| Rey, PM; Villavicencio, H | 1 |
| Billemont, B; Boudou-Rouquette, P; Goldwasser, F; Loriot, Y; Ropert, S | 1 |
| Tuma, RS | 1 |
| Moch, H | 1 |
| Kakehi, Y | 1 |
| Aguilar-Ponce, JL; Buzaid, AC; de la Garza, J; Fernandes, Gdos S; Kann, AG; Maluf, FC | 1 |
| Bukowski, RM; Vakkalanka, BK | 1 |
| Hahn, OM; Karczmar, G; Karrison, T; Kistner, E; Manchen, E; Medved, M; Mitchell, M; Ratain, MJ; Stadler, WM; Yang, C | 1 |
| Haseke, N; Karl, A; Stadler, T; Staehler, M; Stief, CG; Zilinberg, K | 1 |
| Chowdhury, S; Gore, ME; Larkin, JM | 1 |
| Ferrière, JM; Grenier, N; Kilkoski, F; Ravaud, A; Sire, M; Wallerand, H | 1 |
| Figlin, RA; Hutson, TE; Kuhn, JG; Motzer, RJ | 1 |
| Bojic, A; Bojic, M; Hejna, M; Ruhsam, M; Schmidinger, H; Schmidinger, M; Schukro, C; Vogl, UM; Zielinski, CC | 1 |
| Anderson, S; Bukowski, R; Cihon, F; Eisen, T; Escudier, B; Gravis, G; Heinzer, H; Middleton, R; Oudard, S; Shah, S; Szczylik, C | 1 |
| Bamias, A | 1 |
| Bex, A; Cosentino, M; Ficarra, V; Flörcken, A; Grünwald, V; Johannsen, M; Kloeters, C; Miller, K; Rief, M; Rogalla, P; Roigas, J | 1 |
| Cicek, D; Dagli, FA; Haligur, BD; Kandi, B; Karaoglu, A | 1 |
| Kroog, GS; Motzer, RJ | 1 |
| Hakenberg, OW; Klebingat, KJ; Protzel, C; Ruppin, S | 1 |
| Dham, A; Dudek, AZ; Lindgren, BR; Szczylik, C; Zolnierek, J | 1 |
| Aydin, H; Bukowski, RM; Elson, P; Garcia, JA; George, S; Golshayan, AR; Heng, DY; Mekhail, TM; Rini, BI; Wood, LS; Zhou, M | 1 |
| Borrás-Blasco, J; Casterá, ME; Galán Brotons, A; Rosique-Robles, JD; Vicent Verge, JM | 1 |
| Masumori, N; Ohmoto, Y; Tochizawa, S; Tsukamoto, T; Yabuuchi, Y; Yanai, Y | 1 |
| Bukowski, RM; Cella, D; Demkow, T; Escudier, B; Hutson, TE; Laferriere, N; Negrier, S; Rolland, F; Scheuring, UJ; Shah, S; Staehler, M; Szczylik, C | 1 |
| Mills, EJ; O'Regan, C; Perri, D; Rachlis, B; Thabane, L | 1 |
| Alken, P; Bolenz, C; Häcker, A; Herrmann, E; Honeck, P; Michel, MS; Schöppler, G; Trojan, L | 1 |
| Bergmann, L; Jäger, E; Jakse, G; Keilholz, U; Miller, K; Wirth, M | 1 |
| Hill, KL; Lipson, AC; Sheehan, JM | 1 |
| Ansari, J; Bhatt, RI; Chaudhri, S; Fatima, A; James, ND; Wallace, M | 1 |
| Bukowski, RM | 3 |
| Dubauskas, Z; Hwu, P; Jonasch, E; Kunishige, J; Prieto, VG; Tannir, NM | 1 |
| Desmedt, E; Digue, L; Milano, G; Mortier, L; Ravaud, A | 1 |
| Bellmunt, J; Calvo, E; Castellano, D; Climent, MA; Esteban, E; García del Muro, X; González-Larriba, JL; Maroto, P; Trigo, JM | 1 |
| Choueiri, TK; Chowdhury, S | 1 |
| Alfaro, C; Dubrot, J; Erro, L; Gonzalez, A; Grande-Pulido, E; Gurpide, A; Hervas-Stubbs, S; Lopez-Picazo, JM; Melero, I; Palazon, A; Perez-Gracia, JL; Solano, S; Suarez, N | 1 |
| Mizutani, Y | 1 |
| Dreyer, C; Faivre, S; Raymond, E | 1 |
| Asemissen, AM; Keilholz, U; Knoedler, M; Miller, K; Schmittel, A; Steiner, U; Thiel, E; Zimmermann, K | 1 |
| Jarkowski, A; Wong, MK | 1 |
| Abe, K; Arimura, A; Hojo, K; Iguchi, M; Matsumoto, M; Matsuo, Y; Wada, T | 1 |
| Bastien, L; Culine, S; de la Taille, A; Ledbai, S; Patard, JJ; Paule, B | 1 |
| Carrie, C; Diaz, O; Martin, E; Mazeron, R | 1 |
| Dabora, SL; Lee, N; Messina, MP; Nobil, AM; Rauktys, AE; Woodrum, CL | 1 |
| Ball, SA; Plowman, PN; Reznek, R; Richards, TM | 1 |
| Jonkers, IJAM; van Buren, M | 1 |
| Rini, BI | 5 |
| Ravaud, A; Sire, M | 1 |
| Secasan, CC | 1 |
| Ferraris, E; Imarisio, I; Paglino, C; Porta, C | 1 |
| Drummond, M; Evans, B; Karakiewicz, P; LeLorier, J; MacLeod, S; Martin, D; Tugwell, P | 1 |
| Balleyguier, C; Celier, C; Escudier, B; Gautier, J; Medioni, J; Negrier, S; Oudard, S; Ravaud, A; Sablin, MP | 1 |
| Molina, AM; Motzer, RJ | 1 |
| Anderson, S; Bukowski, RM; Chevreau, C; Demkow, T; Desai, AA; Eisen, T; Escudier, B; Gore, M; Hofilena, G; Hutson, TE; Lathia, C; Negrier, S; Oudard, S; Pena, C; Rolland, F; Shan, M; Stadler, WM; Staehler, M; Szczylik, C | 1 |
| Desar, IM; Mulder, SF; Mulders, PF; Stillebroer, AB; van der Graaf, WT; van Herpen, CM; van Spronsen, DJ | 1 |
| Alsop, DC; Atkins, MB; Goldberg, SN; Lenkinski, RE; Marquis, RP; Pedrosa, I; Regan, M; Schor-Bardach, R; Signoretti, S; Solazzo, SA; Wang, X | 1 |
| Feito Rodríguez, M; Feltes, RA; González-Beato, MJ | 1 |
| Berchem, G; Dewilde, S; Mahassen, P | 1 |
| Bilaç, C; Ermertcan, AT; Kayhan, TC; Müezzinoğlu, T; Oztürkcan, S; Temeltaş, G; Temiz, P | 1 |
| Alasker, A; Guevremont, C; Karakiewicz, PI | 1 |
| Abel, EJ; Wood, CG | 1 |
| Akaza, H; Miyanaga, N | 1 |
| Chang, SE; Choi, JH; Kang, YK; Koh, JK; Lee, JL; Lee, MW; Lee, WJ; Moon, KC | 1 |
| Abe, H; Fukabori, Y; Furuya, N; Kamai, T; Tokui, N; Yoshida, K | 1 |
| Campbell, SC; Fergany, A; Garcia, JA; Gill, IS; Klein, EA; Krishnamurthi, V; Novick, AC; Rini, BI; Stephenson, AJ; Thomas, AA; Zhou, M | 1 |
| Dai, B; Dong, B; Huang, Y; Lu, JJ; Shen, Y; Yao, X; Ye, D; Zhang, H; Zhang, S; Zhu, Y | 1 |
| Awasthi, S; Rao Lelsani, PC; Sahu, M; Sehrawat, A; Singhal, P; Singhal, SS; Vatsyayan, R; Yadav, S | 1 |
| Aieta, M; Autorino, R; Bruni, G; Cartenì, G; De Laurentiis, M; De Placido, S; Di Lorenzo, G; Ficorella, C; Giannarini, G; Gonnella, A; Imbimbo, C; Longo, N; Mirone, V; Palmieri, G; Perdonà, S; Pignata, S; Rescigno, P; Rizzo, M; Tudini, M | 1 |
| Dutcher, JP; Hudes, G; Kim, S; Rini, BI; Rosbrook, B; Stadler, WM; Tarazi, J; Trask, PC; Wilding, G; Wood, L | 1 |
| Samlowski, W; Vogelzang, NJ; Weissman, A | 1 |
| Heilbrun, L; Parsa, V; Sethi, A; Smith, D; Vaishampayan, U | 1 |
| Benghiat, H; Collins, S; James, N; Karina, M; Oldroyd, A; Parry, H; Pascoe, J; Porfiri, E; Ray, D; Zachariah, A | 1 |
| Cella, D | 2 |
| Jaworsky, C; Kish, LS; Kwon, EJ | 1 |
| Kuszatal, E; Langiewicz, P; Nurzyński, P; Oborska, S; Obrocka, B; Szczylik, C; Waśko-Grabowska, A; Zołnierek, J | 1 |
| Carbonell, CE; Coleman, TA; Davis, CH; Davis, WB; La Vine, DB | 1 |
| Anderson, S; Bellmunt, J; Bukowski, R; Cihon, F; Escudier, B; Jäger, E; Lewis, J; McDermott, D; Moore, M; Negrier, S; Porta, C | 1 |
| Beynat, C; Coudert, B; Diaz, P; Favier, L; Ghiringhelli, F; Ladoire, S | 1 |
| Garnock-Jones, KP; Keating, GM | 1 |
| Atkins, MB; Bukowski, RM; Cheng, T; Chi, KN; Choueiri, TK; Eigl, BJ; Golshayan, AR; Heng, DY; Knox, JJ; Kollmannsberger, C; McDermott, DF; North, S; Oh, WK; Regan, MM; Rini, BI; Ruether, JD; Sahi, C; Venner, P; Warren, MA; Xie, W | 1 |
| Kuczyk, MA; Merseburger, AS; Simon, A; Waalkes, S | 1 |
| Escudier, B; Fizazi, K; Gross-Goupil, M; Massard, C; Szczylik, C; Zonierek, J | 1 |
| Hasegawa, Y; Matsubara, A; Mita, K; Ohdan, H | 1 |
| Andreu, J; Carles, J; Serrano, C; Suárez, C | 1 |
| Aparicio, A; Ashe, RG; Corn, P; Johnson, MM; Jonasch, E; Ng, C; Pagliaro, LC; Tamboli, P; Tannir, NM; Warneke, CL; Wright, JJ | 1 |
| Goldschmeding, R; Overkleeft, EN; van Reekum, F; Verheul, HM; Voest, EE | 1 |
| Breau, RH; Leibovich, BC | 1 |
| Flaherty, KT | 3 |
| Chevreau, C; Delord, JP; Sibaud, V | 1 |
| Furukawa, M; Hakariya, T; Ide, S; Ishimoto, H; Kohno, S; Nagashima, S; Nakamura, Y; Sawai, T; Soda, H; Takemoto, S; Tomari, S | 1 |
| Johnston, KW; Walid, MS | 1 |
| Cheng, CL; Dahm, P; Ou, YC; Wang, SS | 1 |
| Tai, CJ | 1 |
| Cowey, CL; Fielding, JR; Rathmell, WK | 1 |
| Doehn, C; Hegele, A; Heinzer, H; Oberneder, R; Siebels, M; Staehler, M; Varga, Z | 1 |
| Arima, Y; Fukushima, H; Nakamura, S; Noda, K; Ogawa, H; Oshima, S; Shono, M; Taniguchi, I | 1 |
| Digue, L; Ravaud, A; Smith, D; Trufflandier, N | 1 |
| Thompson, JA | 1 |
| Wood, LS | 1 |
| Brade, AM; Chung, C; Dawson, LA; Joshua, AM | 1 |
| Gore, M; Larkin, J | 1 |
| Dupre-Goetghebeur, D; Jantzem, H; Merrer, J; Spindler, P | 1 |
| Dudek, AZ; Kamada, P | 1 |
| Liu, ZZ; Piao, Y; Xie, XD | 1 |
| Autorino, R; Di Lorenzo, G | 1 |
| Green, C; Hoyle, M; Liu, Z; Moxham, T; Stein, K; Thompson Coon, J; Welch, K | 1 |
| Bitzer, M; Claussen, CD; Hartmann, JT; Horger, M; Maksimovic, O; Pintoffl, J; Schraml, C | 1 |
| Lieber, ML; Shah, SN; Smith, AD | 1 |
| Bellmunt, J; Dutcher, JP; Escudier, B; Tannir, N | 1 |
| Hasskarl, J | 1 |
| Barete, S; Billemont, B; Blanchet, B; Cabanes, L; Coriat, R; Francès, C; Garrigue, H; Goldwasser, F; Knebelmann, B | 1 |
| Bukowski, RM; Chu, L; Cupit, L; Curti, BD; Drabkin, HA; Dutcher, JP; Ernstoff, MS; Figlin, RA; George, JR; Hainsworth, JD; Hajdenberg, J; Henderson, CA; Hotte, SJ; Kindwall-Keller, TL; Knox, JJ; McDermott, DF; Miller, WH; Ryan, CW; Stadler, WM; Xia, C | 1 |
| Antoun, S; Baracos, VE; Birdsell, L; Escudier, B; Sawyer, MB; Venner, P | 1 |
| Antoun, S; Baracos, VE; Birdsell, L; Escudier, B; Sawyer, MB | 1 |
| Bukowski, R; Elson, P; Garcia, J; Golshayan, A; Khan, G; Rini, B; Wood, L | 1 |
| Peter, S; Rohde, D; Tong, TQ | 1 |
| Abe, K; Amagai, Y; Hojo, K; Ide, N; Iguchi, M; Kato, A; Matsumoto, M; Shichijo, M; Tanaka, H; Wada, T | 1 |
| Oya, M | 1 |
| Kurashige, Y; Otani, A; Yoshimura, N | 1 |
| Billemont, B; Boccon-Gibod, L; Bompas, E; Camparo, P; Couturier, J; Dutcher, J; Escudier, B; Guillot, A; Malouf, GG; Molinié, V; Oudard, S; Rixe, O; Rustine, A; Schleiermacher, G; Theodore, C | 1 |
| Amin, C; Cowey, CL; Crane, J; Fielding, JR; Godley, PA; Grigson, G; Jalkut, M; Kim, WY; Moore, DT; Nance, KV; Nielsen, ME; Pruthi, RS; Rathmell, WK; Wallen, EM; Watkins, C; Whang, YE | 1 |
| Albanell, J; Bellmunt, J; Calvo, E; Carles, J; Lázaro, M; López, R; Pérez-Gracia, JL; Rubió, J; Trigo, JM; Virizuela, JA | 1 |
| Gschwend, JE | 1 |
| Fournier, C; Tisman, G | 1 |
| Bierer, S; Herrmann, E; Wülfing, C | 1 |
| Chevreau, C; Dielenseger, P; Ederhy, S; Goldwasser, F; Grange, JD; Mortier, L; Neidhardt-Berard, ME; Robert, C; Rosmorduc, O; Scotté, F; Seitz, JF | 1 |
| Amato, AM; Atkins, MB; Cho, DC; Choueiri, TK; Clement, J; McDermott, D; Oh, WK; Regan, MM; Rosenberg, JE; Signoretti, S | 1 |
| Fujimoto, T; Itatani, H; Kamoto, A; Kanemitu, T; Kobayashi, Y; Mori, N; Satoh, M; Sekii, K; Yoshioka, T | 1 |
| Hutson, T | 1 |
| Inui, K; Kamba, T; Mizuno, T; Nakamura, E; Ogawa, O; Shinsako, K; Terada, T; Watanabe, J | 1 |
| Barbastefano, J; Campbell, SC; Dreicer, R; Elson, P; Garcia, JA; Lane, BR; Rini, BI; Wood, LS | 1 |
| Kats-Ugurlu, G; Kiemeney, LA; Leenders, WP; Mulders, PF; Old, LJ; Oosterwijk, E; Oosterwijk-Wakka, JC | 1 |
| Grossgoupil, M; Ravaud, A | 1 |
| Choueiri, TK | 1 |
| Cuesta Alcalá, JA; De Pablo Cárdenas, A; Millán Serrano, JA; Sánchez Zalabardo, D | 1 |
| Hara, T; Hatano, K; Inoue, H; Kinoshita, T; Kinouchi, T; Kobayashi, M; Nonomura, N; Takada, T | 1 |
| Albouy, B; Escudier, B; Gross Goupil, M; Massard, C | 1 |
| Ayllon, J; Barrascout, E; Cuenod, CA; Elaidi, R; Medioni, J; Mejean, A; Oudard, S; Scotte, F; Tartour, E | 1 |
| Escudier, B; Gross-Goupil, M | 1 |
| Boyle, H; Fléchon, A; Négrier, S | 1 |
| Eto, M; Inokuchi, J; Kuroiwa, K; Masubuchi, D; Naito, S; Seki, N; Shiota, M; Tada, Y; Takeuchi, A; Tatsugami, K; Uchiumi, T; Yokomizo, A | 1 |
| Kondo, M; Nieder, C; Norum, J | 1 |
| Vaishampayan, U | 1 |
| Rini, BI; Shah, SN | 1 |
| Karakiewicz, PI; Lughezzani, G; Perrotte, P; Sun, M | 1 |
| Beljanski, V; Knaak, C; Smith, CD; Zhuang, Y | 1 |
| Albers, P; Bergmann, L; Gschwend, J; Jäger, E; Keilholz, U; Miller, K | 1 |
| Lieber, ML; Remer, EM; Rini, BI; Shah, SN; Smith, AD | 2 |
| Burger, AM; Egorin, MJ; Heilbrun, LK; Horiba, MN; Ivy, P; Li, J; Lorusso, PM; Pacey, S; Sausville, EA; Vaishampayan, UN | 1 |
| Amoh, Y; Eto, H; Iwamura, M; Katsuoka, K; Mii, S; Tanabe, K | 1 |
| Balvay, D; Banu, E; Chatellier, G; Cuenod, CA; Fournier, LS; Frija, G; Medioni, J; Oudard, S; Thiam, R; Trinquart, L | 1 |
| Bigatti, GL; Castagneto, B; Cosimi, MF; Giorcelli, L; Montefiore, F; Pisacco, P; Stevani, I | 1 |
| Bellmunt, J; Eisen, T; Fishman, M; Quinn, D | 1 |
| Fujisawa, M; Inoue, TA; Kondo, Y; Kurahashi, T; Miyake, H; Takenaka, A; Yamanaka, K | 1 |
| Fukui, I; Hatake, K; Kodaira, M; Saotome, T; Takahashi, S; Takeuchi, K; Yonese, J; Yuasa, T | 1 |
| Beck, J; Bellmunt, J; Escudier, B | 1 |
| Antón-Torres, A; Bellmunt, J; Carles, J; Guillem, V; López-Martín, JA; Maroto-Rey, P; Trigo, JM; Urruticoechea, L | 1 |
| Chang, JW; Chang, NJ; Chuang, CK; Hou, MM; Hsieh, JJ; Hsu, T; Huang, HY; Wang, HM | 1 |
| Herrmann, TR; Kramer, M; Kuczyk, MA; Merseburger, AS; Schrader, AJ; Waalkes, S | 1 |
| Fukasawa, S; Ichikawa, T; Imamura, Y; Komaru, A; Maruoka, M; Naya, Y; Nihei, N; Sazuka, T; Suyama, T; Ueda, T | 1 |
| Bukowski, RM; Escudier, B; Lathia, C; Peña, C; Shan, M | 1 |
| Anderson, S; Bellmunt, J; Bukowski, R; Eisen, T; Escudier, B; Hutson, TE; Nadel, A; Porta, C; Staehler, M; Szczylik, C | 1 |
| Lekili, M; Muezzinoglu, T; Nese, N; Temeltas, G | 1 |
| Bader, M; Haseke, N; Karl, A; Roosen, A; Siebels, M; Stadler, T; Staehler, M; Stief, CG | 1 |
| Hashimoto, Y; Iizuka, J; Kobayashi, H; Kondo, T; Nakano, M; Nishikawa, T; Tanabe, K | 1 |
| Berros, JP; Blay, P; Corral, N; Esteban, E; Estrada, E; Fernández, Y; Fonseca, PJ; Fra, J; Izquierdo, M; Lacave, ÁJ; Luque, M; Muriel, C; Pardo, P; Sanmamed, M; Vieitez, JM; Villanueva, N | 1 |
| Tomita, Y | 1 |
| Bukowski, RM; Chu, L; Cupit, L; Curti, BD; Drabkin, HA; Dutcher, JP; Ernstoff, MS; Figlin, RA; Hainsworth, JD; Hajdenberg, J; Henderson, CA; Hotte, SJ; Kindwall-Keller, TL; Knox, JJ; McDermott, DF; Miller, WH; Ryan, CW; Stadler, WM; Xia, C | 1 |
| Bukowski, RM; Cowey, CL; Dreicer, R; Elson, P; Garcia, JA; Gilligan, T; Hutson, TE; Nemec, C; Rini, BI | 1 |
| Büchler, T | 1 |
| Chen, H; Chen, HJ; Huang, Y; Li, X; Wei, Q; Wu, YJ; Xie, X; Yang, YR; Zeng, H; Zhou, Q; Zhu, YC | 1 |
| Breaker, K; Costa, LJ; Crighton, F; Drabkin, H; Flaig, TW; Gustafson, DL; Kim, FJ; Schultz, MK | 1 |
| Adema, GJ; de Vries, IJ; Desar, IM; Hulsbergen-vandeKaa, CA; Jacobs, JH; Mulders, PF; Oyen, WJ; van der Graaf, WT; van Herpen, CM | 1 |
| Banerji, U; Berns, B; de Boer, C; Edmonds, K; Ferguson, TR; Gore, ME; James, MG; Larkin, JM; Pickering, LM; Thomas, K | 1 |
| Baba, S; Kinoshita, M; Kurita, Y; Kyono, Y; Mugiya, S; Ozono, S; Takayama, T | 1 |
| Bojic, M; Clodi, M; Haitel, A; Heinzl, H; Kramer, G; Lamm, W; Schmidinger, M; Vogl, UM; Zielinski, CC | 1 |
| Jeske, S; Kung, S; Lehrer, D; Matulich, D; Mazumdar, M; Milowsky, MI; Nanus, DM; Selzer, J; Sung, M; Tagawa, ST; Wright, JJ | 1 |
| Iiduka, H; Ishida-Yamamoto, A; Komatsu, S; Minami-Hori, M | 1 |
| Sahai, S; Swick, BL | 1 |
| Aglietta, M; Aieta, M; Buonerba, C; D'Aniello, C; De Placido, S; Di Lorenzo, G; Federico, P; Felici, A; Imbimbo, C; Longo, N; Milella, M; Mirone, V; Ortega, C; Palmieri, G; Rescigno, P; Ruggeri, EM | 1 |
| Heinz, WJ; Helle-Beyersdorf, A; Kahle, K; Keller, D; Klinker, H; Langmann, P; Lenker, U; Schirmer, D | 1 |
| Childs, R; Lundqvist, A; Su, S; Yokoyama, H | 1 |
| Homma, Y; Kaneko, T; Matsushima, H; Morimoto, H; Tsuzaka, Y | 1 |
| Cruikshanks, N; Curiel, DT; Dent, P; Dmitriev, IP; Eulitt, PJ; Fisher, PB; Hossein, H; Park, MA; Yacoub, A; Yang, C | 1 |
| Fujisawa, M; Miyake, H | 1 |
| Figlin, RA; Pal, SK | 1 |
| Boerman, OC; Desar, IM; Leenders, WP; Mulders, PF; Oosterwijk, E; Oyen, WJ; Stillebroer, AB; van der Graaf, WT; van Herpen, CM | 1 |
| Eto, M; Kiyoshima, K; Naito, S; Oki, T; Takeuchi, A; Tatsugami, K; Yamada, H; Yoshikai, Y | 1 |
| Choueiri, TK; Heng, DY; Knox, JJ; Kollmannsberger, C; Lampard, JG; McDermott, DF; North, S; Rini, BI; Xie, W | 1 |
| Bellmunt, J; Eisen, T; Mulders, P; Porta, C; Szczylik, C | 1 |
| Rini, B | 1 |
| Biglietto, M; Buonerba, C; Cartenì, G; Chiurazzi, B; Di Lorenzo, G; Riccardi, F; Scognamiglio, F | 1 |
| Asemissen, A; Braun, F; Busse, A; Fusi, A; Keilholz, U; Miller, K; Nonnenmacher, A; Ochsenreither, S; Schmittel, A; Stather, D; Thiel, E | 1 |
| Bierer, S; Herrmann, E; Hertle, L; Hoffmeister, I; Köpke, T; Papavassilis, P; Riesenbeck, LM; Thielen, B | 1 |
| Jungmeechoke, K; Kanjanapayak, B; Ruangkanchanasetr, P | 1 |
| Oudard, S | 1 |
| Asemissen, AM; Braun, F; Busse, A; Fusi, A; Keilholz, U; Miller, K; Nonnenmacher, A; Ochsenreither, S; Schmittel, A; Stather, D; Thiel, E | 1 |
| Dunn, RL; Filson, CP; Miller, DC; Redman, BG | 1 |
| Benedict, A; Charbonneau, C; Figlin, RA; Hariharan, S; Harmenberg, U; Négrier, S; Remák, E; Sandin, R; Sandström, P; Ullén, A | 1 |
| Brion, N; Paule, B | 1 |
| Andreadis, C; Bamias, A; Dimopoulos, M; Karadimou, A; Kontovinis, L; Laschos, K; Papazisis, K; Paraskevopoulos, P | 1 |
| Atkins, MB; Choueiri, TK; Guo, M; Heng, DY; Jagannathan, J; Krajewski, KM; McDermott, DF; Pedrosa, I; Ramaiya, N; Schutz, FA; Van den Abbeele, AD; Yap, J | 1 |
| Fukui, I; Hatake, K; Inamura, K; Ishikwa, Y; Kodaira, M; Nakano, K; Takahashi, S; Urakami, S; Yamamoto, S; Yonese, J; Yuasa, T | 1 |
| Bellini, E; Berruti, A; Brizzi, MP; Dogliotti, L; Pia, A; Tampellini, M; Terzolo, M; Torta, M | 1 |
| Bajetta, E; Beck, J; Bokemeyer, C; Bracarda, S; Burock, K; Escudier, B; Keilholz, U; Mersmann, S; Negrier, S; Procopio, G; Richel, DJ; Staehler, M; Strauss, UP; Szczylik, C | 1 |
| Cano Megías, M; Carrasco De La Fuente, M; González Albarrán, O; Menacho Román, M; Pérez López, G | 1 |
| Adnot-Desanlis, L; Bernard, P; Reguiaï, Z | 1 |
| Hutson, TE | 2 |
| Abe, H; Fukuda, T; Furuya, N; Kamai, T; Kambara, T; Mizuno, T; Nakamura, F; Nakanishi, K; Shirataki, H; Yanai, Y; Yoshida, K | 1 |
| Demlová, R; Komínek, J; Ondrácková, B | 1 |
| Allen, GI; Chung, BI; Gill, HS; Harshman, LC; Srinivas, S; Yu, RJ | 1 |
| Hashimoto, Y; Iizuka, J; Ishimori, I; Kennoki, T; Kimata, N; Kobayashi, H; Kondo, T; Murakami, J; Nakazawa, H; Takagi, T; Tanabe, K; Yoshida, K | 1 |
| Ikeda, R; Iseki, K; Maeda, H; Nakano, K; Shibayama, Y; Sugawara, M; Taguchi, M; Takeda, Y; Yamada, K | 1 |
| Brocks, DR; Fong, L; Harzstark, AL; Lin, AM; Rosenberg, JE; Ryan, CJ; Small, EJ; Sun, J; Weinberg, VK | 1 |
| Behnsawy, HM; Fujisawa, M; Fukuhara, T; Inoue, TA; Kusuda, Y; Miyake, H | 1 |
| Cheng, CW; Chong, TW; Huynh, H; Lau, WK; Sim, MY; Siml, HG; Yuen, JS | 1 |
| Arranz, JÁ; Climent, MÁ; González-Larriba, JL; León, L; Maroto, JP | 1 |
| Canipari, C; Chen, K; Duh, MS; Imarisio, I; Neary, M; Paglino, C; Porta, C | 1 |
| Blumenstengel, K; Grimm, MO; Groschek, M; Herrmann, E; Hutzschenreuter, U; Marschner, N; Ohlmann, CH; Overkamp, F; Pühse, G; Steiner, T | 1 |
| Maráz, A | 1 |
| Du, DZ; Herynk, MH; Heymach, JV; Jonasch, E; Khajavi, M; Logothetis, CJ; McKee, KS; Tannir, NM; Tran, HT; Wang, X; Xu, L; Yan, S; Zurita, AJ | 1 |
| Bushmakin, AG; Bycott, P; Cappelleri, JC; Kim, S; Rini, B; Rosbrook, B; Stadler, WM; Tarazi, J; Trask, PC | 1 |
| Duh, MS; Feinberg, BA; Fortner, B; Gilmore, J; Jolly, P; Neary, MP; Scott, J; Wang, ST | 1 |
| Tanji, N; Yokoyama, M | 1 |
| Dai, B; Shen, YJ; Shi, GH; Wang, CF; Yao, XD; Ye, DW; Zhang, HL; Zhang, SL; Zhu, Y; Zhu, YP | 1 |
| Akaza, H; Fukino, K; Murai, M; Naito, S; Tsukamoto, T | 1 |
| Karakiewicz, PI; Maurin, C; Perrotte, P; Sun, M; Thuret, R | 1 |
| Allen, P; Jonasch, E; Mahajan, A; Tannir, N; Verma, J | 1 |
| Busch, J; Flörcken, A; Grünwald, V; Johannsen, M; Keilholz, U; Kempkensteffen, C; Miller, K; Weikert, S; Weinkauf, L; Westermann, J; Zimmermann, K | 1 |
| Abrahamova, J; Brabec, P; Buchler, T; Dusek, L; Klapka, R; Melichar, B; Vyzula, R | 1 |
| Eto, M; Inokuchi, J; Kiyoshima, K; Kuroiwa, K; Naito, S; Shiota, M; Takeuchi, A; Tatsugami, K; Yokomizo, A | 1 |
| Arai, Y; Imazu, T; Inoue, H; Kajikawa, J; Kawashima, A; Kinoshita, T; Nin, M; Nishimura, K; Nonomura, N; Takada, S; Takayama, H; Tanigawa, G; Tsujimura, A; Yasunaga, Y | 1 |
| Boldrini, R; Cortesi, E; De Pasquale, MD; Donfrancesco, A; Ilari, I; Jenkner, A; Pessolano, R | 1 |
| Alsop, DC; Atkins, MB; Bhasin, M; Bhatt, RS; Collins, MP; Goldberg, SN; Libermann, T; Mier, JW; Panka, D; Putheti, P; Schor-Bardach, R; Signoretti, S; Wang, X; Zhang, L | 1 |
| Doehn, C; Hegele, A; Heinzer, H; Oberneder, R; Siebels, M; Varga, Z | 1 |
| Buonerba, C; Casciano, R; De Placido, S; Di Lorenzo, G; Liu, Z; Malangone, E; Sherman, S; Wang, X; Willet, J | 1 |
| Wu, Y; Zhao, Y | 1 |
| Bajetta, E; Bearz, A; Calcagno, A; Cartenì, G; Chiappino, I; Guadalupi, V; Imarisio, I; Landi, L; Paglino, C; Porta, C; Procopio, G; Re, GL; Ricotta, R; Rizzo, M; Ruggeri, EM; Sabbatini, R; Verzoni, E; Zustovich, F | 1 |
| Greil, R; Grundbichler, M; Kappacher, A; Mlineritsch, B; Moik, M; Ressler, S; Rosenlechner, S | 1 |
| Boers-Doets, C; Chrysou, M; Edmonds, K; Hull, D; Koldenhof, J; Molassiotis, A; Spencer-Shaw, A | 1 |
| Cohen, JD; Gallegos, AC; Lau, SS; Mastrandrea, NJ; Monks, TJ; Tham, KY | 1 |
| Chan, AL; Leung, HW | 1 |
| Escudier, B | 3 |
| de Vries, IJ; Desar, IM; Galama, JM; Jacobs, JF; Mulder, SF; Mulders, PF; Olde Nordkamp, MA; Punt, CJ; Teerenstra, S; Torensma, R; van Herpen, CM; Vissers, KC | 1 |
| Bergmann, L; Gschwend, J; Keilholz, U; Miller, K | 1 |
| Fujii, M; Fujisawa, M; Kitajima, K; Maeda, T; Miyake, H; Ohno, Y; Sugimura, K; Takahashi, S; Yoshikawa, T | 1 |
| Busch, J; Grünwald, V; Hinz, S; Kempkensteffen, C; Magheli, A; Miller, K; Seidel, C; Weikert, S; Weinkauf, L; Wolff, I | 1 |
| Albiges, L; Escudier, B; Rini, B; Salem, M | 1 |
| Atkinson, B; Choueiri, TK; Chowdhury, S; Matrana, MR; Tannir, NM; Tsang, C | 1 |
| Demartines, N; Dormond, O; Dormond-Meuwly, A; Dufour, M; Roulin, D; Waselle, L | 1 |
| Busch, J; Grünwald, V; Hinz, S; Johannsen, M; Kempkensteffen, C; Magheli, A; Miller, K; Seidel, C; Weikert, S; Wolff, I | 1 |
| Atkins, M; Bukowski, R; Choueiri, TK; Dutcher, J; Eisen, T; Elson, P; Escudier, B; Heng, DY; Manola, J; Mazumdar, M; McCormack, JB; Motzer, R; Négrier, S; Royston, P | 1 |
| Calvani, N; Cinefra, M; Cinieri, S; Gnoni, A; Leo, S; Lombardi, L; Lorusso, V; Maiello, E; Morelli, F; Orlando, L | 1 |
| Becker, C; Berger, F; Hittinger, M; Reiser, M; Schramm, N; Staehler, M; Ubleis, C | 1 |
| Hammock, BD; Hwang, SH; Inoue, H; Wecksler, AT; Weiss, RH | 1 |
| Fukui, I; Habuchi, T; Hatake, K; Horikawa, Y; Inoue, T; Nakano, K; Narita, S; Saito, M; Takahashi, S; Tsuchiya, N; Urakami, S; Yamamoto, S; Yonese, J; Yuasa, T | 1 |
| Joly, F | 1 |
| Bracarda, S; Cortesi, E; D'Angelo, A; Ferraù, F; Merlano, M; Monti, M; Ruggeri, EM; Santoro, A | 1 |
| Grünberger, B | 1 |
| Giménez-Bachs, JM; Nam Cha, S; Salinas-Sánchez, AS; Sánchez-Prieto, R; Serrano-Oviedo, L | 1 |
| Hara, T; Kajikawa, J; Kawashima, A; Meguro, N; Miyoshi, S; Nishimura, K; Nonomura, N; Oka, T; Takayama, H; Tanigawa, G; Yamaguchi, S; Yosioka, T | 1 |
| Awasthi, S; Nagaprashantha, LD; Singhal, J; Singhal, SS; Vatsyayan, R | 1 |
| Busch, J; Fenner, M; Ganser, A; Grünwald, V; Seidel, C; Weikert, S | 1 |
| de Waal, R; Hulsbergen-van de Kaa, C; Kats-Ugurlu, G; Leenders, W; Maass, C; Mulders, P; Oosterwijk, E; van Herpen, C | 1 |
| Procopio, G | 1 |
| Hughes, M; Pickert, A; Wells, M | 1 |
| Bex, A; Haanen, J | 1 |
| Castellano, D; Cella, D; Chen, C; Escudier, B; Gorbunova, VA; Gore, ME; Hutson, TE; Kaprin, A; Kim, S; Lim, HY; Michaelson, MD; Motzer, RJ; Negrier, S; Ou, YC; Rini, BI; Rosbrook, B; Rusakov, IG; Szczylik, C; Tarazi, J; Tomczak, P; Uemura, H | 1 |
| Bjarnason, GA; Choueiri, TK; Donskov, F; Heng, DY; Knox, JJ; Kollmannsberger, C; Mackenzie, MJ; North, S; Rini, BI; Tan, MH; Vaishampayan, UN; Wang, Y; Wood, L | 1 |
| Baba, S; Bessho, H; Fujita, T; Ishikawa, W; Iwamura, M; Maeyama, R; Sugita, A; Tabata, K; Tokuyama, Y; Yoshida, K | 1 |
| Di Fiore, F; Ménager, C; Michel, P; Pfister, C; Rigal, O | 1 |
| Fujisawa, M; Harada, K; Kusuda, Y; Miyake, H; Sakai, I | 1 |
| Calvo Aller, E; Castellano, D; Díaz Cerezo, S; González Larriba, JL; Kreif, N; López-Brea, M; Maroto, P; Martí, B | 1 |
| Dörken, B; Flörcken, A; Hopfenmüller, W; Pezzutto, A; Singh, A; Takvorian, A; Van Lessen, A; Westermann, J | 1 |
| Amato, RJ; Flaherty, AL; Stepankiw, M | 1 |
| Chen, X; Guan, W; Hu, Z; Li, Y; Liu, F; Peng, E; Ye, Z; Zhuang, Q | 1 |
| Gotoh, M; Kashiwagi, Y; Nakano, Y; Takeda, H; Yoshino, Y | 1 |
| Alsop, DC; Atkins, MB; Bhasin, M; Bhatt, RS; Brown, V; Goldberg, SN; Mier, JW; Signoretti, S; Wang, X; Zhang, L | 1 |
| Alonso, S; Calabrò, F; Caristo, R; Catalano, A; Cerbone, L; Di Paola, ED; Leone, A; Mancuso, A; Messina, C; Sternberg, CN; Vigna, L; Zivi, A | 1 |
| Lanocita, R; Procopio, G; Verzoni, E | 1 |
| Dranitsaris, G; Fang, F; Huang, L; Lacouture, ME; Vincent, MD; Yu, J | 1 |
| Albiges, L; Caty, A; Dietrich, PY; Duclos, B; Escudier, B; Geoffrois, L; Gravis, G; Guillot, A; Joly, F; Kohser, F; Laguerre, B; Legouffe, E; Negrier, S; Oudard, S; Rolland, F; Theodore, CA | 1 |
| Eisen, T; Escudier, B; Izzedine, H; Mulders, P; Pyle, L; Robert, C; Sternberg, CN; Zbinden, S | 1 |
| Ahn, H; Ahn, JH; Ahn, S; Ahn, Y; Hong, JH; Kim, CS; Kim, TW; Lee, JL; Park, I; Park, K; Park, S; Song, C | 1 |
| Colecchia, M; Iacovelli, R; Mariani, L; Procopio, G; Torelli, T; Verzoni, E | 1 |
| Bies, RR; Jin, Y; Karrison, TG; Maitland, ML; Ratain, MJ; Sharma, MR; Stadler, WM | 1 |
| Bruyere, F; Carmier, D; Combe, P; D'Arcier, BF; Linassier, C; Narciso, B | 1 |
| Boulanger, G; Edeline, J; Jouan, F; Martin, B; Oger, E; Patard, JJ; Rioux-Leclercq, N; Vigneau, C; Zerrouki, S | 1 |
| Hatanaka, Y; Minami, T; Nozawa, M; Shimizu, N; Tsuji, H; Uemura, H; Yamamoto, Y | 1 |
| Imarisio, I; Paglino, C; Porta, C | 2 |
| Gupta, GN; Singer, EA; Srinivasan, R | 1 |
| Aste, MG; Buti, S; Conte, PF; Cosmai, L; Del Giovane, C; Di Lorenzo, G; Grosso, F; Iacovelli, R; Invernizzi, R; Lucia Manenti, A; Masini, C; Moscetti, L; Onofri, A; Ortega, C; Pagano, M; Porta, C; Procopio, G; Sabbatini, R | 1 |
| Czeche, S; Feldt, S; Franzmann, A; Ludwig, WD; Quinzler, R; Schulz, M; Schüssel, K | 1 |
| LeBlanc, M; Tangen, C | 1 |
| Camidge, DR; Dasari, A; Diab, S; Drabkin, HA; Flaig, TW; Gore, L; Jimeno, A; Lewis, KD; Messersmith, WA; Weekes, CD | 1 |
| Ahn, H; Ahn, JH; Ahn, S; Ahn, Y; Hong, JH; Kim, CS; Lee, JL; Park, I; Park, K; Park, S; Song, C | 1 |
| Amato, R; DeFoe, M; Saxena, S; Willis, J; Zhai, J | 1 |
| Aktürk, M; Baloş Törüner, F; Coşkun, U; Demirci, U; Konca Degertekin, C | 1 |
| Lucas, LM | 1 |
| Fujisawa, M; Gleave, ME; Kususda, Y; Miyake, H | 1 |
| Powles, T | 1 |
| Daimon, M; Kaino, W; Kameda, W; Karasawa, S; Kato, T; Oizumi, T; Susa, S; Takase, K; Tomita, Y; Wada, K | 1 |
| Kuczyk, MA; Schnoeller, TJ; Schrader, AJ; Schrader, M; Steffens, S | 1 |
| Cheng, CW; Chong, TW; Huynh, H; Lau, WK; Ong, RW; Sim, HG; Sim, MY; Yuen, JS | 1 |
| Aiello, RA; Alì, M; Caruso, M; La Rocca, R; Licciardello, P; Sanò, MV; Scandurra, G; Taibi, E; Todaro, FM | 1 |
| He, H; Shen, Z; Wang, H; Wang, X; Wu, Y; Zhang, C; Zhao, J; Zhou, W; Zhu, Y | 1 |
| Buchler, T; Cathomas, R; Chastonay, R; Haile, SR; Knuth, A; Liewen, H; Porta, C; Renner, C; Rothermundt, C; Samaras, P; Siciliano, RD; Stenner, F; Stoll, S | 1 |
| Agarwala, SS; Chen, CC; Garay, CC; Gesme, DH; Guo, A; Hess, GP; Hill, JW; Liu, Z | 1 |
| Bilim, VN; Kato, T; Kawazoe, H; Nagaoka, A; Naito, S; Tomita, Y; Ugolkov, AV; Yuuki, K | 1 |
| Filipiak, KJ; Nurzyński, P; Opolski, G; Szczylik, C; Szmit, S; Waśko-Grabowska, A; Zaborowska, M; Żołnierek, J | 1 |
| Bass, MB; Deptala, A; Dirix, LY; Escudier, B; Fishman, M; Koralewski, P; Kracht, K; Puhlmann, M; Ramlau, R; Ravaud, A; Rini, B; Rogowski, W; Sun, YN; Szczylik, C; Tannir, NM; Tomczak, P | 1 |
| Abrahamova, J; Bortlicek, Z; Buchler, T; Dusek, L; Melichar, B; Pavlik, T; Poprach, A; Puzanov, I; Vyzula, R | 1 |
| Cowey, CL; Gohil, H; Khandani, AH; Moore, DT; Rathmell, WK | 1 |
| Abrahamova, J; Bortlicek, Z; Buchler, T; Melichar, B; Pavlik, T; Poprach, A; Vyzula, R | 1 |
| Fujita, T; Ikeda, M; Iwamura, M; Matsumoto, K; Mii, S; Satoh, T; Tabata, K; Tanabe, K | 1 |
| Kashima, T; Ohno, Y; Tachibana, M | 1 |
| Banerjee, P; Basu, A; Choi, AM; Gasser, M; Mizumura, K; Otterbein, LE; Pal, S; Waaga-Gasser, AM; Wegiel, B | 1 |
| Choi, J; Hwang, JJ; Jang, S; Jeong, IG; Kim, CS; Kim, DE; Kim, MJ; Lee, JH; Ro, S | 1 |
| Arai, Y; Kawashima, A; Nakai, Y; Nin, M; Nishimura, K; Nonomura, N; Takayama, H; Tanigawa, G; Tsujimura, A; Uemura, M | 1 |
| Caccialanza, R; Ganini, C; Imarisio, I; Magnani, L; Paglino, C; Porta, C | 1 |
| Inoue, T; Kawa, G; Kawabata, T; Kinoshita, H; Komai, Y; Matsuda, T; Uemura, Y | 1 |
| Saito, K | 1 |
| Krzemieniecki, K; Sowa-Staszczak, A; Zygulska, AL | 1 |
| Boni, C; Bracarda, S; Caserta, C; Cinquini, M; Cortesi, E; De Angelis, V; Di Costanzo, F; Falcone, A; Gasparro, D; Labianca, R; Mucciarini, C; Paglino, C; Pazzola, A; Porta, C; Santoro, A | 1 |
| Chowdhury, NF; Kuge, Y; Murakami, M; Nishijima, K; Takiguchi, M; Tamaki, N; Yu, W; Zhao, S; Zhao, Y | 1 |
| Kondo, T | 1 |
| Puche-Sanz, I; Vázquez-Alonso, F | 1 |
| O'Connor, TM; O'Reilly, SP; Power, DG; Teo, M | 1 |
| Breaker, K; Clemons, J; Flaig, TW; Gao, D; Garfield, D; Naam, M | 1 |
| Atkinson, B; Chen, A; Sevin, A | 1 |
| Kimura, T; Miyagawa, T; Suetomi, T; Tsutsumi, M | 1 |
| Dai, B; Qin, XJ; Shi, GH; Wang, CF; Yao, XD; Ye, DW; Zhang, HL; Zhang, SL; Zhu, Y; Zhu, YP | 1 |
| Rosenthal, H; von Falck, C; Wacker, F | 1 |
| Albiges, L; Escudier, B; Iacovelli, R; Lanoy, E | 1 |
| Berkers, J; Beuselinck, B; Body, JJ; Debruyne, P; Dumez, H; Elaidi, R; Karadimou, A; Lerut, E; Paridaens, R; Rogiers, A; Schöffski, P; Van Cann, T; Van Poppel, H; Willems, L; Wolter, P | 1 |
| Atkins, MB; Cheng, S; Choueiri, TK; Pastorek, J; Qu, AQ; Signoretti, S | 1 |
| Bex, A; de Bruijn, R; Horenblas, S; Kroon, BK; Powles, T; Prevoo, W | 1 |
| Hegde, U; Kaloudis, E; Patel, V | 1 |
| Adenis, A; Alt, M; Caty, A; Fumagalli, I; Penel, N; Vanhuyse, M; Zini, L | 1 |
| Benitez, A; Bowen, T; Lokeshwar, VB; Shamaldevi, N; Yates, TJ | 1 |
| Collier, J; Eisen, T; Fairfax, BP; Kaplan, R; Macaulay, VM; Meade, AM; Pratap, S; Protheroe, A; Ritchie, AW; Roberts, IS | 1 |
| Hu, GY; Yang, L; Yu, SY | 1 |
| Fujishima, N; Habuchi, T; Hasunuma, N; Hatakeyama, S; Horikawa, Y; Inoue, T; Narita, S; Notoya, T; Numakura, K; Ohyama, C; Satoh, S; Tsuchiya, N | 1 |
| Arai, Y; Nakayama, M; Nishimura, K | 1 |
| Ambring, A; Björholt, I; Lesén, E; Odén, A; Stierner, U | 1 |
| Flaherty, KT; Heitjan, DF; Kang, HC; Keefe, SM; O'Dwyer, PJ; Rosen, MA; Siegelman, ES; Tan, KS | 1 |
| Cappelleri, JC; Chen, C; Foley, G; Healey, PJ; Kroes, M; Larkin, J; Mitchell, S; Paine, A; Tumur, I | 1 |
| Agarwal, S; Chi, M; Dudek, AZ; Elmquist, WF; Mittapalli, RK; Oberoi, R; Raza, A; Singhal, M | 1 |
| Bogot, N; Grenader, T; Rosenbaum, E; Shavit, L; Zilber, S | 1 |
| Borker, R; Fonseca, E; Hess, G | 1 |
| Pal, SK; Vogelzang, NJ | 1 |
| Alasker, A; Bianchi, M; Hanna, N; Hansen, J; Ismail, S; Karakiewicz, PI; Meskawi, M; Perrotte, P; Sun, M; Tian, Z | 1 |
| Bellmunt, J; Bracarda, S; Brueckner, A; Dutcher, J; Escudier, B; Hutson, TE; Knox, J; Molnar, I; Procopio, G | 1 |
| Fang, F; Feng, G; Huang, H; Li, G; Pu, C; Ye, X | 1 |
| Chi, ZH; Cui, CL; Guo, J; Lian, B; Mao, LL; Sheng, XN; Si, L; Yang, SY | 1 |
| Beuselinck, B; Blesius, A; Chevreau, C; Escudier, B; Oudard, S; Ravaud, A; Rolland, F | 1 |
| Angevin, E; Castellano, D; Chang, J; Escudier, B; Gschwend, JE; Harzstark, A; Kay, A; Lin, CC; Lopez-Martin, JA; Sen, P; Shi, M; Soria, JC | 1 |
| Ashikari, A; Kobayashi, H; Kohno, Y; Namitome, R; Nishiyama, T; Saito, S; Yagi, Y | 1 |
| Andrés, R; Arranz, JA; Cruz, J; del Muro, XG; Domenech, M; Gallardo, E; Maroto, JP; Meana, JA; Mellado, B; Perez-Gracia, JL | 1 |
| Ashida, S; Fukuhara, H; Inoue, K; Kamada, M; Karashima, T; Kuroda, N; Shuin, T; Taguchi, T; Tamura, K | 1 |
| Cortesi, E; Iacovelli, R; Mezi, S; Naso, G; Palazzo, A; Pellegrino, D; Trenta, P | 1 |
| Afonso, FJ; Anido, U; Antón-Aparicio, L; Fernández-Calvo, O; Lázaro, M; León, L; Ramos, M; Vázquez-Estévez, S | 1 |
| Ahmad, T; Eisen, T | 1 |
| Desai, AA; Stadler, WM | 1 |
| Awada, A; Bartholomeus, S; Brendel, E; de Valeriola, D; Gil, T; Haase, CG; Hendlisz, A; Mano, M; Piccart, M; Schwartz, B; Strumberg, D | 1 |
| Marx, J | 1 |
| Branca, MA | 1 |
| Motzer, RJ; Rini, BI; Sosman, JA | 1 |
| Cooney, MM; Remick, SC; Vogelzang, NJ | 2 |
| Gollob, JA | 1 |
| Chaganti, RS; Motzer, RJ; Patel, PH | 1 |
| Kanetake, H; Koga, S | 1 |
| Abbruzzese, JL; Desai, AA; Eisen, T; Flaherty, KT; Gore, M; Kaye, SB; O'Dwyer, PJ; Patnaik, A; Ratain, MJ; Rosner, GL; Rowinsky, E; Schwartz, B; Simantov, R; Stadler, WM; Xia, C; Xiong, HQ | 1 |
| Boogaerts, M; Cools, J; Folens, C; Lierman, E; Marynen, P; Mentens, N; Scheers, W; Stover, EH; Van Miegroet, H; Vandenberghe, P | 1 |
| Bukowski, RM; Reddy, GK | 1 |
| Escudier, B; Gore, ME | 1 |
| Hampton, T | 1 |
| Eto, M; Naito, S | 1 |
| Bukowski, RM; Rini, BI; Shaheen, PE | 1 |
| Mancuso, A; Sternberg, CN | 1 |
| Biedrzycki, BA | 1 |
| King, CR | 1 |
| Chami, L; Escudier, B; Lamuraglia, M; Lassau, N; Leclère, J; Roche, A; Schwartz, B | 1 |
| Figg, WD; Jain, L; Venitz, J | 1 |
| Stadler, W | 1 |
| Hahn, O; Stadler, W | 1 |
| Berry, WR; Galsky, MD; Hutson, TE; Sonpavde, G | 1 |
| Carter, C; Dumas, J; Kelley, S; Lowinger, T; Lynch, M; Schwartz, B; Simantov, R; Smith, RA; Wilhelm, S | 1 |
| Haseke, N; Heinemann, G; Schöppler, G; Stadler, T; Staehler, M; Stief, CG | 1 |
| Burton, A | 1 |
| Carter, C; Feldman, MD; Lassoued, W; Lee, WM; Makonnen, S; Murphy, DA | 1 |
| Gascón, P; Mellado, B | 1 |
| Wetherbee, SL | 1 |
| Bukowski, RM; Motzer, RJ | 1 |
| Adnane, J; Bortolon, E; Carter, CA; Chang, YS; Chen, C; Henderson, A; Ichetovkin, M; Levy, J; Lynch, M; McNabola, A; Taylor, IC; Trail, PA; Wilhelm, S; Wilkie, D; Xue, D | 1 |
| Culine, S; Pouessel, D | 3 |
| Chadalavada, RS; Chaganti, RS; Motzer, RJ; Patel, PH | 1 |
| Booth, B; Chidambaram, N; Farrell, AT; Garvey, P; Jee, JM; Justice, R; Kane, RC; Liang, C; Morse, D; Pazdur, R; Saber, H; Sridhara, R; Tang, S; Williams, G | 1 |
| Bukowski, RM; Chevreau, C; Demkow, T; Desai, AA; Eisen, T; Escudier, B; Freeman, S; Gore, M; Hutson, TE; Negrier, S; Oudard, S; Rolland, F; Schwartz, B; Shan, M; Siebels, M; Simantov, R; Solska, E; Stadler, WM; Szczylik, C | 1 |
| Brugarolas, J | 1 |
| Kuzel, T; Lacouture, ME; Lai, SE | 1 |
| Dreicer, R | 1 |
| Creel, P; George, D; Speca, J; Yenser, S | 1 |
| Miller, K | 1 |
| McKeage, K; Wagstaff, AJ | 1 |
| Figlin, RA | 1 |
| Angevin, E; Armand, JP; Brendel, E; Chami, L; Escudier, B; Lamuraglia, M; Landreau, V; Lassau, N; Robert, C; Schwartz, B; Soria, JC; Zafarana, E | 1 |
| Michaelson, MD | 1 |
| Alexandrescu, DT; Dasanu, CA; Dutcher, J | 1 |
| Dudek, AZ; Mulamalla, K; Truskinovsky, AM | 1 |
| Amar, S; Tan, WW; Wu, KJ | 1 |
| Autran Gomez, AM; Di Silverio, F; Gentile, V; Gentilucci, A; Parente, U; Salciccia, S; Sciarra, A | 1 |
| Kruck, S; Kuczyk, M; Merseburger, AS | 1 |
| Linehan, WM; Novakovic, KR; Pinto, PA; Vira, MA | 1 |
| De Mulder, PH; Mulder, SF; van Spronsen, DJ | 1 |
| Brocheriou, I; Deray, G; Izzedine, H; Rixe, O | 1 |
| Bargetzi, M; Puric, E; Schönenberger, A; Sendi, P | 1 |
| Bukowski, R; Cella, D; Escudier, B; Gondek, K | 1 |
| Ernstoff, MS; George, DJ; Kasibhatla, M; Meyer, J; Steinberg, P | 1 |
| Di Lorenzo, G | 1 |
| Baz, RC; Bukowski, RM; Choueiri, TK; Elson, P; Garcia, JA; Golshayan, AR; Khasawneh, M; Rini, BI; Usman, S; Wood, L | 1 |
| Bracarda, S; Caserta, C; Crinò, L; Hamzay, A; Rossi, M; Sordini, L | 1 |
| Flaherty, KT; Stein, MN | 1 |
| Atkins, MB | 1 |
| Rini, BI; Unnithan, J | 1 |
| Atkins, MB; Goldberg, SN; Hakimé, A; Hines-Peralta, A; Peddi, H; Regan, M; Signoretti, S; Sukhatme, VP | 1 |
| Albers, P; Bergmann, L; Geschwend, JE; Jäger, E; Jakse, G; Marschner, N; Miller, K | 1 |
| Goldspiel, BR; Grandinetti, CA | 1 |
| Bodrogi, I | 1 |
| Gollob, JA; Grigson, G; Gu, L; Marino, CB; Miller, EK; Peterson, BL; Rathmell, WK; Richmond, TM; Watkins, C; Wright, JJ | 1 |
| Beer, TM; Crawford, ED; Drabkin, HA; Goldman, BH; Lara, PN; Lemmon, D; Mack, PC; Pan, CX; Ryan, CW; Tangen, CM | 1 |
| Buer, J; Hegele, A; Hofmann, R; Jeron, A; Olbert, P; Schrader, AJ | 1 |
| Raspollini, MR | 1 |
| George, D; Medioni, J; Motzer, R; Oudard, S | 1 |
| Billemont, B; Izzedine, H; Méric, JB; Rixe, O; Sultan-Amar, V; Taillade, L | 1 |
| Distelrath, A; Hoeffkes, HG; Hofmann, E; Ranze, O | 1 |
| Fiedler, W; Grünwald, V; Heinzer, H | 1 |
| Li, M; Srinivas, S | 1 |
| Bjelogrlic, SK; Radulovic, S | 1 |
| Akaza, H; Murai, M; Naito, S; Nakajima, K; Tsukamoto, T | 1 |
| Manchen, B; Wood, LS | 1 |
| Bukowski, R; Dreicer, R; Elson, P; Garcia, J; Ioachimescu, AG; Mekhail, T; Rini, BI; Tamaskar, I; Wood, L | 1 |
| Beldner, M; Burges, GE; Chaudhary, UB; Dewaay, D; Jacobson, M; Maize, JC | 1 |
| Albanell, J; Bellmunt, J; Climent, MA; González-Larriba, JL; López-Vivanco, G; Urruticoechea, L | 1 |
| Easson, AM; Eng, FC; Knox, JJ; Szentgyorgyi, E | 1 |
| Brozmanova, K; Mardiak, J; Mego, M; Obertova, J; Reckova, M; Sycova-Mila, Z | 1 |
| Bukowski, RM; Dreicer, R; Elson, P; Garcia, JA; Mekhail, T; Rini, BI; Tamaskar, I; Wood, L | 1 |
| Culine, S; Patard, JJ; Pouessel, D; Verhoest, G | 1 |
| Bhojani, N; Hutterer, G; Jeldres, C; Karakiewicz, PI; Oudard, S; Patard, JJ; Patenaude, F; Perrotte, P; Suardi, N | 1 |
| Chang, JW; Chang, YC; Chuang, CK; Hsieh, JJ; Kuo, TT; Lin, WC; Lin, YC; Pang, ST; Yang, CH | 1 |
| Bukowski, RM; Choueiri, TK; Elson, P; Escudier, B; Negrier, S; Oudard, S; Plantade, A; Ravaud, A; Rini, BI; Zhou, M | 1 |
| Flaherty, KT; Gallagher, ML; Heitjan, DF; O'Dwyer, PJ; Rosen, MA; Schnall, MD; Schwartz, B | 1 |
| Cohen, AF; Dubois, EA; Osanto, S; van Bronswijk, H | 1 |
| Miki, T; Mizuno, M; Mizutani, Y; Nakanishi, H; Yoshida, J | 1 |
| Allison, RR; Cavalieri, R; Finley, J; Gay, HA; Quan, WD | 1 |
| de Mulder, PH; Gietema, JA; Groenewegen, G; Haanen, JB; Jansen, RL; Kruit, WH; Mulders, PF; Osanto, S; Richel, DJ; Sleijfer, S; van den Eertwegh, AJ; Voest, EE | 1 |
| Berthold, DR; Chin, S; Knox, JJ; Moore, MJ; Riechelmann, RP; Tannock, IF; Wang, L | 1 |
| Godley, P; Rathmell, WK; Rini, BI | 1 |
| Athar, U; Gentile, TC | 1 |
| Avakian, R; Belldegrun, AS; Kabbinavar, FF; LaRochelle, JC; Pantuck, AJ; Patard, JJ; Riggs, SB; Shuch, B | 1 |
| Bajetta, E; Catena, L; Gevorgyan, A; Guadalupi, V; Mancin, M; Martinetti, A; Platania, M; Procopio, G; Pusceddu, S; Verzoni, E | 1 |
| Peters, NA; Richel, DJ; Stalpers, LJ; Verhoeff, JJ | 1 |
| Jonasch, E; Margulis, V; Matin, SF; Swanson, DA; Tamboli, P; Tannir, N; Wood, CG | 1 |
179 review(s) available for sorafenib and Kidney Neoplasms
| Article | Year |
|---|---|
Recent developments in small molecule therapies for renal cell carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Discovery; Humans; Kidney; Kidney Neoplasms; Molecular Targeted Therapy; Small Molecule Libraries | 2017 |
Sorafenib in Metastatic Papillary Thyroid Carcinoma with
Topics: Aged; Carcinoma, Hepatocellular; Humans; Iodine Radioisotopes; Kidney Neoplasms; Liquid Biopsy; Liver Neoplasms; Male; Mutation; Proto-Oncogene Proteins B-raf; Quality of Life; Sorafenib; Thyroid Cancer, Papillary; Thyroid Neoplasms | 2022 |
Optimizing targeted drug selection in combination therapy for patients with advanced or metastatic renal cell carcinoma: A systematic review and network meta-analysis of safety.
Topics: Antineoplastic Agents; Bayes Theorem; Carcinoma, Renal Cell; Everolimus; Humans; Kidney Neoplasms; Network Meta-Analysis; Phenylurea Compounds; Sorafenib; Vascular Endothelial Growth Factor A | 2023 |
Sorafenib exhibits lower toxicity and comparable efficacy to sunitinib as a first-line treatment for metastatic renal cell carcinoma: A systematic review and meta-analysis.
Topics: Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Neutropenia; Sorafenib; Sunitinib | 2023 |
Drug-Induced Hypertension Caused by Multikinase Inhibitors (Sorafenib, Sunitinib, Lenvatinib and Axitinib) in Renal Cell Carcinoma Treatment.
Topics: Axitinib; Carcinoma, Renal Cell; Humans; Hypertension; Kidney Neoplasms; Phenylurea Compounds; Quinolines; Sorafenib; Sunitinib | 2019 |
Optimizing treatment of renal cell carcinoma with VEGFR-TKIs: a comparison of clinical pharmacology and drug-drug interactions of anti-angiogenic drugs.
Topics: Angiogenesis Inhibitors; Anilides; Axitinib; Carcinoma, Renal Cell; Drug Interactions; Humans; Indazoles; Kidney Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Quinolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib | 2020 |
Comparative efficacy and safety of sunitinib vs sorafenib in renal cell carcinoma: A systematic review and meta-analysis.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Kidney Neoplasms; Proportional Hazards Models; Sorafenib; Sunitinib | 2020 |
Targeted therapy for metastatic renal cell carcinoma.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Immunological; Axitinib; Bevacizumab; Bias; Carcinoma, Renal Cell; Everolimus; Humans; Indazoles; Ipilimumab; Kidney Neoplasms; Phenylurea Compounds; Progression-Free Survival; Protein Kinase Inhibitors; Pyrimidines; Quality of Life; Quinolines; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sulfonamides; Sunitinib | 2020 |
New frontiers against sorafenib resistance in renal cell carcinoma: From molecular mechanisms to predictive biomarkers.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Renal Cell; Clinical Decision-Making; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Genomics; Humans; Kidney Neoplasms; Protein Kinase Inhibitors; Signal Transduction; Sorafenib; Treatment Outcome | 2021 |
[Interdisciplinary Recommendations for the Treatment of Metastatic Renal Cell Carcinoma].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Drug Administration Schedule; Drug Delivery Systems; Humans; Interdisciplinary Communication; Intersectoral Collaboration; Kidney Neoplasms; Neoplasm Metastasis; Retreatment; Sorafenib; Sunitinib; Survival Rate | 2017 |
Cabozantinib versus everolimus, nivolumab, axitinib, sorafenib and best supportive care: A network meta-analysis of progression-free survival and overall survival in second line treatment of advanced renal cell carcinoma.
Topics: Anilides; Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Renal Cell; Everolimus; Humans; Kidney Neoplasms; Neoplasm Staging; Niacinamide; Nivolumab; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Pyridines; Retreatment; Sorafenib; Treatment Outcome | 2017 |
Second-line systemic therapy in metastatic renal-cell carcinoma: A review.
Topics: Anilides; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Everolimus; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinolines; Sorafenib | 2017 |
The role of tivozanib in advanced renal cell carcinoma therapy.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Neoplasm Metastasis; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Sorafenib | 2018 |
The Effectiveness of Sorafenib over Other Targeted Agents in the Second-Line Treatment of Metastatic Renal Cell Carcinoma: a Meta-Analysis.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Molecular Targeted Therapy; Prognosis; Sorafenib | 2019 |
Adjuvant therapy after nephrectomy for renal cell carcinoma.
Topics: Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease-Free Survival; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Progression-Free Survival; Pyrimidines; Sorafenib; Sulfonamides; Sunitinib | 2018 |
Sorafenib: key lessons from over 10 years of experience.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Liver Neoplasms; Molecular Targeted Therapy; Sorafenib; Thyroid Neoplasms | 2019 |
A meta-analysis of efficacy and safety of sorafenib versus other targeted agents for metastatic renal cell carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Odds Ratio; Progression-Free Survival; Randomized Controlled Trials as Topic; Sorafenib; Treatment Outcome | 2019 |
Role and relevance of quality indicators in the selection of first-line treatment of patients with metastatic renal cell carcinoma: a position paper of the MeetURO Group.
Topics: Carcinoma, Renal Cell; Humans; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Quality of Life; Quinolines; Sorafenib; Sulfonamides; Sunitinib; Treatment Outcome | 2019 |
Skin cancer associated with the use of sorafenib and sunitinib for renal cell carcinoma.
Topics: Adult; Antineoplastic Agents; Carcinoma, Basal Cell; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Skin Neoplasms; Sorafenib; Sunitinib | 2013 |
Bisphosphonates and vascular endothelial growth factor-targeted drugs in the treatment of patients with renal cell carcinoma metastatic to bone.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Renal Cell; Diphosphonates; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A; Zoledronic Acid | 2013 |
Active targeted therapy for metastatic collecting duct carcinoma of the kidney: a case report and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carcinoma, Renal Cell; Disease Progression; Drug Delivery Systems; Fatal Outcome; Humans; Immunohistochemistry; Kidney Neoplasms; Kidney Tubules, Collecting; Lung Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Nephrectomy; Niacinamide; Phenylurea Compounds; Rare Diseases; Risk Assessment; Sorafenib; Tomography, X-Ray Computed | 2013 |
Molecular markers to predict response to therapy.
Topics: Antibodies, Monoclonal, Humanized; Antigens, Neoplasm; Bevacizumab; Biomarkers, Tumor; Carbonic Anhydrase IX; Carbonic Anhydrases; Carcinoma, Renal Cell; Gene Dosage; Humans; Immunotherapy; Indazoles; Indoles; Kidney Neoplasms; Mutation; Neoplastic Cells, Circulating; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Polymorphism, Genetic; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Von Hippel-Lindau Tumor Suppressor Protein | 2013 |
Small molecule targeted therapies for the second-line treatment for metastatic renal cell carcinoma: a systematic review and indirect comparison of safety and efficacy.
Topics: Antineoplastic Agents; Axitinib; Bayes Theorem; Carcinoma, Renal Cell; Everolimus; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyrimidines; Randomized Controlled Trials as Topic; Sirolimus; Sorafenib; Sulfonamides | 2013 |
Targeted therapies and complete responses in first line treatment of metastatic renal cell carcinoma. A meta-analysis of published trials.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; Humans; Indazoles; Indoles; Induction Chemotherapy; Interferons; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Prognosis; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Sorafenib; Sulfonamides; Sunitinib; Treatment Outcome | 2014 |
[Medical treatment of renal cell carcinoma].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Everolimus; Humans; Immunotherapy; Indoles; Interferon alpha-2; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Recombinant Proteins; Sirolimus; Societies, Medical; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2013 |
Advanced kidney cancer: treating the elderly.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Everolimus; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyrroles; Sirolimus; Sorafenib; Sunitinib | 2013 |
Axitinib for the treatment of advanced renal cell carcinoma.
Topics: Animals; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Survival Rate | 2014 |
Molecular marker for predicting treatment response in advanced renal cell carcinoma: does the promise fulfill clinical need?
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2014 |
Sorafenib in renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Receptors, Vascular Endothelial Growth Factor; Sorafenib | 2014 |
Treatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: an up-to-date review and meta-analysis of clinical trials.
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Fatigue; Humans; Incidence; Indazoles; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Risk; Sorafenib; Sulfonamides; Sunitinib | 2015 |
Incidence and risk of sorafenib-induced hypertension: a systematic review and meta-analysis.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Therapy; Humans; Hypertension; Incidence; Kidney Neoplasms; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Risk Factors; Sorafenib; Treatment Outcome | 2014 |
Comparing comparators: a look at control arms in kidney cancer studies over the years.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Interferon-alpha; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Sorafenib | 2015 |
A systematic review of the efficacy and safety experience reported for sorafenib in advanced renal cell carcinoma (RCC) in the post-approval setting.
Topics: Carcinoma, Renal Cell; Clinical Trials as Topic; Drug Approval; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Safety; Sorafenib | 2015 |
Efficacy and Safety of Sorafenib Therapy on Metastatic Renal Cell Carcinoma in Korean Patients: Results from a Retrospective Multicenter Study.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Kidney Neoplasms; Korea; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Retrospective Studies; Safety; Sorafenib; Treatment Outcome | 2015 |
[Systemic Treatment of Metastatic Renal Cell Cancer--Back to the Future?].
Topics: Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Disease Progression; Everolimus; Humans; Imidazoles; Immunotherapy; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Prognosis; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis | 2015 |
Real-World Effectiveness of Everolimus Subsequent to Different First Targeted Therapies for the Treatment of Metastatic Renal Cell Carcinoma: Synthesis of Retrospective Chart Reviews.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Everolimus; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Pyrimidines; Pyrroles; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis; Treatment Outcome | 2016 |
Efficacy and Safety of Selective Vascular Endothelial Growth Factor Receptor Inhibitors Compared with Sorafenib for Metastatic Renal Cell Carcinoma: a Meta-analysis of Randomised Controlled Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Axitinib; Benzimidazoles; Carcinoma, Renal Cell; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Quinolines; Quinolones; Randomized Controlled Trials as Topic; Sorafenib; Survival Rate; Vascular Endothelial Growth Factor A | 2016 |
Is there still a role for sorafenib in metastatic renal cell carcinoma? A systematic review and meta-analysis of the effectiveness of sorafenib over other targeted agents.
Topics: Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Sorafenib | 2016 |
A decade of pharmacogenomics research on tyrosine kinase inhibitors in metastatic renal cell cancer: a systematic review.
Topics: Antineoplastic Agents; Biomarkers, Pharmacological; Carcinoma, Renal Cell; Gene Expression; Humans; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Pharmacogenetics; Phenylurea Compounds; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2016 |
First-line therapy for treatment-naive patients with advanced/metastatic renal cell carcinoma: a systematic review of published randomized controlled trials.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Humans; Imidazoles; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Quality of Life; Quinazolines; Quinolines; Randomized Controlled Trials as Topic; Sirolimus; Sorafenib; Sulfonamides; Sunitinib | 2016 |
Outcome and Safety of Sorafenib in Metastatic Renal Cell Carcinoma Dialysis Patients: A Systematic Review.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Renal Dialysis; Sorafenib; Survival Analysis; Treatment Outcome | 2016 |
Systemic adjuvant therapy for renal cell carcinoma: Any hope for future clinical trials?
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Clinical Trials as Topic; Disease-Free Survival; Forecasting; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib | 2016 |
[Side effect management of tyrosine kinase inhibitors in urology : Fatigue and hypothyroidism].
Topics: Anilides; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Disease Progression; Enzyme Inhibitors; Fatigue; Humans; Hypothyroidism; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quality of Life; Sorafenib; Sulfonamides; Sunitinib | 2016 |
Upper tract urothelial carcinoma topical issue 2016: treatment of metastatic cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Immunotherapy; Indoles; Kidney Neoplasms; Kidney Pelvis; Niacinamide; Paclitaxel; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Taxoids; Ureteral Neoplasms | 2017 |
Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy.
Topics: Anilides; Antibodies, Monoclonal; Antineoplastic Agents; Axitinib; Bevacizumab; Biomarkers, Tumor; Carcinoma, Renal Cell; DNA-Binding Proteins; Everolimus; Gene Expression Regulation, Neoplastic; Histone-Lysine N-Methyltransferase; Humans; Imidazoles; Immunologic Factors; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; MicroRNAs; Molecular Targeted Therapy; Mutation; Niacinamide; Nivolumab; Nuclear Proteins; Phenylurea Compounds; Precision Medicine; Prognosis; Pyridines; Pyrimidines; Pyrroles; Quinolines; Receptors, CCR4; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Transcription Factors; Tumor Suppressor Proteins; Ubiquitin Thiolesterase; Vascular Endothelial Growth Factor A; Von Hippel-Lindau Tumor Suppressor Protein | 2016 |
A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma.
Topics: Anilides; Antineoplastic Agents; Axitinib; Benzimidazoles; Bevacizumab; Carcinoma, Renal Cell; Comparative Effectiveness Research; Disease-Free Survival; Erlotinib Hydrochloride; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Interferons; Interleukin-2; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Pyrrolidinones; Quinolines; Quinolones; Sirolimus; Sorafenib; Sulfonamides; Sunitinib | 2017 |
Impact of targeted therapies in metastatic renal cell carcinoma on patient-reported outcomes: Methodology of clinical trials and clinical benefit.
Topics: Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Quality of Life; Randomized Controlled Trials as Topic; Sirolimus; Sorafenib; Treatment Outcome | 2017 |
Efficacy of sequential therapies with sorafenib-sunitinib versus sunitinib-sorafenib in metastatic renal cell carcinoma: A systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2017 |
Targeted Therapy for Metastatic Renal Cell Carcinoma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Everolimus; Humans; Imidazoles; Immunologic Factors; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sulfonamides; Sunitinib | 2016 |
Long-term Treatment With Sequential Molecular Targeted Therapy for Xp11.2 Translocation Renal Cell Carcinoma: A Case Report and Review of the Literature.
Topics: Adult; Age of Onset; Antineoplastic Agents; Axitinib; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Carcinoma, Renal Cell; Catheter Ablation; Child; Combined Modality Therapy; Everolimus; Fatal Outcome; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Molecular Targeted Therapy; Niacinamide; Oncogene Fusion; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Translocation, Genetic; Young Adult | 2017 |
[Value of targeted therapies for renal cell cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Disease Progression; Drug Delivery Systems; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Indoles; Kidney Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Sirolimus; Sorafenib; Sunitinib; Survival Rate | 2008 |
An update on the medical therapy of advanced metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; raf Kinases; Severity of Illness Index; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome | 2008 |
Targeted therapy in renal cell carcinoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2008 |
New therapies in renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2007 |
[Molecular basis of targeted therapy in metastatic renal cancer].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Drug Delivery Systems; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Signal Transduction; Sirolimus; Sorafenib; Sunitinib; Von Hippel-Lindau Tumor Suppressor Protein | 2008 |
[Molecular targeted therapy for renal cell carcinoma].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Gene Targeting; Humans; Indoles; Kidney Neoplasms; Niacinamide; Oncogene Protein v-akt; Phenylurea Compounds; Protein Kinases; Pyridines; Pyrroles; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A; Von Hippel-Lindau Tumor Suppressor Protein | 2008 |
Exploring the role of novel agents in the treatment of renal cell carcinoma.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Delivery Systems; Female; Humans; Indoles; Kidney Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Nephrectomy; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Survival Analysis; Treatment Outcome | 2008 |
Novel drugs for renal cell carcinoma.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sulfonamides; Sunitinib | 2008 |
Recent advances in the treatment of renal cell carcinoma and the role of targeted therapies.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib | 2008 |
Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Humans; Indoles; Interferon alpha-2; Interferon-alpha; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Recombinant Proteins; Sirolimus; Sorafenib; Sunitinib | 2008 |
Systemic therapy for metastatic renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Cytotoxins; Disease-Free Survival; Drug Therapy, Combination; Everolimus; Humans; Immunosuppressive Agents; Immunotherapy; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Kinases; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Sirolimus; Sorafenib; Stem Cell Transplantation; Sunitinib; TOR Serine-Threonine Kinases; Transplantation, Homologous | 2008 |
Metastatic renal cell cancer treatments: an indirect comparison meta-analysis.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Sirolimus; Sorafenib; Sunitinib | 2009 |
Recent advances in the systemic treatment of metastatic papillary renal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Papillary; Carcinoma, Renal Cell; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Humans; Indoles; Kidney Neoplasms; Neoadjuvant Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Kinases; Pyridines; Pyrroles; Quinazolines; Randomized Controlled Trials as Topic; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases | 2009 |
Recent advances in molecular targeted therapy for metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib | 2009 |
[Targeted therapies and their indications in solid neoplasias].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Gefitinib; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Receptor, ErbB-2; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2009 |
Response to sorafenib after sunitinib-induced acute heart failure in a patient with metastatic renal cell carcinoma: case report and review of the literature.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Case-Control Studies; Female; Heart Failure; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2009 |
Targeted therapies in metastatic renal cancer in 2009.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factors | 2009 |
Vascular endothelial growth factor-targeted therapy in metastatic renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A | 2009 |
Prognostic markers and new, innovative treatments in renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Cancer Vaccines; Carcinoma, Renal Cell; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2009 |
Sorafenib tosylate in advanced kidney cancer: past, present and future.
Topics: Antineoplastic Agents; Benzenesulfonates; Clinical Trials as Topic; Disease-Free Survival; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2009 |
Management of sorafenib, sunitinib, and temsirolimus toxicity in metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Drug-Related Side Effects and Adverse Reactions; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Practice Guidelines as Topic; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib | 2009 |
Cytoreductive nephrectomy for metastatic RCC in the era of targeted therapy.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Combined Modality Therapy; Drug Delivery Systems; Humans; Indoles; Kidney Neoplasms; Nephrectomy; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Sorafenib; Sunitinib | 2009 |
[Sorafenib(Nexavar)].
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2009 |
[Interferon alpha and half-dose sorafenib is an effective treatment modality for interferon alpha-resistant metastatic renal cell carcinoma: a case report].
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Humans; Immunologic Factors; Interferon-alpha; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2009 |
Quality of life in patients with metastatic renal cell carcinoma: the importance of patient-reported outcomes.
Topics: Antineoplastic Agents; Axitinib; Benzenesulfonates; Carcinoma, Renal Cell; Everolimus; Health Status; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Niacinamide; Patient Satisfaction; Phenylurea Compounds; Pyridines; Pyrroles; Quality of Life; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome | 2009 |
Sorafenib reveals efficacy in sequential treatment of metastatic renal cell cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Drug Delivery Systems; Drug Resistance, Neoplasm; Humans; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2009 |
Metastatic renal cell carcinoma: current standards of care.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Combined Modality Therapy; Everolimus; Humans; Indoles; Interleukin-2; Kidney Neoplasms; Neoplasm Metastasis; Nephrectomy; Niacinamide; Oncology Nursing; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib | 2009 |
Management of vascular endothelial growth factor and multikinase inhibitor side effects.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Diarrhea; Drug Eruptions; Drug Monitoring; Fatigue; Humans; Indoles; Interleukin-2; Intracellular Signaling Peptides and Proteins; Kidney Neoplasms; Male; Niacinamide; Oncology Nursing; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyridines; Pyrroles; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2009 |
Sorafenib therapy for metastatic renal carcinoma in patients with low cardiac ejection fraction: report of two cases and literature review.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Heart Diseases; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Stroke Volume | 2010 |
Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Cost-Benefit Analysis; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib | 2010 |
Sorafenib.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Receptors, Vascular Endothelial Growth Factor; Sorafenib | 2010 |
Toxicity of sorafenib: clinical and molecular aspects.
Topics: Animals; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Exanthema; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; raf Kinases; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib | 2010 |
Progress in the management of advanced renal cell carcinoma (RCC).
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Cell Transformation, Neoplastic; Everolimus; Humans; Indoles; Kidney Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Von Hippel-Lindau Tumor Suppressor Protein | 2010 |
[Current aspects of second-line and sequence therapy of metastatic renal cell carcinoma].
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cytokines; Disease Progression; Drug Administration Schedule; Drug Delivery Systems; Drugs, Investigational; Everolimus; Evidence-Based Medicine; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Practice Guidelines as Topic; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Survival Rate | 2010 |
Update on systemic therapies of metastatic renal cell carcinoma.
Topics: Algorithms; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Biopsy, Needle; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Delivery Systems; Everolimus; Female; Follow-Up Studies; Humans; Immunohistochemistry; Indoles; Interferon-alpha; Kidney Neoplasms; Male; Maximum Tolerated Dose; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Risk Assessment; Sirolimus; Sorafenib; Sunitinib; Survival Analysis | 2010 |
[Use of sorafenib in patients with hepatocellular or renal carcinoma].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Clinical Trials as Topic; Diarrhea; Fatigue; Foot Dermatoses; Hand Dermatoses; Humans; Hypertension; Kidney Neoplasms; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome | 2010 |
[Treatment of locally advanced renal tumors].
Topics: Adrenalectomy; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Humans; Indoles; Intracellular Signaling Peptides and Proteins; Kidney Neoplasms; Lymph Node Excision; Neoadjuvant Therapy; Neoplasm Proteins; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases | 2010 |
[Angiogenesis inhibition: review of the activity of sorafenib, sunitinib and bevacizumab].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2010 |
Sunitinib, sorafenib, temsirolimus or bevacizumab in the treatment of metastatic renal cell carcinoma: a review of health economic evaluations.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Cost-Benefit Analysis; Humans; Indoles; Kidney Neoplasms; Markov Chains; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quality-Adjusted Life Years; Sirolimus; Sorafenib; Sunitinib | 2010 |
Treatment of metastatic renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Combined Modality Therapy; Humans; Interferons; Interleukin-2; Kidney Neoplasms; Nephrectomy; Niacinamide; Phenylurea Compounds; Pyridines; Sirolimus; Sorafenib | 2010 |
Expert opinion on the use of first-line sorafenib in selected metastatic renal cell carcinoma patients.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2010 |
Present state of target therapy for disseminated renal cell carcinoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Combined Modality Therapy; Everolimus; Humans; Indoles; Kidney Neoplasms; Nephrectomy; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib | 2010 |
[Molecular targeted therapy for renal cell carcinoma and other urological cancers].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quality of Life; Sorafenib; Sunitinib; Urologic Neoplasms | 2010 |
A new patient-focused approach to the treatment of metastatic renal cell carcinoma: establishing customized treatment options.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Designer Drugs; Humans; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Patient-Centered Care; Phenylurea Compounds; Pyridines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Treatment Outcome | 2011 |
The therapy of kidney cancer with biomolecular drugs.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Biomarkers, Tumor; Carcinoma, Renal Cell; Disease-Free Survival; Everolimus; Humans; Immunotherapy; Indazoles; Interferons; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrimidines; Sirolimus; Sorafenib; Sulfonamides; TOR Serine-Threonine Kinases | 2010 |
Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Combined Modality Therapy; Disease-Free Survival; Everolimus; Humans; Immunotherapy; Indoles; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome | 2011 |
Beyond traditional outcomes: improving quality of life in patients with renal cell carcinoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Everolimus; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quality of Life; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome | 2011 |
Treatment-associated adverse event management in the advanced renal cell carcinoma patient treated with targeted therapies.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Everolimus; Humans; Immunotherapy; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2011 |
Sorafenib in renal cell carcinoma.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Kidney; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Sorafenib | 2011 |
[Novelties in the treatment for advanced renal-cell cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Everolimus; Humans; Indazoles; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2011 |
Treatment of metastatic renal cell carcinoma and renal pelvic cancer.
Topics: Benzenesulfonates; Carcinoma, Renal Cell; Cisplatin; Deoxycytidine; Everolimus; Gemcitabine; Humans; Indoles; Kidney Neoplasms; Kidney Pelvis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib | 2011 |
[Treatment of metastatic renal cell carcinoma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Humans; Immunotherapy; Indazoles; Indoles; Interferons; Interleukin-2; Kidney Neoplasms; Neoplasm Metastasis; Nephrectomy; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sulfonamides; Sunitinib | 2011 |
Strategies for assessing and managing the adverse events of sorafenib and other targeted therapies in the treatment of renal cell and hepatocellular carcinoma: recommendations from a European nursing task group.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Diarrhea; Drug Eruptions; Europe; Fatigue; Foot Dermatoses; Hand Dermatoses; Humans; Kidney Neoplasms; Liver Neoplasms; Molecular Targeted Therapy; Mucositis; Niacinamide; Nursing Assessment; Phenylurea Compounds; Practice Guidelines as Topic; Pyridines; Randomized Controlled Trials as Topic; Societies, Nursing; Sorafenib | 2012 |
Multikinase inhibitors in metastatic renal cell carcinoma: indirect comparison meta-analysis.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib | 2011 |
Sorafenib for the management of advanced renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Delivery Systems; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2011 |
Vascular endothelial growth factor-targeted therapies in advanced renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Kidney Neoplasms; Models, Biological; Niacinamide; Phenylurea Compounds; Pyridines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Vascular Endothelial Growth Factor A | 2011 |
Systemic therapy for metastatic non-clear-cell renal cell carcinoma: recent progress and future directions.
Topics: Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; Treatment Outcome | 2011 |
[Renal carcinoma and fatigue: which challenge in the era of antiangiogenic drugs?].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Fatigue; Humans; Indazoles; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Sorafenib; Sulfonamides; Sunitinib | 2011 |
Early detection, prevention and management of cutaneous adverse events due to sorafenib: recommendations from the Sorafenib Working Group.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Disease Management; Exanthema; Humans; Keratoacanthoma; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pruritus; Pyridines; Severity of Illness Index; Skin; Sorafenib | 2012 |
[Systemic treatment of renal cell carcinoma - recent update].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease-Free Survival; Evidence-Based Medicine; Humans; Indazoles; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Staging; Nephrectomy; Niacinamide; Palliative Care; Phenylurea Compounds; Practice Guidelines as Topic; Prognosis; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib | 2011 |
[Role of mitogen-activated protein kinase (MAPK) in the sporadic renal cell carcinoma].
Topics: Antigens, Neoplasm; Antineoplastic Agents; Benzenesulfonates; Carbonic Anhydrase IX; Carbonic Anhydrases; Carcinoma, Renal Cell; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; Enzyme Activation; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Kidney Neoplasms; MAP Kinase Signaling System; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Pyridines; Radiation Tolerance; Sorafenib; Von Hippel-Lindau Tumor Suppressor Protein | 2012 |
Tyrosine kinase inhibitors for metastatic renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Costs; Humans; Indazoles; Indoles; Kidney Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Practice Guidelines as Topic; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A | 2011 |
[Myocardial metastasis from renal cell carcinoma treated with sorafenib].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Heart Neoplasms; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2011 |
VEGF pathway-targeted therapy for advanced renal cell carcinoma: a meta-analysis of randomized controlled trials.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Humans; Indoles; Interferons; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyrroles; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2011 |
Targeted therapies for renal cell carcinoma: review of adverse event management strategies.
Topics: Anorexia; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Cardiovascular System; Drug Eruptions; Europe; Everolimus; Evidence-Based Medicine; Gastrointestinal Tract; Humans; Hypothyroidism; Indazoles; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pneumonia; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A; Weight Loss; Wound Healing | 2012 |
Sorafenib for the treatment of renal cancer.
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Evidence-Based Medicine; Humans; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Precision Medicine; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Sorafenib; Time Factors; Treatment Outcome | 2012 |
Targeted therapeutic strategies for the management of renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Disease-Free Survival; Female; Humans; Indazoles; Kidney Neoplasms; Male; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Sorafenib; Sulfonamides; Tuberous Sclerosis; United States | 2012 |
[First-line therapy of advanced or metastasized renal cell cancer: open randomized phase III sequence study to examine the effectiveness and tolerance of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the first-line treatment of
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indazoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Sorafenib; Sulfonamides | 2012 |
Neoadjuvant therapy of renal cell carcinoma: a novel treatment option in the era of targeted therapy?
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Vena Cava, Inferior | 2012 |
Hypothyroidism during treatment with tyrosine kinase inhibitors.
Topics: Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Gastrointestinal Neoplasms; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Neoplasm Metastasis; Neoplasms; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Thyroid Diseases; Thyroid Function Tests; Thyroid Gland; Thyroid Neoplasms | 2012 |
[Role of VEGFR-TKIs in the treatment of renal cell carcinoma].
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib | 2012 |
Probability of downsizing primary tumors of renal cell carcinoma by targeted therapies is related to size at presentation.
Topics: Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Neoadjuvant Therapy; Niacinamide; Phenylurea Compounds; Probability; Protein Kinase Inhibitors; Pyrroles; Sorafenib; Sunitinib; Tumor Burden | 2013 |
Second-line treatments for the management of advanced renal cell carcinoma: systematic review and meta-analysis.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Bayes Theorem; Carcinoma, Renal Cell; Disease Progression; Disease-Free Survival; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyrimidines; Randomized Controlled Trials as Topic; Sorafenib; Sulfonamides; Treatment Outcome; Young Adult | 2013 |
Management of metastatic renal cell carcinoma progressed after sunitinib or another antiangiogenic treatment.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Treatment Failure; Vascular Endothelial Growth Factor Receptor-2 | 2014 |
Comprehensive overview of the efficacy and safety of sorafenib in advanced or metastatic renal cell carcinoma after a first tyrosine kinase inhibitor.
Topics: Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Salvage Therapy; Sorafenib; Survival Rate; Treatment Outcome | 2013 |
Novel kinase inhibitors in renal cell carcinoma: progressive development of static agents.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Enzyme Inhibitors; ErbB Receptors; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2005 |
Therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: biology, clinical results and future development.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2005 |
Promising systemic therapy for renal cell carcinoma.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Drug Administration Schedule; Epothilones; Erlotinib Hydrochloride; Humans; Indoles; Kidney Neoplasms; Lenalidomide; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thalidomide | 2005 |
Novel agents for the treatment of advanced kidney cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Clinical Trials as Topic; Epothilones; Gefitinib; Humans; Indoles; Kidney Neoplasms; Lenalidomide; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thalidomide | 2004 |
Sorafenib: scientific rationales for single-agent and combination therapy in clear-cell renal cell carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; ErbB Receptors; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-sis; Pyridines; Signal Transduction; Sorafenib; Transforming Growth Factor alpha; Vascular Endothelial Growth Factor A; Von Hippel-Lindau Tumor Suppressor Protein | 2005 |
Targeted therapy for metastatic renal cell carcinoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Enzyme Inhibitors; Humans; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2006 |
Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Kidney Neoplasms; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Receptors, Vascular Endothelial Growth Factor; Sarcoma; Sorafenib | 2005 |
[Progress in therapeutic strategy for renal cell carcinoma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Catheter Ablation; Combined Modality Therapy; Female; Humans; Imidazoles; Indazoles; Indoles; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Male; Minimally Invasive Surgical Procedures; Nephrectomy; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib | 2006 |
Sorafenib.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Drug Administration Schedule; Humans; Kidney Neoplasms; Liver Neoplasms; Melanoma; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; raf Kinases; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Treatment Outcome; Xenograft Model Antitumor Assays | 2006 |
VEGF-targeted therapy in renal cell carcinoma: active drugs and active choices.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; ErbB Receptors; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Platelet-Derived Growth Factor; Pyridines; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A; Von Hippel-Lindau Tumor Suppressor Protein | 2006 |
Molecule of the month. Sorafenib.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Randomized Controlled Trials as Topic; Sorafenib | 2006 |
Sorafenib: recent update on activity as a single agent and in combination with interferon-alpha2 in patients with advanced-stage renal cell carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Interferon alpha-2; Interferon-alpha; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Recombinant Proteins; Sorafenib; Survival Rate; Treatment Outcome | 2006 |
Emerging efficacy endpoints for targeted therapies in advanced renal cell carcinoma.
Topics: Antimetabolites, Antineoplastic; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease Progression; Drug Delivery Systems; Endpoint Determination; Floxuridine; Fluorouracil; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Risk; Sorafenib; Survival Analysis; Treatment Outcome | 2006 |
Molecular targeting therapy for renal cell carcinoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sunitinib | 2006 |
New treatment approaches in metastatic renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Erlotinib Hydrochloride; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sulfonamides; Sunitinib | 2006 |
Multitargeted agents for therapeutically challenging tumor: an introduction for oncology nurses.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Delivery Systems; Drug Monitoring; Gastrointestinal Stromal Tumors; Humans; Indoles; Kidney Neoplasms; Niacinamide; Nurse's Role; Nursing Assessment; Oncology Nursing; Patient Education as Topic; Phenylurea Compounds; Pyridines; Pyrroles; Signal Transduction; Sorafenib; Sunitinib | 2006 |
Sorafenib.
Topics: Antineoplastic Agents; Benzenesulfonates; Clinical Trials as Topic; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Receptors, Vascular Endothelial Growth Factor; Sorafenib | 2006 |
Discovery and development of sorafenib: a multikinase inhibitor for treating cancer.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Combinatorial Chemistry Techniques; Drug Design; Humans; Kidney Neoplasms; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; raf Kinases; Receptors, Vascular Endothelial Growth Factor; Sorafenib | 2006 |
[Managing the side effects of angiogenetic inhibitors in metastatic renal cell carcinoma].
Topics: Adult; Angiogenesis Inhibitors; Benzenesulfonates; Carcinoma, Renal Cell; Drug Eruptions; Female; Gastrointestinal Diseases; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2006 |
Molecular biology of renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Exons; Humans; Indoles; Kidney Neoplasms; Molecular Biology; Mutation; Niacinamide; Phenylurea Compounds; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Pyridines; Pyrroles; raf Kinases; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sirolimus; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A; von Hippel-Lindau Disease | 2006 |
New weapons to snuff out kidney cancer.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Immunotherapy; Indoles; Kidney Neoplasms; Nephrectomy; Niacinamide; Phenylurea Compounds; Postoperative Care; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2006 |
Targeted therapy for metastatic renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Sirolimus; Sorafenib; Sunitinib; Von Hippel-Lindau Tumor Suppressor Protein | 2006 |
Molecularly targeted therapy in renal cell carcinoma: where do we go from here?
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Case Management; Clinical Trials as Topic; Combined Modality Therapy; Cytokines; Humans; Indoles; Kidney Neoplasms; Neovascularization, Pathologic; Nephrectomy; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2006 |
Targeted therapies in metastatic renal cell carcinoma: the light at the end of the tunnel.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Drug Delivery Systems; Drug Therapy, Combination; Forecasting; Humans; Immunologic Factors; Immunotherapy; Indoles; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Kinases; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases | 2006 |
Targeting von Hippel-Lindau pathway in renal cell carcinoma.
Topics: Benzenesulfonates; Biomedical Research; Carcinoma, Renal Cell; Enzyme Inhibitors; Everolimus; Humans; Indoles; Kidney Neoplasms; Models, Biological; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Signal Transduction; Sirolimus; Sorafenib; Sunitinib; Von Hippel-Lindau Tumor Suppressor Protein | 2006 |
Sorafenib for the treatment of advanced renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; Double-Blind Method; Drug Evaluation; Humans; Kidney Neoplasms; Models, Biological; Niacinamide; Phenylurea Compounds; Placebos; Pyridines; Randomized Controlled Trials as Topic; Sorafenib; United States; United States Food and Drug Administration | 2006 |
Tyrosine kinase inhibitors compared with cytokine therapy for metastatic renal cell carcinoma: overview of recent clinical trials differentiating clinical response and adverse effects.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cytokines; Humans; Indoles; Interferons; Interleukin-2; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2006 |
Improving outcomes with novel therapies for patients with newly diagnosed renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Indoles; Kidney Neoplasms; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2006 |
Sorafenib in renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Disease Progression; Disease-Free Survival; Humans; Kidney Neoplasms; Models, Biological; Niacinamide; Phenylurea Compounds; Pyridines; Receptors, Vascular Endothelial Growth Factor; Research Design; Sorafenib; Time Factors | 2007 |
Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Indoles; Kidney Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2007 |
Sorafenib: in advanced renal cancer.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Cell Proliferation; Humans; Kidney Neoplasms; MAP Kinase Signaling System; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Randomized Controlled Trials as Topic; Receptor Protein-Tyrosine Kinases; Sorafenib | 2007 |
[Efficacy of multikinase inhibitors in the treatment of advanced renal cell cancer. A snapshot].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cytokines; Drug Approval; Humans; Indoles; Kidney Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2007 |
Genetic basis of kidney cancer: a model for developing molecular-targeted therapies.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Leiomyomatosis; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; von Hippel-Lindau Disease | 2007 |
Sorafenib: delivering a targeted drug to the right targets.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Clinical Trials as Topic; Disease-Free Survival; Humans; Kidney Neoplasms; Liver Neoplasms; Melanoma; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Receptors, Vascular Endothelial Growth Factor; Skin Neoplasms; Sorafenib | 2007 |
[Clinical results of Nexavar for the treatment of kidney cancer].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; raf Kinases; Receptors, Vascular Endothelial Growth Factor; Sorafenib | 2007 |
Protein kinase inhibitors in the treatment of renal cell carcinoma: sorafenib.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Double-Blind Method; Drug Evaluation; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Randomized Controlled Trials as Topic; Sorafenib | 2007 |
CCR drug updates: sorafenib and sunitinib in renal cell carcinoma.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2007 |
The effect of recent drug approvals on translational research and drug development.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Biomedical Research; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Approval; Drug Resistance, Neoplasm; Humans; Indoles; Kidney Neoplasms; MAP Kinase Signaling System; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sorafenib; Sunitinib; United States; United States Food and Drug Administration | 2007 |
The role of targeted therapy in metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Drug Delivery Systems; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sirolimus; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2007 |
Sorafenib and sunitinib: novel targeted therapies for renal cell cancer.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Drug Delivery Systems; Drug Interactions; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Receptors, Growth Factor; Sorafenib; Sunitinib | 2007 |
[Effect of angiogenesis inhibitors on renal cell carcinoma].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinases; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sunitinib; Survival Analysis; TOR Serine-Threonine Kinases; Treatment Outcome; Vascular Endothelial Growth Factor A | 2007 |
Treatment options in renal cell carcinoma: past, present and future.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Cytokines; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib | 2007 |
[Angiogenesis and renal cell carcinoma].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Drug Resistance, Neoplasm; Humans; Hypertension; Indoles; Kidney Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Proteinuria; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Sorafenib; Sunitinib; Vascular Endothelial Growth Factors | 2007 |
Managing side effects of angiogenesis inhibitors in renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Practice Guidelines as Topic; Practice Patterns, Physicians'; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2007 |
Safety and tolerability of sorafenib in clear-cell renal cell carcinoma: a Phase III overview.
Topics: Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2007 |
Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
Topics: Angiogenesis Inhibitors; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Renal Cell; Drug Resistance, Neoplasm; Everolimus; Humans; Indoles; Kidney Neoplasms; Niacinamide; Patient Selection; Phenylurea Compounds; Practice Guidelines as Topic; Protein Kinase Inhibitors; Protein Kinases; Pyridines; Pyrroles; Receptor, Platelet-Derived Growth Factor beta; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Treatment Outcome | 2007 |
Sorafenib: a promising new targeted therapy for renal cell carcinoma.
Topics: Administration, Oral; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Diarrhea; Drug Delivery Systems; Drug Eruptions; Drug Interactions; Drug Monitoring; Fatigue; Humans; Hypertension; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Nurse's Role; Nursing Assessment; Oncology Nursing; Patient Compliance; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyridines; Risk Factors; Social Support; Sorafenib; Survival Rate; Treatment Outcome | 2007 |
[Angiogenesis targeting in renal carcinomas].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sunitinib | 2007 |
[Renal cell carcinoma and antiangiogenic therapies].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Humans; Indoles; Kidney Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2008 |
Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sunitinib | 2008 |
[Molecular targeted therapy for renal cell carcinoma].
Topics: Antineoplastic Agents; Apoptosis Regulatory Proteins; Benzenesulfonates; Carcinoma, Renal Cell; Drug Delivery Systems; Humans; Indoles; Interferon-beta; Intracellular Signaling Peptides and Proteins; Kidney Neoplasms; Liposomes; Mitochondrial Proteins; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib | 2008 |
[Angiogenesis inhibitors for the systemic treatment of metastatic renal cell carcinoma: sunitinib, sorafenib, bevacizumab and temsirolimus].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Immunotherapy; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Signal Transduction; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome | 2008 |
Renal cell carcinoma.
Topics: Algorithms; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Mutation; Niacinamide; Nomograms; Phenylurea Compounds; Prognosis; Pyridines; Sirolimus; Sorafenib; Vascular Endothelial Growth Factor A; von Hippel-Lindau Disease | 2008 |
Treatment options for metastatic renal cell carcinoma: a review.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Graft vs Host Disease; Humans; Immunologic Factors; Indoles; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Risk Assessment; Signal Transduction; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome | 2008 |
137 trial(s) available for sorafenib and Kidney Neoplasms
| Article | Year |
|---|---|
Adjuvant therapy in patients with sarcomatoid renal cell carcinoma: post hoc analysis from Eastern Cooperative Oncology Group-American College of Radiology Imaging Network (ECOG-ACRIN) E2805.
Topics: Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Disease-Free Survival; Humans; Kidney Neoplasms; Radiology; Sorafenib; Sunitinib | 2022 |
External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase III Trial of Adjuvant Sorafenib in Renal Cell Cancer.
Topics: Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Nephrectomy; Prognosis; Recurrence; Sorafenib | 2022 |
Temporal Characteristics of Adverse Events of Tivozanib and Sorafenib in Previously Treated Kidney Cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; Vascular Endothelial Growth Factor A | 2022 |
Tivozanib in Patients with Advanced Renal Cell Carcinoma Previously Treated With Axitinib: Subgroup Analysis from TIVO-3.
Topics: Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Phenylurea Compounds; Sorafenib | 2023 |
Cardiovascular Implications of Vascular Endothelial Growth Factor Inhibition Among Adolescents/Young Adults in ECOG-ACRIN E2805.
Topics: Adolescent; Cardiovascular Diseases; Female; Humans; Hypertension; Kidney Neoplasms; Retrospective Studies; Sorafenib; Stroke Volume; Sunitinib; Vascular Endothelial Growth Factor A; Ventricular Function, Left; Young Adult | 2023 |
Expression of PBRM1 as a prognostic predictor in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitor.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; DNA-Binding Proteins; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Prognosis; Progression-Free Survival; Proportional Hazards Models; Protein Kinase Inhibitors; Sorafenib; Sunitinib; Transcription Factors; Treatment Outcome | 2020 |
Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Female; Follow-Up Studies; Humans; Kidney Neoplasms; Male; Middle Aged; Phenylurea Compounds; Prognosis; Quinolines; Research Design; Sorafenib; Survival Rate | 2020 |
Sunitinib Versus Sorafenib as Initial Targeted Therapy for mCC-RCC With Favorable/Intermediate Risk: Multicenter Randomized Trial CROSS-J-RCC.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Female; Follow-Up Studies; Humans; Kidney Neoplasms; Male; Middle Aged; Prognosis; Sorafenib; Sunitinib; Survival Rate | 2020 |
Final Overall Survival Results from a Phase 3 Study to Compare Tivozanib to Sorafenib as Third- or Fourth-line Therapy in Subjects with Metastatic Renal Cell Carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Kidney Neoplasms; Male; Phenylurea Compounds; Quinolines; Retreatment; Sorafenib; Survival Rate | 2020 |
Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup Trial.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Placebos; Protein Kinase Inhibitors; Risk Factors; Sorafenib; Survival Rate | 2020 |
Radical metastasectomy followed by sorafenib versus observation in patients withclear cell renal cell carcinoma: extended follow -up of efficacy results from the randomized phase II RESORT trial.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Follow-Up Studies; Humans; Kidney Neoplasms; Metastasectomy; Neoplasm Recurrence, Local; Probability; Sorafenib | 2021 |
Q-TWiST Analysis of Tivozanib Versus Sorafenib in Patients With Advanced Renal Cell Carcinoma in the TIVO-3 Study.
Topics: Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Neoplasm Recurrence, Local; Phenylurea Compounds; Quinolines; Sorafenib | 2021 |
High fat mass associates with occurrence of targeted therapy-induced left ventricular ejection fraction reduction in patients with renal cell carcinoma.
Topics: Adipose Tissue; Antineoplastic Agents; Body Composition; Carcinoma, Renal Cell; Drug Delivery Systems; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Sorafenib; Sunitinib; Tomography, X-Ray Computed; Ventricular Function, Left | 2018 |
Early response of C-reactive protein as a predictor of survival in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; C-Reactive Protein; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2017 |
Validation of a new prognostic model to easily predict outcome in renal cell carcinoma: the GRANT score applied to the ASSURE trial population.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Female; Follow-Up Studies; Health Status Indicators; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Prognosis; Prospective Studies; Pyrroles; Risk Factors; Sorafenib; Sunitinib; Survival Rate | 2017 |
Tumor Microvessel Density as a Prognostic Marker in High-Risk Renal Cell Carcinoma Patients Treated on ECOG-ACRIN E2805.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Female; Humans; Kidney Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Staging; Neovascularization, Pathologic; Prognosis; Sorafenib; Sunitinib; Tomography, X-Ray Computed | 2018 |
Patients' preferences for adjuvant sorafenib after resection of renal cell carcinoma in the SORCE trial: what makes it worthwhile?
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Patient Preference; Sorafenib; Surveys and Questionnaires | 2018 |
Fatigue among patients with renal cell carcinoma receiving adjuvant sunitinib or sorafenib: patient-reported outcomes of ECOG-ACRIN E2805 trial.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Disease-Free Survival; Fatigue; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Patient Reported Outcome Measures; Reproducibility of Results; Sorafenib; Sunitinib; Survival Analysis; Treatment Outcome | 2018 |
Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a phase 3 study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Cross-Over Studies; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Phenylurea Compounds; Quinolines; Sorafenib; Treatment Outcome; Young Adult | 2018 |
First-line axitinib versus sorafenib in Asian patients with metastatic renal cell carcinoma: exploratory subgroup analyses of Phase III data.
Topics: Adult; Aged; Antineoplastic Agents; Asian People; Axitinib; Carcinoma, Renal Cell; Female; Humans; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Sorafenib; Treatment Outcome | 2019 |
The combination of bevacizumab/temsirolimus after first-line anti-VEGF therapy in advanced renal-cell carcinoma: a clinical and biomarker study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Carcinoma, Renal Cell; Humans; Indazoles; Kidney Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Pyrimidines; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2019 |
Genetic Variants of
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Carcinoma, Renal Cell; Cell Proliferation; Double-Blind Method; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; Kidney Neoplasms; Male; Middle Aged; Mutation; Prognosis; Sorafenib; Survival Rate; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-3; Young Adult | 2019 |
Important Group Differences on the Functional Assessment of Cancer Therapy-Kidney Symptom Index Disease-Related Symptoms in Patients with Metastatic Renal Cell Carcinoma.
Topics: Activities of Daily Living; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Female; Humans; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Quality of Life; Sorafenib; Sunitinib; Surveys and Questionnaires | 2018 |
SWITCH II: Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33/11).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Female; Follow-Up Studies; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Patient Safety; Prognosis; Pyrimidines; Sorafenib; Sulfonamides; Survival Rate; Young Adult | 2019 |
Association between age and sex and mortality after adjuvant therapy for renal cancer.
Topics: Age Factors; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Prognosis; Proportional Hazards Models; Risk Assessment; Sex Factors; Sorafenib; Sunitinib; Survival Analysis; Treatment Outcome | 2019 |
Is Axitinib Still a Valid Option for mRCC in the Second-Line Setting? Prognostic Factor Analyses From the AXIS Trial.
Topics: Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Kidney Neoplasms; Male; Prognosis; Sorafenib; Treatment Outcome | 2019 |
Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Self Report; Sorafenib; Treatment Outcome; Young Adult | 2013 |
Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.
Topics: Aged; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Imidazoles; Indazoles; Intention to Treat Analysis; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Quality of Life; Sorafenib; Surveys and Questionnaires; Time Factors; Treatment Outcome | 2013 |
Sorafenib and everolimus in advanced clear cell renal carcinoma: a phase I/II trial of the SCRI Oncology Research Consortium.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Disease-Free Survival; Everolimus; Female; Hand-Foot Syndrome; Humans; Kidney Neoplasms; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Phenylurea Compounds; Sirolimus; Sorafenib; Treatment Outcome | 2013 |
Efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from the global randomized Phase 3 AXIS trial.
Topics: Adult; Aged; Aged, 80 and over; Asian People; Axitinib; Carcinoma, Renal Cell; Diarrhea; Disease-Free Survival; Female; Hand-Foot Syndrome; Humans; Hypertension; Hypothyroidism; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proteinuria; Sorafenib; Treatment Outcome; Young Adult | 2013 |
"Real world" treatment of metastatic renal cell carcinoma in a joint community-academic cohort: progression-free survival over three lines of therapy.
Topics: Carcinoma, Renal Cell; Cohort Studies; Disease-Free Survival; Everolimus; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome | 2013 |
Tumor growth rate provides useful information to evaluate sorafenib and everolimus treatment in metastatic renal cell carcinoma patients: an integrated analysis of the TARGET and RECORD phase 3 trial data.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Everolimus; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Prospective Studies; Sirolimus; Sorafenib; Time Factors; Treatment Outcome; Tumor Burden | 2014 |
Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Health Status; Humans; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Staging; Nephrectomy; Niacinamide; Odds Ratio; Phenylurea Compounds; Quality of Life; Quinolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Treatment Outcome | 2013 |
Overall survival for sorafenib plus interleukin-2 compared with sorafenib alone in metastatic renal cell carcinoma (mRCC): final results of the ROSORC trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Interleukin-2; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Sorafenib; Treatment Outcome | 2013 |
[Efficacies of sorafenib plus interferon in advanced renal cell carcinoma: a report of 57 cases].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Interferons; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2013 |
Efficacy of sorafenib in advanced renal cell carcinoma independent of prior treatment, histology or prognostic group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib | 2014 |
Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial.
Topics: Adult; Aged; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Confounding Factors, Epidemiologic; Disease-Free Survival; Europe; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; North America; Odds Ratio; Phenylurea Compounds; Protein Kinase Inhibitors; Research Design; Severity of Illness Index; Sorafenib; Treatment Outcome | 2013 |
Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Disease Progression; Disease-Free Survival; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sunitinib; Time Factors; TOR Serine-Threonine Kinases; Treatment Failure; Young Adult | 2014 |
A cross-sectional investigation of fatigue in advanced renal cell carcinoma treatment: results from the FAMOUS study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Cross-Sectional Studies; Everolimus; Fatigue; Female; Humans; Incidence; Indoles; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Physicians; Pyrroles; Quality of Life; Self Report; Sirolimus; Sorafenib; Sunitinib; Surveys and Questionnaires | 2014 |
A randomized multicenter phase II trial on the efficacy of a hydrocolloid dressing containing ceramide with a low-friction external surface for hand-foot skin reaction caused by sorafenib in patients with renal cell carcinoma.
Topics: Aged; Antineoplastic Agents; Bandages, Hydrocolloid; Carcinoma, Renal Cell; Ceramides; Female; Hand-Foot Syndrome; Humans; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Surface Properties; Treatment Outcome | 2014 |
A phase I, open-label study of trebananib combined with sorafenib or sunitinib in patients with advanced renal cell carcinoma.
Topics: Adult; Aged; Angiogenic Proteins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyrroles; Recombinant Fusion Proteins; Sorafenib; Sunitinib; Treatment Outcome | 2014 |
Tyrosine kinase inhibitor sorafenib decreases 111In-girentuximab uptake in patients with clear cell renal cell carcinoma.
Topics: Aged; Antibodies, Monoclonal; Carcinoma, Renal Cell; Drug Synergism; Female; Humans; Immunohistochemistry; Indium Radioisotopes; Kidney Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Niacinamide; Phenylurea Compounds; Platelet Endothelial Cell Adhesion Molecule-1; Protein-Tyrosine Kinases; Radionuclide Imaging; Sorafenib | 2014 |
Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzimidazoles; Carcinoma, Renal Cell; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolones; Sorafenib; Vascular Endothelial Growth Factor A | 2014 |
Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial.
Topics: Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Female; Humans; Hypertension; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib | 2015 |
A phase I study of high-dose interleukin-2 with sorafenib in patients with metastatic renal cell carcinoma and melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Female; Humans; Interleukin-2; Kidney Neoplasms; Male; Melanoma; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; STAT5 Transcription Factor; T-Lymphocytes, Regulatory | 2014 |
Impairment of cognitive functioning during Sunitinib or Sorafenib treatment in cancer patients: a cross sectional study.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Cognition; Cognition Disorders; Cross-Sectional Studies; Female; Humans; Indoles; Kidney Neoplasms; Male; Memory; Middle Aged; Neoplasm Metastasis; Neuropsychological Tests; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Sorafenib; Sunitinib | 2014 |
Neoadjuvant sorafenib treatment of clear cell renal cell carcinoma and release of circulating tumor fragments.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Kaplan-Meier Estimate; Kidney; Kidney Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Nephrectomy; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2014 |
[First-line therapy of advanced or metastasized renal cell carcinoma: phase III, open, randomized sequence study to examine efficacy and tolerance of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the first-line treatment of pat
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Germany; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyrimidines; Sorafenib; Sulfonamides; Survival Rate; Young Adult | 2014 |
Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial.
Topics: Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Cytokines; Disease-Free Survival; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome; Tumor Burden | 2014 |
A Phase II trial of dosage escalation of sorafenib in Asian patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Carcinoma, Renal Cell; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome; Young Adult | 2014 |
Clinical efficacy and prognostic factors of tumor progression in Japanese patients with advanced renal cell carcinoma treated with sorafenib.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Treatment Outcome | 2015 |
[Metastasized renal cell carcinoma. Measurement of plasma levels of the tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Monitoring; Feasibility Studies; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Reproducibility of Results; Sensitivity and Specificity; Sorafenib; Sulfonamides; Sunitinib | 2015 |
Phase II study of sorafenib and bortezomib for first-line treatment of metastatic or unresectable renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Kaplan-Meier Estimate; Kidney Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2015 |
Comparison of volumetric and linear serial CT assessments of lung metastases in renal cell carcinoma patients in a clinical phase IIB study.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Interferon-alpha; Kidney Neoplasms; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Prospective Studies; Sorafenib; Tomography, X-Ray Computed; Tumor Burden | 2015 |
Genotype Correlations With Blood Pressure and Efficacy From a Randomized Phase III Trial of Second-Line Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma.
Topics: Aged; Angiogenesis Inhibitors; Axitinib; Blood Pressure; Carcinoma, Renal Cell; Disease-Free Survival; Female; Genetic Association Studies; Humans; Imidazoles; Indazoles; Kaplan-Meier Estimate; Kidney Neoplasms; Linkage Disequilibrium; Male; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Polymorphism, Single Nucleotide; Proportional Hazards Models; Sorafenib; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2015 |
SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Lymph Nodes; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Pyrroles; Sorafenib; Sunitinib | 2015 |
Effects of Adjuvant Sorafenib and Sunitinib on Cardiac Function in Renal Cell Carcinoma Patients without Overt Metastases: Results from ASSURE, ECOG 2805.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Cardiovascular Diseases; Chemotherapy, Adjuvant; Double-Blind Method; Female; Heart Failure; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prospective Studies; Pyrroles; Risk Factors; Sorafenib; Sunitinib; Ventricular Function, Left | 2015 |
BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the ECOG-ACRIN C
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; raf Kinases; Sirolimus; Sorafenib; TOR Serine-Threonine Kinases; Treatment Outcome; Vascular Endothelial Growth Factor A | 2015 |
Phase I/II study of S-1 in combination with sorafenib for metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Disease-Free Survival; Drug Combinations; Female; Humans; Kidney Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Oxonic Acid; Phenylurea Compounds; Sorafenib; Tegafur; Treatment Outcome | 2015 |
Phase 2 trial of sorafenib in children and young adults with refractory solid tumors: A report from the Children's Oncology Group.
Topics: Adolescent; Angiogenesis Inhibitors; Antineoplastic Agents; Child; Child, Preschool; Female; Humans; Kidney Neoplasms; Male; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Rhabdomyosarcoma; Salvage Therapy; Sorafenib; Treatment Failure; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Wilms Tumor; Young Adult | 2015 |
Biological Effects After Discontinuation of VEGFR Inhibitors in Metastatic Renal Cell Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Renal Cell; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Prospective Studies; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Withholding Treatment | 2015 |
Phase II clinical trial of sorafenib plus interferon-alpha treatment for patients with metastatic renal cell carcinoma in Japan.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Female; Humans; Interferon-alpha; Japan; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2015 |
The influence of genetic variants of sorafenib on clinical outcomes and toxic effects in patients with advanced renal cell carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Disease-Free Survival; Female; Hand-Foot Syndrome; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Polymorphism, Genetic; Sorafenib; Survival Rate | 2016 |
Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial.
Topics: Administration, Oral; Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2016 |
Comparison of central and local serial CT assessments of metastatic renal cell carcinoma patients in a clinical phase IIB study.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Data Interpretation, Statistical; Humans; Interferon alpha-2; Interferon-alpha; Kidney; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Recombinant Proteins; Reproducibility of Results; Retrospective Studies; Sorafenib; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden | 2017 |
Axitinib Versus Sorafenib in First-Line Metastatic Renal Cell Carcinoma: Overall Survival From a Randomized Phase III Trial.
Topics: Axitinib; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Survival Analysis; Treatment Outcome | 2017 |
Sorafenib dose escalation in treatment-naïve patients with metastatic renal cell carcinoma: a non-randomised, open-label, Phase 2b study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Research Design; Sorafenib; Treatment Outcome | 2017 |
Effective downsizing but enhanced intratumoral heterogeneity following neoadjuvant sorafenib in patients with non-metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Double-Blind Method; Female; Hepatectomy; Humans; Kidney Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Niacinamide; Phenylurea Compounds; Pilot Projects; Prospective Studies; Sorafenib; Treatment Outcome | 2017 |
Patterns of Care and Clinical Outcomes in Patients With Metastatic Renal Cell Carcinoma-Results From a Tertiary Cancer Center in India.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Everolimus; Female; Humans; Indazoles; India; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Practice Patterns, Physicians'; Prospective Studies; Pyrimidines; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis; Tertiary Care Centers; Treatment Outcome; Young Adult | 2017 |
Adjuvant Treatment for High-Risk Clear Cell Renal Cancer: Updated Results of a High-Risk Subset of the ASSURE Randomized Trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyrroles; Risk Factors; Sorafenib; Sunitinib; Survival Rate | 2017 |
Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Double-Blind Method; Drug Eruptions; Female; Foot Dermatoses; France; Hand Dermatoses; Humans; Incidence; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prospective Studies; Protein Kinase Inhibitors; Pyridines; Severity of Illness Index; Sorafenib | 2008 |
Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Area Under Curve; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Renal Cell; Contrast Media; Double-Blind Method; Female; Gadolinium DTPA; Humans; Kidney Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Placebos; Proportional Hazards Models; Prospective Studies; Pyridines; Sorafenib; Survival Analysis; Treatment Outcome | 2008 |
Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Quality of Life; Retrospective Studies; Sorafenib | 2008 |
Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Interferon alpha-2; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Recombinant Proteins; Sorafenib | 2009 |
Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Cross-Over Studies; Diarrhea; Disease-Free Survival; Double-Blind Method; Fatigue; Female; Humans; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Multivariate Analysis; Nausea; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Sorafenib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2009 |
Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2009 |
Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Axitinib; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2009 |
Efficacy and safety of sorafenib in patients with advanced renal cell carcinoma with and without prior cytokine therapy, a subanalysis of TARGET.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Cardiovascular Diseases; Diarrhea; Disease-Free Survival; Double-Blind Method; Female; Hematologic Diseases; Humans; Interferon-alpha; Interleukin-2; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Progestins; Protein Kinase Inhibitors; Pyridines; Sorafenib; Treatment Outcome; Vinca Alkaloids | 2010 |
Incidence of brain metastases in renal cell carcinoma treated with sorafenib.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Benzenesulfonates; Brain Neoplasms; Carcinoma, Renal Cell; Female; Follow-Up Studies; Humans; Incidence; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Sorafenib; Survival Rate | 2010 |
Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysis.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2010 |
Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Double-Blind Method; Fatigue; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Muscle, Skeletal; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Placebos; Prognosis; Pyridines; Sorafenib; Survival Rate; Treatment Outcome; Wasting Syndrome | 2010 |
Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Body Mass Index; Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sarcopenia; Sorafenib | 2010 |
Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Feasibility Studies; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pilot Projects; Prospective Studies; Pyridines; Sorafenib; Treatment Outcome; Young Adult | 2010 |
Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Drug Administration Schedule; Drug Synergism; Female; Fluorouracil; Gemcitabine; Humans; Kidney Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Survival Analysis | 2010 |
Safety, efficacy, pharmacokinetics, and pharmacodynamics of the combination of sorafenib and tanespimycin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Benzoquinones; Clinical Trials, Phase II as Topic; Cohort Studies; Colorectal Neoplasms; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Humans; Kidney Neoplasms; Lactams, Macrocyclic; Male; Melanoma; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Survival Analysis | 2010 |
Metastatic renal carcinoma: evaluation of antiangiogenic therapy with dynamic contrast-enhanced CT.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Reproducibility of Results; Sensitivity and Specificity; Sorafenib; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
A phase II trial of first-line sorafenib in patients with metastatic renal cell carcinoma unwilling to receive or with early intolerance to immunotherapy: SOGUG Study 06-01.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Bone Neoplasms; Carcinoma, Renal Cell; Female; Humans; Immunotherapy; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Remission Induction; Sorafenib | 2010 |
Biomarkers predicting outcome in patients with advanced renal cell carcinoma: Results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation Trial.
Topics: Aged; Antigens, Neoplasm; Benzenesulfonates; Biomarkers, Tumor; Carbonic Anhydrase IX; Carbonic Anhydrases; Carcinoma, Renal Cell; Disease Progression; Drug Administration Schedule; Female; Humans; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Prognosis; Proto-Oncogene Proteins p21(ras); Pyridines; Sorafenib; Survival Analysis; Tissue Inhibitor of Metalloproteinase-1; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2010 |
Long-term safety of sorafenib in advanced renal cell carcinoma: follow-up of patients from phase III TARGET.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Female; Follow-Up Studies; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Young Adult | 2010 |
Sorafenib after combination therapy with gemcitabine plus doxorubicine in patients with sarcomatoid renal cell carcinoma: a prospective evaluation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Radiography; Sorafenib | 2010 |
Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Drug Resistance, Neoplasm; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib | 2010 |
A phase I/II trial of sorafenib and infliximab in advanced renal cell carcinoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Disease Progression; Female; Humans; Infliximab; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Survival Analysis; Treatment Outcome | 2010 |
A phase I trial of sorafenib plus gemcitabine and capecitabine for patients with advanced renal cell carcinoma: New York Cancer Consortium Trial NCI 6981.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bone Neoplasms; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Survival Rate; Treatment Outcome | 2011 |
Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Compassionate Use Trials; Disease-Free Survival; Europe; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome | 2011 |
A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Everolimus; Female; Humans; Kidney Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sirolimus; Sorafenib; TOR Serine-Threonine Kinases | 2011 |
Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial.
Topics: Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Interleukin-2; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome | 2011 |
A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Renal Cell; Cluster Analysis; Cytokines; Disease-Free Survival; Enzyme-Linked Immunosorbent Assay; Humans; Interferon-alpha; Kaplan-Meier Estimate; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Vascular Endothelial Growth Factor A | 2012 |
Baseline patient-reported kidney cancer-specific symptoms as an indicator for median survival in sorafenib-refractory metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Resistance, Neoplasm; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Quality of Life; Research Design; Self Report; Sorafenib; Surveys and Questionnaires; Survival Analysis; Treatment Outcome | 2011 |
Overall survival and good tolerability of long-term use of sorafenib after cytokine treatment: final results of a phase II trial of sorafenib in Japanese patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Cytokines; Disease-Free Survival; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome | 2011 |
An adjusted indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory metastatic renal cell carcinoma patients using repeated matched samples.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Drug Resistance, Neoplasm; Everolimus; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Survival; Treatment Outcome | 2011 |
Multikinase inhibitors in metastatic renal cell carcinoma: indirect comparison meta-analysis.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib | 2011 |
Cancer patients treated with sunitinib or sorafenib have sufficient antibody and cellular immune responses to warrant influenza vaccination.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Immunity, Cellular; Immunity, Humoral; Indoles; Influenza Vaccines; Influenza, Human; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Time Factors; Vaccination | 2011 |
Thyroid size change by CT monitoring after sorafenib or sunitinib treatment in patients with renal cell carcinoma: comparison with thyroid function.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Hypothyroidism; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Organ Size; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Thyroid Gland; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
[Third-line therapy for metastasized renal cell carcinoma: a randomized, multicenter non-blinded phase III study to compare safety and effectiveness of TF1258 versus sorafenib in patients with metastasized renal cell carcinoma following failure of antiang
Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Benzimidazoles; Carcinoma, Renal Cell; Disease Progression; Female; Germany; Humans; Kidney Neoplasms; Male; Molecular Targeted Therapy; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Quinolones; Sorafenib; Survival Rate; TOR Serine-Threonine Kinases; Treatment Failure; Vascular Endothelial Growth Factor A | 2011 |
Treatment of everolimus-resistant metastatic renal cell carcinoma with VEGF-targeted therapies.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Disease-Free Survival; Drug Resistance, Neoplasm; Everolimus; Female; Humans; Interferons; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Sirolimus; Sorafenib; Treatment Failure; Treatment Outcome; Vascular Endothelial Growth Factor A | 2011 |
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Young Adult | 2011 |
Sorafenib, but not sunitinib, induces regulatory T cells in the peripheral blood of patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; CD3 Complex; CD4 Antigens; Female; Forkhead Transcription Factors; Humans; Indoles; Interleukin-2 Receptor alpha Subunit; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Sorafenib; Sunitinib; T-Lymphocytes, Regulatory; Treatment Outcome | 2012 |
Phase I trial of everolimus plus sorafenib for patients with advanced renal cell cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Everolimus; Female; Follow-Up Studies; Humans; Kidney Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sirolimus; Sorafenib; Treatment Outcome | 2012 |
Phase II escalation study of sorafenib in patients with metastatic renal cell carcinoma who have been previously treated with anti-angiogenic treatment.
Topics: Adult; Aged; Aged, 80 and over; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Renal Cell; Diarrhea; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Hand-Foot Syndrome; Humans; Kidney Neoplasms; Male; Middle Aged; Mucositis; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyridines; Receptors, Vascular Endothelial Growth Factor; Salvage Therapy; Sorafenib; Treatment Outcome | 2012 |
Development and validation of a prediction index for hand-foot skin reaction in cancer patients receiving sorafenib.
Topics: Adenocarcinoma, Clear Cell; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Administration Schedule; Female; Hand-Foot Syndrome; Humans; Kidney Neoplasms; Male; Middle Aged; Models, Statistical; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Pyridines; Reproducibility of Results; Risk Factors; Sorafenib; Young Adult | 2012 |
A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Kidney Neoplasms; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Vorinostat | 2013 |
A phase II trial of intrapatient dose-escalated sorafenib in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome | 2012 |
[First-line therapy of advanced or metastasized renal cell cancer: open randomized phase III sequence study to examine the effectiveness and tolerance of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the first-line treatment of
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indazoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Sorafenib; Sulfonamides | 2012 |
Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Diarrhea; Disease-Free Survival; Fatigue; Female; Follow-Up Studies; Hand-Foot Syndrome; Humans; Indoles; Kidney; Kidney Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Postoperative Period; Prospective Studies; Pyrroles; Risk Factors; Sorafenib; Sunitinib; Treatment Outcome | 2013 |
AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase 2 study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Renal Cell; Double-Blind Method; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Recombinant Fusion Proteins; Sorafenib; Survival Rate | 2012 |
Primary renal cell carcinoma: relationship between 18F-FDG uptake and response to neoadjuvant sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Benzenesulfonates; Biological Transport; Carcinoma, Renal Cell; Feasibility Studies; Female; Fluorodeoxyglucose F18; Humans; Kidney Neoplasms; Male; Middle Aged; Multimodal Imaging; Neoadjuvant Therapy; Niacinamide; Phenylurea Compounds; Positron-Emission Tomography; Pyridines; Safety; Sorafenib; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome; Young Adult | 2012 |
Could interferon still play a role in metastatic renal cell carcinoma? A randomized study of two schedules of sorafenib plus interferon-alpha 2a (RAPSODY).
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Renal Cell; Disease-Free Survival; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Interferon alpha-2; Interferon-alpha; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prospective Studies; Recombinant Proteins; Sorafenib; Treatment Outcome | 2013 |
Tumour burden is an independent prognostic factor in metastatic renal cell carcinoma.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prospective Studies; Pyridines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome; Tumor Burden | 2012 |
Risk factors for sorafenib-induced high-grade skin rash in Japanese patients with advanced renal cell carcinoma.
Topics: Aged; Antineoplastic Agents; Asian People; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Renal Cell; Cytochrome P-450 CYP3A; Dose-Response Relationship, Drug; Exanthema; Female; Glucuronosyltransferase; HLA-A24 Antigen; Humans; Kidney Neoplasms; Male; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib | 2013 |
MRI assessment of early tumor response in metastatic renal cell carcinoma patients treated with sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Contrast Media; Female; Gadolinium; Humans; Kidney Neoplasms; Liver Neoplasms; Lymphatic Metastasis; Magnetic Resonance Imaging; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2013 |
[Phase II clinical trial of sorafenib plus local chemotherapy in the treatment of metastatic renal cell carcinoma with pleural effusion].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pleural Effusion; Sorafenib; Treatment Outcome | 2012 |
Are tyrosine kinase inhibitors still active in patients with metastatic renal cell carcinoma previously treated with a tyrosine kinase inhibitor and everolimus? Experience of 36 patients treated in France in the RECORD-1 Trial.
Topics: Adult; Aged; Antineoplastic Agents; Benzimidazoles; Carcinoma, Renal Cell; Disease-Free Survival; Everolimus; Female; France; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Quinolones; Salvage Therapy; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Treatment Failure; Treatment Outcome | 2013 |
Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carcinoma, Renal Cell; Drug Evaluation, Preclinical; Female; Follow-Up Studies; Humans; Kidney Neoplasms; Male; Maximum Tolerated Dose; Mice; Mice, Nude; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Quinolones; Receptor, Fibroblast Growth Factor, Type 1; Receptor, Platelet-Derived Growth Factor beta; Sorafenib; Survival Rate; Tissue Distribution; Vascular Endothelial Growth Factor Receptor-1 | 2013 |
Phase II trial of sequential subcutaneous interleukin-2 plus interferon alpha followed by sorafenib in renal cell carcinoma (RCC).
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Female; Humans; Immunotherapy; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Probability; Protein Kinase Inhibitors; Sorafenib; Time Factors; Treatment Outcome | 2013 |
Kinase inhibition with BAY 43-9006 in renal cell carcinoma.
Topics: Benzenesulfonates; Carcinoma, Renal Cell; Enzyme Inhibitors; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Tomography, X-Ray Computed | 2004 |
Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours.
Topics: Adult; Aged; Benzenesulfonates; Carcinoma, Renal Cell; Drug Administration Schedule; Female; Humans; Kidney Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2005 |
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Survival Analysis; Treatment Outcome | 2006 |
Randomized discontinuation trial of sorafenib (BAY 43-9006).
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease Progression; Double-Blind Method; Drug Administration Schedule; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Placebos; Pyridines; Reproducibility of Results; Research Design; Sorafenib; Treatment Outcome | 2006 |
Sorafenib in advanced clear-cell renal-cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease Progression; Double-Blind Method; Female; Humans; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2007 |
Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma.
Topics: Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Renal Cell; Female; Humans; Immune System; Interferon alpha-2; Interferon-alpha; Kidney Neoplasms; Male; Melanoma; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Recombinant Proteins; Sorafenib; Treatment Outcome | 2007 |
Effects of sorafenib on symptoms and quality of life: results from a large randomized placebo-controlled study in renal cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Double-Blind Method; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Quality of Life; Sorafenib; Survival Analysis | 2007 |
Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Interferon alpha-2; Interferon-alpha; Kidney Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Niacinamide; North Carolina; Phenylurea Compounds; Pyridines; Recombinant Proteins; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome | 2007 |
Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Renal Cell; DNA Mutational Analysis; Female; Humans; Immunohistochemistry; Interferon alpha-2; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Recombinant Proteins; Sorafenib; Survival Analysis; Treatment Outcome | 2007 |
Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Benzenesulfonates; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Eruptions; Female; Humans; Kidney Neoplasms; Lipase; Male; Middle Aged; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2007 |
Sorafenib TARGET trial results in Spanish patients.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Spain; Treatment Outcome | 2007 |
Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Benzenesulfonates; Carcinoma, Renal Cell; Disease Progression; Disease-Free Survival; Female; Humans; Kidney Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pilot Projects; Proto-Oncogene Proteins c-raf; Pyridines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Survival Analysis | 2008 |
Sorafenib for metastatic renal cancer: the Princess Margaret experience.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzenesulfonates; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Kidney Neoplasms; Logistic Models; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prospective Studies; Protein Kinase Inhibitors; Pyridines; Sorafenib; Survival Analysis | 2008 |
561 other study(ies) available for sorafenib and Kidney Neoplasms
| Article | Year |
|---|---|
Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors.
Topics: Carcinoma, Renal Cell; Clinical Trials as Topic; Crystallography, X-Ray; Disease-Free Survival; Human Umbilical Vein Endothelial Cells; Humans; Kidney Neoplasms; Models, Molecular; Molecular Conformation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2 | 2012 |
Isochromophilones A-F, Cytotoxic Chloroazaphilones from the Marine Mangrove Endophytic Fungus Diaporthe sp. SCSIO 41011.
Topics: Apoptosis; Aquatic Organisms; Benzopyrans; Cell Line, Tumor; Circular Dichroism; Cytotoxins; Fungi; Humans; Kidney Neoplasms; Magnetic Resonance Spectroscopy; Pigments, Biological; Pyridones | 2018 |
Exploring the Natural Piericidins as Anti-Renal Cell Carcinoma Agents Targeting Peroxiredoxin 1.
Topics: Aminoglycosides; Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Delivery Systems; Humans; Kidney Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Peroxiredoxins; Protein Structure, Secondary; Pyridines; Xenograft Model Antitumor Assays | 2019 |
PGK1 contributes to tumorigenesis and sorafenib resistance of renal clear cell carcinoma via activating CXCR4/ERK signaling pathway and accelerating glycolysis.
Topics: Animals; Carcinogenesis; Carcinoma, Renal Cell; Cell Line, Tumor; Glycolysis; Humans; Kidney Neoplasms; Mice; Phosphoglycerate Kinase; Receptors, CXCR4; Signal Transduction; Sorafenib | 2022 |
Oral targeted therapy dose adaptation in older patients with cancer: A real-life French cohort.
Topics: Administration, Oral; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Everolimus; Humans; Indoles; Kidney Neoplasms; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome | 2022 |
Effect of systemic therapies or best supportive care after disease progression to both nivolumab and cabozantinib in metastatic renal cell carcinoma: The Meet-Uro 19BEYOND study.
Topics: Anilides; Antineoplastic Agents; Carcinoma, Renal Cell; Disease Progression; Everolimus; Humans; Kidney Neoplasms; Nivolumab; Pyridines; Retrospective Studies; Sorafenib | 2022 |
Effectiveness and safety of sorafenib for renal cell, hepatocellular and thyroid carcinoma: pooled analysis in patients with renal impairment.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Humans; Kidney; Kidney Neoplasms; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Prospective Studies; Retrospective Studies; Sorafenib; Thyroid Neoplasms; Vascular Endothelial Growth Factor A | 2022 |
TOPK/PBK is phosphorylated by ERK2 at serine 32, promotes tumorigenesis and is involved in sorafenib resistance in RCC.
Topics: Carcinoma, Renal Cell; Cell Transformation, Neoplastic; Humans; Kidney Neoplasms; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase Kinases; Serine; Sorafenib | 2022 |
Clinicopathological characteristics and prognosis of metastatic collecting duct carcinoma.
Topics: Axitinib; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Neoplasms, Second Primary; Prognosis; Retrospective Studies; Sorafenib | 2022 |
[Metastatic Renal Cancer with Stevens-Johnson Syndrome after Nivolumab Treatment : A Case Report].
Topics: Aged; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Male; Nivolumab; Sorafenib; Stevens-Johnson Syndrome | 2022 |
Resistance to tyrosine kinase inhibitors promotes renal cancer progression through MCPIP1 tumor-suppressor downregulation and c-Met activation.
Topics: Cadherins; Carcinoma, Renal Cell; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Humans; Interleukin-6; Interleukin-8; Kidney; Kidney Neoplasms; Matrix Metalloproteinase 9; Neovascularization, Pathologic; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Ribonucleases; Sorafenib; Sunitinib; Transcription Factors | 2022 |
Comprehensive analysis of cellular senescence-related genes in the prognosis, tumor microenvironment, and immunotherapy/chemotherapy of clear cell renal cell carcinoma.
Topics: Axitinib; Biomarkers, Tumor; Bortezomib; Carcinoma, Renal Cell; Cellular Senescence; Humans; Immunologic Factors; Immunotherapy; Kidney Neoplasms; Prognosis; Sorafenib; Sunitinib; Tumor Microenvironment | 2022 |
Analysis of Anti-Angiogenesis-Related Adverse Events Associated with Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitors (VEGFR-TKIs) in Patients with Metastatic Renal Cell Carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Cross-Sectional Studies; Humans; Hypertension; Kidney Neoplasms; Protein Kinase Inhibitors; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Tyrosine Kinase Inhibitors; Vascular Endothelial Growth Factor A | 2023 |
Preclinical Evidence that Arctigenin Effectively and Selectively Targets Clear Cell Renal Cell Carcinoma Via Suppressing EGFR and RhoA.
Topics: Animals; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Fluorouracil; Humans; Kidney Neoplasms; Mice; rhoA GTP-Binding Protein; Sorafenib | 2023 |
CPT2-mediated fatty acid oxidation inhibits tumorigenesis and enhances sorafenib sensitivity via the ROS/PPARγ/NF-κB pathway in clear cell renal cell carcinoma.
Topics: Carcinogenesis; Carcinoma; Carcinoma, Renal Cell; Carnitine O-Palmitoyltransferase; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Fatty Acids; Gene Expression Regulation, Neoplastic; Humans; Kidney Neoplasms; NF-kappa B; PPAR gamma; Reactive Oxygen Species; Sorafenib | 2023 |
A novel drug specific mRNA biomarker predictor for selection of patients responding to dovitinib treatment of advanced renal cell carcinoma and other solid tumors.
Topics: Biomarkers; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Patient Selection; Phosphatidylinositol 3-Kinases; Prospective Studies; Retrospective Studies; RNA, Messenger; Sorafenib | 2023 |
DPP9 Stabilizes NRF2 to Suppress Ferroptosis and Induce Sorafenib Resistance in Clear Cell Renal Cell Carcinoma.
Topics: Carcinoma, Renal Cell; Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; Ferroptosis; Humans; Kelch-Like ECH-Associated Protein 1; Kidney Neoplasms; NF-E2-Related Factor 2; Signal Transduction; Sorafenib | 2023 |
ORM1 promotes tumor progression of kidney renal clear cell carcinoma (KIRC) through CALR-mediated apoptosis.
Topics: Apoptosis; bcl-2-Associated X Protein; Carcinoma, Renal Cell; Caspase 3; Humans; Kidney; Kidney Neoplasms; Neoplastic Processes; Proto-Oncogene Proteins c-bcl-2; Sorafenib | 2023 |
Overcoming the compensatory increase in NRF2 induced by NPL4 inhibition enhances disulfiram/copper-induced oxidative stress and ferroptosis in renal cell carcinoma.
Topics: Animals; Carcinoma, Renal Cell; Copper; Disulfiram; Ferroptosis; Kidney Neoplasms; Mice; NF-E2-Related Factor 2; Oxidative Stress; Sorafenib | 2023 |
Inflammatory response-based prognostication and personalized therapy decisions in clear cell renal cell cancer to aid precision oncology.
Topics: Axitinib; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Precision Medicine; Prognosis; Sorafenib | 2023 |
Peglated-H1/pHGFK1 nanoparticles enhance anti-tumor effects of sorafenib by inhibition of drug-induced autophagy and stemness in renal cell carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; beta-Cyclodextrins; Carcinoma, Renal Cell; Cell Cycle; Cell Movement; Cell Proliferation; Drug Synergism; Female; Folic Acid; Hepatocyte Growth Factor; Humans; Kidney Neoplasms; Kringles; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Neoplastic Stem Cells; Polyethylene Glycols; Polyethyleneimine; Sorafenib; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2019 |
Angiogenic Factor and Cytokine Analysis among Patients Treated with Adjuvant VEGFR TKIs in Resected Renal Cell Carcinoma.
Topics: Biomarkers, Tumor; Carcinoma, Renal Cell; Chemokine CXCL10; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Disease-Free Survival; Humans; Kidney Neoplasms; Nephrectomy; Placenta Growth Factor; Prognosis; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2019 |
Local Recurrence Following Resection of Intermediate-High Risk Nonmetastatic Renal Cell Carcinoma: An Anatomical Classification and Analysis of the ASSURE (ECOG-ACRIN E2805) Adjuvant Trial.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Disease-Free Survival; Female; Follow-Up Studies; Humans; Kidney; Kidney Neoplasms; Male; Middle Aged; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Neoplasm Staging; Nephrectomy; Prognosis; Prospective Studies; Randomized Controlled Trials as Topic; Risk Assessment; Sorafenib; Sunitinib | 2020 |
Comparison of efficacy and safety among axitinib, sunitinib, and sorafenib as neoadjuvant therapy for renal cell carcinoma: a retrospective study.
Topics: Adult; Aged; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Protein Kinase Inhibitors; Sorafenib; Sunitinib; Treatment Outcome | 2019 |
Sunitinib versus sorafenib for patients with advanced renal cell carcinoma with renal impairment before the immune-oncology therapy era.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Administration Schedule; Female; Glomerular Filtration Rate; Humans; Japan; Kidney Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Renal Insufficiency; Sorafenib; Sunitinib; Survival Analysis | 2019 |
Sequencing therapy for advanced renal cancer.
Topics: Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Phenylurea Compounds; Quinolines; Sorafenib | 2020 |
Bone metastasis is associated with poor prognosis in metastatic papillary renal cell carcinoma patients treated with first agent angiogenesis inhibitors.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Axitinib; Bone Neoplasms; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Prognosis; Pyrimidines; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib; Survival Rate; Treatment Outcome | 2020 |
Real-world use of sorafenib for advanced renal cell carcinoma patients with cardiovascular disease: nationwide survey in Japan.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Cardiovascular Diseases; Disease-Free Survival; Female; Humans; Japan; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Sorafenib; Surveys and Questionnaires; Survival Rate; Treatment Outcome | 2020 |
The impact of cytoreductive nephrectomy on survival outcomes in patients treated with tyrosine kinase inhibitors for metastatic renal cell carcinoma in a real-world cohort.
Topics: Aged; Carcinoma, Renal Cell; Cohort Studies; Combined Modality Therapy; Cytoreduction Surgical Procedures; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Retrospective Studies; Sorafenib; Sunitinib; Survival Rate; Treatment Outcome | 2020 |
Final Data Analysis Supports Tivozanib as Superior Treatment for Patients With RCC.
Topics: Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Drug Resistance, Neoplasm; Humans; Kidney Neoplasms; Multicenter Studies as Topic; Neoplasm Metastasis; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Randomized Controlled Trials as Topic; Sorafenib; Survival Rate | 2020 |
PD-L1 and VEGFR-2 expression in synchronous metastatic renal cell carcinoma treated with targeted therapy following cytoreductive nephrectomy.
Topics: Aged; Antineoplastic Agents; B7-H1 Antigen; Carcinoma, Renal Cell; Combined Modality Therapy; Cytoreduction Surgical Procedures; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Retrospective Studies; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor Receptor-2 | 2021 |
Long non‑coding RNA PLK1S1 was associated with renal cell carcinoma progression by interacting with microRNA‑653 and altering C‑X‑C chemokine receptor 5 expression.
Topics: Adult; Aged; Carcinogenesis; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Movement; Cell Proliferation; Computational Biology; Disease Progression; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Kaplan-Meier Estimate; Kidney; Kidney Neoplasms; Male; MicroRNAs; Middle Aged; Neoplasm Invasiveness; Nephrectomy; Receptors, CXCR5; RNA, Long Noncoding; Sorafenib; Xenograft Model Antitumor Assays | 2020 |
Self Nanoemulsifying Drug Delivery System of Sorafenib Tosylate: Development and
Topics: Administration, Oral; Animals; Biological Availability; Carcinoma, Renal Cell; Chemistry, Pharmaceutical; Drug Compounding; Drug Delivery Systems; Drug Liberation; Emulsions; Kidney Neoplasms; Models, Animal; Nanoparticles; Oils; Particle Size; Protein Kinase Inhibitors; Rats; Rats, Wistar; Solubility; Sorafenib; Surface-Active Agents; Thermodynamics | 2020 |
Mast cell density in metastatic renal cell carcinoma: Association with prognosis and tumour-infiltrating lymphocytes.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Count; Female; Humans; Kidney Neoplasms; Lymphocytes, Tumor-Infiltrating; Male; Mast Cells; Middle Aged; Prognosis; Progression-Free Survival; Proportional Hazards Models; Retrospective Studies; Sorafenib; Sunitinib; Survival Analysis; Tumor Microenvironment | 2021 |
Predictive value of De Ritis ratio in metastatic renal cell carcinoma treated with tyrosine-kinase inhibitors.
Topics: Alanine Transaminase; Aspartate Aminotransferases; Carcinoma, Renal Cell; Cytoreduction Surgical Procedures; Female; Humans; Indazoles; Karnofsky Performance Status; Kidney Neoplasms; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Nephrectomy; Predictive Value of Tests; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis | 2021 |
Targeted therapy in Xp11 translocation renal cell carcinoma.
Topics: Adult; Antineoplastic Agents; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Carcinoma, Renal Cell; Chromosomes, Human, X; Crizotinib; Disease Progression; Everolimus; Fatal Outcome; Female; Humans; Indazoles; Kidney Neoplasms; Molecular Targeted Therapy; Nivolumab; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrimidines; Sorafenib; Sulfonamides; Sunitinib; Tomography, X-Ray Computed | 2021 |
NUPR1 is a novel potential biomarker and confers resistance to sorafenib in clear cell renal cell carcinoma by increasing stemness and targeting the PTEN/AKT/mTOR pathway.
Topics: Aged; Animals; Apoptosis; Basic Helix-Loop-Helix Transcription Factors; Biomarkers, Tumor; Carcinoma, Renal Cell; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Disease-Free Survival; Down-Regulation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Kidney Neoplasms; Male; Mice, Inbred BALB C; Middle Aged; Multivariate Analysis; Neoplasm Invasiveness; Neoplasm Proteins; Neoplastic Stem Cells; Prognosis; Proportional Hazards Models; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Signal Transduction; Sorafenib; TOR Serine-Threonine Kinases; Up-Regulation | 2021 |
SHARPIN regulates the development of clear cell renal cell carcinoma by promoting von Hippel-Lindau protein ubiquitination and degradation.
Topics: Animals; Antineoplastic Agents; Apoptosis; Basic Helix-Loop-Helix Transcription Factors; Carcinoma, Renal Cell; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gene Silencing; Heterografts; Humans; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Prognosis; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Proteolysis; Random Allocation; RNA, Small Interfering; Sorafenib; Ubiquitination; Ubiquitins; Up-Regulation; Von Hippel-Lindau Tumor Suppressor Protein | 2021 |
FDA Approval Summary: Tivozanib for Relapsed or Refractory Renal Cell Carcinoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Drug Approval; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Phenylurea Compounds; Quinolines; Randomized Controlled Trials as Topic; Sorafenib; Survival Rate; Treatment Outcome | 2022 |
Description of the EuroTARGET cohort: A European collaborative project on TArgeted therapy in renal cell cancer-GEnetic- and tumor-related biomarkers for response and toxicity.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; Cohort Studies; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; Young Adult | 2017 |
Action of YM155 on clear cell renal cell carcinoma does not depend on survivin expression levels.
Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Survival; Deubiquitinating Enzyme CYLD; Dose-Response Relationship, Drug; Drug Combinations; Forkhead Box Protein O1; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Inhibitor of Apoptosis Proteins; Inhibitor of Differentiation Protein 1; Kidney Neoplasms; Male; Mice; Mice, SCID; Naphthoquinones; Niacinamide; Phenylurea Compounds; Primary Cell Culture; Signal Transduction; Sorafenib; Survivin; Tumor Suppressor Proteins; Von Hippel-Lindau Tumor Suppressor Protein; Xenograft Model Antitumor Assays | 2017 |
Evaluation of First-Line Sorafenib Treatment for Metastatic Renal Cell Carcinoma in Kidney Transplant Patients: A Single-Center Experience With Four Cases.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Kidney Transplantation; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2017 |
The significance of TIMD4 expression in clear cell renal cell carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gene Expression; Humans; Kidney Neoplasms; Male; Membrane Proteins; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; RNA, Small Interfering; Sorafenib | 2017 |
Proton Pump Inhibitors and Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma.
Topics: Aged; Axitinib; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Interactions; Female; Gastrointestinal Diseases; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proton Pump Inhibitors; Pyrroles; Sorafenib; Sunitinib; Survival Analysis; Treatment Outcome | 2017 |
Combination of sorafenib and cytokine-induced killer cells in metastatic renal cell carcinoma: a potential regimen.
Topics: Carcinoma, Renal Cell; Cytokine-Induced Killer Cells; Humans; Immunotherapy; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Sorafenib | 2017 |
Outcomes of Patients With Long-Term Treatment Response to Vascular Endothelial Growth Factor-Targeted Therapy for Metastatic Renal Cell Cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Bevacizumab; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Registries; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis; Treatment Outcome; Vascular Endothelial Growth Factor A | 2017 |
Retroperitoneal Lymphadenectomy for High Risk, Nonmetastatic Renal Cell Carcinoma: An Analysis of the ASSURE (ECOG-ACRIN 2805) Adjuvant Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Kidney Neoplasms; Lymph Node Excision; Male; Middle Aged; Neoplasm Staging; Nephrectomy; Risk; Sorafenib; Sunitinib; Survival Rate; Treatment Outcome | 2018 |
Real-world costs and outcomes in metastatic renal cell carcinoma patients treated with targeted therapies: a cohort study from the French health insurance database.
Topics: Antineoplastic Combined Chemotherapy Protocols; Axitinib; Carcinoma, Renal Cell; Cohort Studies; Databases, Factual; Disease-Free Survival; Everolimus; Female; France; Humans; Imidazoles; Indazoles; Indoles; Insurance, Health; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib | 2017 |
Significance of preoperative prognostic nutrition index as prognostic predictors in patients with metastatic renal cell carcinoma with tyrosine kinase inhibitors as first-line target therapy.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Lymphocyte Count; Male; Middle Aged; Neoadjuvant Therapy; Nephrectomy; Neutrophils; Niacinamide; Nutritional Status; Phenylurea Compounds; Preoperative Period; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Survival Rate; Young Adult | 2017 |
Leg ulcers associated with cutaneous vascular degeneration in a patient receiving pazopanib chemotherapy.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indazoles; Kidney Neoplasms; Leg Ulcer; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Sorafenib; Sulfonamides | 2017 |
Evaluation of renal function change during first-line tyrosine kinase inhibitor therapy for metastatic renal cell carcinoma.
Topics: Aged; Carcinoma, Renal Cell; Disease-Free Survival; Female; Glomerular Filtration Rate; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasms, Second Primary; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Sorafenib; Sunitinib | 2017 |
CXCR1 expression predicts benefit from tyrosine kinase inhibitors therapy in patients with metastatic renal cell carcinoma.
Topics: Aged; Biomarkers, Tumor; Carcinoma, Renal Cell; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyrroles; Receptors, Interleukin-8A; Retrospective Studies; Sorafenib; Sunitinib; Survival Rate | 2018 |
Skull Base Metastasis From Occult Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Combined Modality Therapy; Everolimus; Humans; Immunotherapy; Indoles; Kidney Neoplasms; Male; Neoplasms, Unknown Primary; Nephrectomy; Niacinamide; Phenylurea Compounds; Pyrroles; Skull Base Neoplasms; Sorafenib; Sunitinib | 2018 |
Sorafenib induces renal cell carcinoma apoptosis
Topics: Activating Transcription Factor 4; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Carcinoma, Renal Cell; Cell Survival; Dose-Response Relationship, Drug; Gene Knockdown Techniques; Humans; Kidney Neoplasms; Proto-Oncogene Proteins; Reactive Oxygen Species; Sorafenib; Transcription Factor CHOP; Transfection; Up-Regulation | 2018 |
Monocarboxylate transporters MCT1 and MCT4 are independent prognostic biomarkers for the survival of patients with clear cell renal cell carcinoma and those receiving therapy targeting angiogenesis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Renal Cell; Cohort Studies; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Monocarboxylic Acid Transporters; Muscle Proteins; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Prognosis; Pyrroles; Sorafenib; Sunitinib; Survival Rate; Symporters; Vascular Endothelial Growth Factor A | 2018 |
Niclosamide Exhibits Potent Anticancer Activity and Synergizes with Sorafenib in Human Renal Cell Cancer Cells.
Topics: Carcinoma, Renal Cell; Cell Cycle; Drug Synergism; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Kidney Neoplasms; Neoplasm Proteins; Niacinamide; Niclosamide; Phenylurea Compounds; PTEN Phosphohydrolase; Sorafenib | 2018 |
[Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Diarrhea; Disease Progression; Disease-Free Survival; Hand-Foot Syndrome; Humans; Indoles; Kidney Neoplasms; Multivariate Analysis; Neutropenia; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Pyrroles; Retrospective Studies; Risk Factors; Sorafenib; Sunitinib; Thrombocytopenia; Treatment Outcome | 2018 |
RASSF6-mediated inhibition of Mcl-1 through JNK activation improves the anti-tumor effects of sorafenib in renal cell carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Carcinoma, Renal Cell; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Kidney Neoplasms; MAP Kinase Kinase 4; Mice; Mice, Inbred BALB C; Mice, Nude; Monomeric GTP-Binding Proteins; Myeloid Cell Leukemia Sequence 1 Protein; Prognosis; Sorafenib; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2018 |
Evaluation of efficacy and safety of sorafenib in kidney cancer patients aged 75 years and older: a propensity score-matched analysis.
Topics: Aged; Aged, 80 and over; Disease-Free Survival; Female; Glomerular Filtration Rate; Humans; Kidney Neoplasms; Male; Prognosis; Propensity Score; Protein Kinase Inhibitors; Sorafenib | 2018 |
Long non-coding RNA GAS5 sensitizes renal cell carcinoma to sorafenib via miR-21/SOX5 pathway.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Resistance, Neoplasm; Female; Humans; Kidney Neoplasms; Male; MicroRNAs; Middle Aged; RNA, Long Noncoding; Sorafenib; SOXD Transcription Factors | 2019 |
Retrospective analysis on the efficacy of sunitinib/sorafenib in combination with dendritic cells-cytokine-induced killer in metastasis renal cell carcinoma after radical nephrectomy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Carcinoma, Renal Cell; Combined Modality Therapy; Cytokine-Induced Killer Cells; Dendritic Cells; Female; Humans; Immunotherapy, Adoptive; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Postoperative Care; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Survival Analysis; Treatment Outcome | 2018 |
Angiopoietin-like protein 3 blocks nuclear import of FAK and contributes to sorafenib response.
Topics: Active Transport, Cell Nucleus; Angiopoietin-Like Protein 3; Angiopoietin-like Proteins; Animals; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Nucleus; Focal Adhesion Kinase 1; Gene Expression Regulation, Neoplastic; Humans; Kidney Neoplasms; Male; Mice; Sorafenib; Treatment Outcome; Tumor Suppressor Protein p53; Ubiquitination; Up-Regulation; Xenograft Model Antitumor Assays | 2018 |
Autophagic cell death associated to Sorafenib in renal cell carcinoma is mediated through Akt inhibition in an ERK1/2 independent fashion.
Topics: Autophagy; Blotting, Western; Carcinoma, Renal Cell; Caspase 3; Caspase 7; Cell Line, Tumor; Cell Survival; Humans; Kidney Neoplasms; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinase 7; p38 Mitogen-Activated Protein Kinases; Proto-Oncogene Proteins c-akt; Sorafenib | 2018 |
Patterns of Relapse and Implications for Post-Nephrectomy Surveillance in Patients with High Risk Nonclear Cell Renal Cell Carcinoma: Subgroup Analysis of the Phase 3 ECOG-ACRIN E2805 Trial.
Topics: Adult; Aged; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Disease-Free Survival; Female; Follow-Up Studies; Guideline Adherence; Humans; Incidence; Kidney; Kidney Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Nephrectomy; Postoperative Period; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome | 2019 |
Cost analysis for different sequential treatment regimens for metastatic renal cell carcinoma in China.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Carcinoma, Renal Cell; China; Cost-Benefit Analysis; Disease-Free Survival; Everolimus; Female; Humans; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Models, Econometric; Neoplasm Staging; Sorafenib; Sunitinib | 2018 |
Aortic Dissection and Cardiac Dysfunction Emerged Coincidentally During the Long-Term Treatment with Angiogenesis Inhibitors for Metastatic Renal Cell Carcinoma.
Topics: Aged; Angiogenesis Inhibitors; Aortic Dissection; Axitinib; Carcinoma, Renal Cell; Heart Diseases; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Lung Neoplasms; Male; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Vascular Endothelial Growth Factor A | 2018 |
Tumor hypoxia directed multimodal nanotherapy for overcoming drug resistance in renal cell carcinoma and reprogramming macrophages.
Topics: Acetazolamide; Animals; Antineoplastic Agents; Apoptosis; Carbonic Anhydrase IX; Carcinoma, Renal Cell; Cell Hypoxia; Cell Line, Tumor; Cell Survival; Cellular Reprogramming; Combined Modality Therapy; Drug Carriers; Drug Resistance, Neoplasm; Everolimus; Female; Humans; Kidney Neoplasms; Macrophages; Mice; Mice, Nude; Nanoparticles; Permeability; Proof of Concept Study; Sorafenib; Theranostic Nanomedicine; Tumor Hypoxia | 2018 |
Sunitinib or Sorafenib as Neoadjuvant Therapy May not Improve the Survival Outcomes of Renal Cell Carcinoma with Tumor Thrombus.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Follow-Up Studies; Humans; Kidney Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Prognosis; Retrospective Studies; Severity of Illness Index; Sorafenib; Sunitinib; Thrombosis; Treatment Outcome | 2018 |
Risk prediction models for cancer-specific survival following cytoreductive nephrectomy in the contemporary era.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Cohort Studies; Combined Modality Therapy; Cytoreduction Surgical Procedures; Disease-Free Survival; Female; Humans; Immunotherapy; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Nephrectomy; Proportional Hazards Models; Retrospective Studies; Risk Factors; Sorafenib | 2018 |
Comparing survival functions with interval-censored data in the presence of an intermediate clinical event.
Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Biometry; Carcinoma, Renal Cell; Data Interpretation, Statistical; Humans; Kaplan-Meier Estimate; Kidney Neoplasms; Models, Theoretical; Outcome Assessment, Health Care; Proportional Hazards Models; Randomized Controlled Trials as Topic; Reproducibility of Results; Sorafenib; Sunitinib | 2018 |
Tumor growth velocity: A modified tumor growth rate defining tumor progression during sorafenib treatment in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Disease Progression; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Grading; Neoplasm Metastasis; Protein Kinase Inhibitors; Sorafenib; Survival Analysis; Treatment Outcome; Tumor Burden; Young Adult | 2019 |
Re: Patients' Preferences for Adjuvant Sorafenib after Resection of Renal Cell Carcinoma in the SORCE Trial: What Makes it Worthwhile?
Topics: Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Patient Preference; Phenylurea Compounds; Sorafenib | 2018 |
Symptomatic treatment of brain metastases in renal cell carcinoma with sorafenib.
Topics: Aged; Asian People; Brain Neoplasms; Carcinoma, Renal Cell; Fatal Outcome; Female; Hand-Foot Syndrome; Humans; Kidney Neoplasms; Lung Neoplasms; Protein Kinase Inhibitors; Retreatment; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome | 2018 |
Efficacy of cryoablation combined with sorafenib for the treatment of advanced renal cell carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Cryosurgery; Female; Humans; Kidney Neoplasms; Male; Sorafenib | 2019 |
Efficacy of sorafenib adjuvant therapy in northwestern Chinese patients with non-metastatic renal-cell carcinoma after nephrectomy: A multicenter retrospective study.
Topics: Adult; Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Nephrectomy; Retrospective Studies; Risk Factors; Sorafenib | 2019 |
Hypoxia-Associated Factor (HAF) Mediates Neurofibromin Ubiquitination and Degradation Leading to Ras-ERK Pathway Activation in Hypoxia.
Topics: Basic Helix-Loop-Helix Transcription Factors; Carcinoma, Renal Cell; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Knockdown Techniques; Humans; Intracellular Signaling Peptides and Proteins; Kidney Neoplasms; MAP Kinase Signaling System; Neurofibromin 1; Proteolysis; ras Proteins; Ribonucleoproteins, Small Nuclear; Sorafenib; Sunitinib; Tumor Hypoxia; Ubiquitination; Von Hippel-Lindau Tumor Suppressor Protein | 2019 |
Clinical Outcomes of 42 Renal Cell Carcinoma Patients With Metastases Solely to the Lung Who Received Sorafenib as Second-line Systemic Therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Cytokines; Disease Progression; Disease-Free Survival; Female; Humans; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Prognosis; Retrospective Studies; Sorafenib; Treatment Outcome | 2019 |
Serum Alpha1-Globulin as a Novel Prognostic Factor in Metastatic Renal Cell Carcinoma Treated with Tyrosine Kinase Inhibitors.
Topics: Aged; Alpha-Globulins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Renal Cell; Female; Follow-Up Studies; Humans; Kidney Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Prognosis; Protein Kinase Inhibitors; Retrospective Studies; Sorafenib; Sunitinib; Survival Rate | 2019 |
Prognostic Markers for Refined Stratification of IMDC Intermediate-Risk Metastatic Clear Cell Renal Cell Carcinoma Treated with First-Line Tyrosine Kinase Inhibitor Therapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C-Reactive Protein; Carcinoma, Renal Cell; Female; Follow-Up Studies; Humans; Indazoles; Kidney Neoplasms; Lymphatic Metastasis; Lymphocytes; Male; Molecular Targeted Therapy; Neutrophils; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Risk Assessment; Sorafenib; Sulfonamides; Sunitinib; Survival Rate | 2019 |
Clinical significance of programmed death-1 and programmed death-ligand 1 expression in the tumor microenvironment of clear cell renal cell carcinoma.
Topics: Antibodies, Monoclonal; B7-H1 Antigen; Carcinoma, Renal Cell; Female; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Programmed Cell Death 1 Receptor; Protein Kinase Inhibitors; Sorafenib; Sunitinib; Tumor Microenvironment; Vascular Endothelial Growth Factor A | 2019 |
Extracellular vesicles transmitted miR-31-5p promotes sorafenib resistance by targeting MLH1 in renal cell carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Extracellular Vesicles; Humans; Kidney Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; MutL Protein Homolog 1; Sorafenib; Xenograft Model Antitumor Assays | 2020 |
The Transcription Factor Creb is Involved in Sorafenib-Inhibited Renal Cancer Cell Proliferation, Migration and Invasion.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Cyclic AMP Response Element-Binding Protein; Dose-Response Relationship, Drug; Humans; Kidney Neoplasms; Neoplasm Invasiveness; Proto-Oncogene Mas; Sorafenib; Time Factors | 2018 |
Osteonecrosis of the External Auditory Canal Associated With Oral Sorafenib Therapy: Sorafenib and Temporal Bone Osteonecrosis.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Ear Canal; Ear Diseases; Humans; Kidney Neoplasms; Male; Middle Aged; Osteonecrosis; Sorafenib; Temporal Bone | 2019 |
Estimation of renal cell carcinoma treatment effects from disease progression modeling.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease Progression; Kidney Neoplasms; Models, Statistical; Niacinamide; Phenylurea Compounds; Sorafenib | 2013 |
[Evaluation of the management of metastatic renal cell carcinoma in the era of targeted therapies. retrospective clinical study over six years].
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Female; Follow-Up Studies; Humans; Indoles; Interferons; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Survival Analysis; Treatment Outcome | 2013 |
Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib.
Topics: Aminopyridines; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Everolimus; Humans; Imidazoles; Indoles; Kidney Neoplasms; Liver Neoplasms; Mechanistic Target of Rapamycin Complex 1; Morpholines; Multiprotein Complexes; Niacinamide; Phenylurea Compounds; Phosphoinositide-3 Kinase Inhibitors; Pyrimidines; Pyrroles; Quinolines; Signal Transduction; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases | 2013 |
Second line treatment of metastatic renal cell carcinoma: The Institut Gustave Roussy experience with targeted therapies in 251 consecutive patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Cardiovascular Diseases; Disease Progression; Drug Administration Schedule; Everolimus; Female; Follow-Up Studies; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome; Young Adult | 2013 |
Model-based drug development in oncology: what's next?
Topics: Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Disease Progression; Kidney Neoplasms; Models, Statistical; Niacinamide; Phenylurea Compounds; Sorafenib | 2013 |
Clinical activity of sorafenib in a previously treated advanced urothelial cancer patient.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Sorafenib; Urothelium | 2013 |
Comparative efficacy of sunitinib versus sorafenib as first-line treatment for patients with metastatic renal cell carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Pyrroles; Retrospective Studies; Risk Factors; Sorafenib; Sunitinib; Survival Rate; Treatment Outcome; Young Adult | 2012 |
New options for second-line therapy of advanced renal cancer.
Topics: Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib | 2013 |
Case of sorafenib-induced thyroid storm.
Topics: Adrenal Gland Neoplasms; Aged; Amiodarone; Anti-Arrhythmia Agents; Antineoplastic Agents; Atrial Fibrillation; Biomarkers; Bone Neoplasms; Carcinoma, Renal Cell; Drug Administration Schedule; Fatal Outcome; Heart Arrest; Humans; Kidney Neoplasms; Lung Neoplasms; Male; Muscle Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Respiratory Aspiration; Sorafenib; Thyroid Crisis; Thyroid Hormones | 2013 |
Prolonged exposure to tyrosine kinase inhibitors or early use of everolimus in metastatic renal cell carcinoma: are the two options alike?
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Everolimus; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib | 2013 |
Neoadjuvant targeted molecular therapies in patients undergoing nephrectomy and inferior vena cava thrombectomy: is it useful?
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Combined Modality Therapy; Comorbidity; Dose-Response Relationship, Drug; Female; France; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoadjuvant Therapy; Nephrectomy; Niacinamide; Phenylurea Compounds; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Thrombectomy; Thrombosis; Treatment Outcome; Vena Cava, Inferior | 2014 |
Combination of zoledronic Acid and targeted therapy is active but may induce osteonecrosis of the jaw in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Renal Cell; Cohort Studies; Diphosphonates; Everolimus; Female; Follow-Up Studies; Fractures, Spontaneous; Humans; Imidazoles; Indazoles; Indoles; Interleukin-2; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Radiography, Panoramic; Retrospective Studies; Sirolimus; Sorafenib; Spinal Cord Compression; Sulfonamides; Sunitinib; Survival Rate; Zoledronic Acid | 2013 |
[Drug now immediately available in Germany].
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Drug Approval; Germany; Humans; Kidney Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Sorafenib | 2006 |
Multiple squamous cell carcinomas following treatment with sorafenib for renal cell carcinoma.
Topics: Aged; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Humans; Kidney Neoplasms; Male; Neoplasms, Second Primary; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Skin Neoplasms; Sorafenib | 2013 |
Prognostic factors of survival for patients with metastatic renal cell carcinoma with brain metastases treated with targeted therapy: results from the international metastatic renal cell carcinoma database consortium.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Carcinoma, Renal Cell; Databases, Factual; Humans; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Survival; Treatment Outcome | 2013 |
Successful use of sorafenib after bortezomib failure in metastatic follicular thyroid cancer - a case report.
Topics: Adenocarcinoma, Follicular; Adult; Boronic Acids; Bortezomib; Female; Humans; Kidney Neoplasms; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Pyrazines; Sorafenib; Thyroid Neoplasms; Treatment Failure; Treatment Outcome | 2013 |
A wife asks for futile therapy for her husband, a "fighter": how to respond?
Topics: Carcinoma, Renal Cell; Ethics, Medical; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib | 2013 |
Skeletal muscle density predicts prognosis in patients with metastatic renal cell carcinoma treated with targeted therapies.
Topics: Aged; Antineoplastic Agents; Body Composition; Carcinoma, Renal Cell; Clinical Trials as Topic; Disease-Free Survival; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Muscle, Skeletal; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome | 2013 |
First experience of active surveillance before systemic target therapy in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Asymptomatic Diseases; Blood Cell Count; C-Reactive Protein; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Function Tests; Kidney Neoplasms; Liver Function Tests; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Nephrectomy; Niacinamide; Patient Preference; Phenylurea Compounds; Population Surveillance; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Survival Rate; Time Factors | 2013 |
[A case of metastatic renal cell carcinoma with no evidence of disease for a long term after a favorable response to molecular-targeted therapy followed by metastasectomy].
Topics: Adrenalectomy; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Nephrectomy; Niacinamide; Phenylurea Compounds; Sorafenib | 2013 |
Angiogenic and signalling proteins correlate with sensitivity to sequential treatment in renal cell cancer.
Topics: Angiogenesis Inhibitors; Angiogenic Proteins; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cell Growth Processes; Everolimus; Humans; Indoles; Kidney Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Random Allocation; Signal Transduction; Sirolimus; Sorafenib; Sunitinib; Xenograft Model Antitumor Assays | 2013 |
Hand-foot skin reaction is associated with the clinical outcome in patients with metastatic renal cell carcinoma treated with sorafenib.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Agents; Biomarkers, Tumor; C-Reactive Protein; Carcinoma, Renal Cell; Disease-Free Survival; Female; Hand-Foot Syndrome; Hemoglobins; Humans; Kidney Neoplasms; L-Lactate Dehydrogenase; Male; Middle Aged; Nephrectomy; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Protein Kinase Inhibitors; Retrospective Studies; Risk Assessment; Sorafenib; Treatment Outcome | 2013 |
Stevens-Johnson syndrome induced by sorafenib for metastatic renal cell carcinoma.
Topics: Aged; Betamethasone; Carcinoma, Renal Cell; Fatal Outcome; Humans; Kidney Neoplasms; Male; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prednisolone; Sirolimus; Skin; Sorafenib; Stevens-Johnson Syndrome | 2013 |
[Treatment of hemodialyzed patient by targeted therapy in metastatic renal cell carcinoma: a case report].
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Male; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Renal Dialysis; Sirolimus; Sorafenib | 2013 |
[Complete remission by sorafenib for local reccurence of renal cell carcinoma with a tempraly elevation of C-reactive protein: a case report].
Topics: Aged; Antineoplastic Agents; C-Reactive Protein; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Male; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Remission Induction; Sorafenib | 2013 |
[A case of metastatic renal cell carcinoma associated with Birt-Hogg-Dubé syndrome treated with molecular-targeting agents].
Topics: Animals; Antineoplastic Agents; Birt-Hogg-Dube Syndrome; Carcinoma, Renal Cell; Everolimus; Humans; In Vitro Techniques; Indoles; Kidney Neoplasms; Male; Mice, Knockout; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyrroles; Sirolimus; Sorafenib; Sunitinib | 2013 |
[Extracorporeal partial nephrectomy and auto-transplantation after presurgical targeted therapy with tyrosine kinase inhibitors for renal cell cancer].
Topics: Aged; Carcinoma, Renal Cell; Female; Humans; Kidney Neoplasms; Molecular Targeted Therapy; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Transplantation, Autologous; Treatment Outcome | 2013 |
Slow and steady wins the race: practical (and philosophical) considerations of treatment activity evaluation when novel anticancer agents just slow neoplastic progression.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Everolimus; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Sirolimus; Sorafenib | 2014 |
Sorafenib induced eruptive melanocytic lesions.
Topics: Antineoplastic Agents; Brachytherapy; Carcinoma, Renal Cell; Drug Eruptions; Fatal Outcome; Humans; Kidney Neoplasms; Lentigo; Lung Neoplasms; Male; Middle Aged; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib | 2013 |
Preserving the sanctity of overall survival for drugs approved on the basis of progression-free survival: tivozanib as a case study.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Kidney Neoplasms; Male; Neoadjuvant Therapy; Niacinamide; Phenylurea Compounds; Quinolines; Sorafenib | 2013 |
Sorafenib and sunitinib for elderly patients with renal cell carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Asthenia; Carcinoma, Renal Cell; Disease-Free Survival; Drug Eruptions; Female; Humans; Indoles; Kidney Neoplasms; Male; Neutropenia; Niacinamide; Phenylurea Compounds; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome | 2013 |
Major response with sorafenib in advanced renal cell carcinoma after 14 years of follow-up.
Topics: Adult; Brain Neoplasms; Carcinoma, Renal Cell; Disease Progression; Female; Follow-Up Studies; Humans; Kidney Neoplasms; Lung Neoplasms; Mediastinal Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Treatment Outcome | 2013 |
Exposure-toxicity relationship of sorafenib in Japanese patients with renal cell carcinoma and hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Exanthema; Female; Hand-Foot Syndrome; Humans; Hypertension; Kidney Neoplasms; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Young Adult | 2014 |
Axitinib in advanced renal-cell carcinoma.
Topics: Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Sorafenib | 2013 |
A retrospective analysis of two different sequences of therapy lines for advanced kidney cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Everolimus; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Survival Rate; TOR Serine-Threonine Kinases | 2013 |
Tyrosine kinase inhibitor-induced vasculopathy in clear cell renal cell carcinoma: an unrecognized antitumour mechanism.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neovascularization, Pathologic; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sorafenib; Sunitinib | 2014 |
Association between hemoglobin, calcium, and lactate dehydrogenase variability and mortality among metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Calcium; Carcinoma, Renal Cell; Disease-Free Survival; Female; Hemoglobin A; Humans; Indazoles; Indoles; Kidney Neoplasms; L-Lactate Dehydrogenase; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Risk Assessment; Sorafenib; Sulfonamides; Sunitinib; Survival Rate; Vascular Endothelial Growth Factor A | 2014 |
Clinical and laboratory prognostic factors in patients with metastatic renal cell carcinoma treated with sunitinib and sorafenib after progression on cytokines.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cytokines; Disease Progression; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Survival Rate | 2014 |
Comparative outcomes of everolimus, temsirolimus and sorafenib as second targeted therapies for metastatic renal cell carcinoma: a US medical record review.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Everolimus; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Retrospective Studies; Sirolimus; Sorafenib; Treatment Outcome | 2014 |
Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Carcinoma, Renal Cell; Clinical Trials as Topic; Disease-Free Survival; Eligibility Determination; Humans; Indazoles; Indoles; Kaplan-Meier Estimate; Karnofsky Performance Status; Kidney Neoplasms; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; Treatment Outcome | 2014 |
Characterization of mechanism involved in acquired resistance to sorafenib in a mouse renal cell cancer RenCa model.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Clusterin; Disease Models, Animal; Drug Resistance, Neoplasm; Inhibitory Concentration 50; Kidney Neoplasms; Mice; Niacinamide; Phenylurea Compounds; Sorafenib; Transcriptome | 2014 |
Cost-effectiveness of sorafenib compared to best supportive care in second line renal cell cancer from a payer perspective in Cyprus.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Cost-Benefit Analysis; Cyprus; Decision Support Techniques; Humans; Kidney Neoplasms; Markov Chains; Niacinamide; Phenylurea Compounds; Practice Guidelines as Topic; Quality-Adjusted Life Years; Reimbursement Mechanisms; Sorafenib | 2014 |
Sorafenib-induced tumor response in a patient with metastatic epithelioid angiomyolipoma.
Topics: Adult; Angiomyolipoma; Antineoplastic Agents; Biopsy, Needle; Humans; Kidney Neoplasms; Lung Neoplasms; Male; Nephrectomy; Niacinamide; Phenylurea Compounds; Sorafenib; Tomography, X-Ray Computed | 2014 |
Treatment of collecting duct carcinoma: current status and future perspectives.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Cohort Studies; Humans; Indazoles; Kidney Neoplasms; Middle Aged; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyrimidines; Sirolimus; Sorafenib; Sulfonamides | 2014 |
Maturing of renal cancer therapeutics.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Sirolimus; Sorafenib; Sunitinib | 2014 |
Overall survival after immunotherapy, tyrosine kinase inhibitors and surgery in treatment of metastatic renal cell cancer: outcome of 143 consecutive patients from a single centre.
Topics: Aged; Algorithms; Carcinoma, Renal Cell; Combined Modality Therapy; Denmark; Enzyme Inhibitors; Female; Humans; Immunotherapy; Indoles; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Niacinamide; Phenylurea Compounds; Prognosis; Protein-Tyrosine Kinases; Pyrroles; Retrospective Studies; Risk Factors; Sorafenib; Sunitinib; Survival Rate; Time Factors; TOR Serine-Threonine Kinases; Treatment Outcome | 2014 |
[Systemic treatment of metastatic renal cell carcinoma: change of paradigms after introduction of targeted therapy].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Combined Modality Therapy; Female; Humans; Immunotherapy; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Neoplasm Staging; Nephrectomy; Niacinamide; Phenylurea Compounds; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Survival Rate | 2014 |
Third-line dovitinib in metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Benzimidazoles; Carcinoma, Renal Cell; Female; Humans; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolones; Sorafenib | 2014 |
Therapy of mRCC beyond mTOR-inhibition in clinical practice: results of a retrospective analysis.
Topics: Adult; Aged; Carcinoma, Renal Cell; Clinical Trials as Topic; Everolimus; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases | 2014 |
Outcomes of patients with metastatic renal cell carcinoma and end-stage renal disease receiving dialysis and targeted therapies: a single institution experience.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Everolimus; Female; Humans; Indazoles; Kidney Failure, Chronic; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Renal Dialysis; Retrospective Studies; Sirolimus; Sorafenib; Sulfonamides; Treatment Outcome | 2014 |
Novel combination therapy with imiquimod and sorafenib for renal cell carcinoma.
Topics: Adenocarcinoma; Aminoquinolines; Animals; Antineoplastic Agents; Carcinoma, Renal Cell; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Disease Models, Animal; Drug Therapy, Combination; Female; Imiquimod; Kidney Neoplasms; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2014 |
Management of sorafenib-related adverse events: a clinician's perspective.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Disease Management; Fatigue; Gastrointestinal Diseases; Hand-Foot Syndrome; Humans; Hypertension; Kidney Neoplasms; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Physicians; Sorafenib | 2014 |
Management of common adverse events in patients treated with sorafenib: nurse and pharmacist perspective.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Disease Management; Fatigue; Gastrointestinal Diseases; Hand-Foot Syndrome; Humans; Hypertension; Kidney Neoplasms; Liver Neoplasms; Niacinamide; Nurses; Patient Education as Topic; Pharmacists; Phenylurea Compounds; Randomized Controlled Trials as Topic; Sorafenib | 2014 |
Prognostic significance of bone metastases and bisphosphonate therapy in patients with renal cell carcinoma.
Topics: Aged; Antineoplastic Agents; Axitinib; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Renal Cell; Diphosphonates; Disease-Free Survival; Female; Humans; Hypocalcemia; Imidazoles; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Pamidronate; Phenylurea Compounds; Prognosis; Pyrroles; Renal Insufficiency; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Survival Rate; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A; Zoledronic Acid | 2014 |
Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Follow-Up Studies; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Retrospective Studies; Sorafenib; Treatment Outcome | 2014 |
The relevance of testing the efficacy of anti-angiogenesis treatments on cells derived from primary tumors: a new method for the personalized treatment of renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Carcinoma, Renal Cell; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Gene Expression; Humans; Indoles; Kidney Neoplasms; Mice; Molecular Targeted Therapy; Neoplasm Metastasis; Neoplasm Staging; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Precision Medicine; Pyrroles; Receptor Protein-Tyrosine Kinases; Sorafenib; Sunitinib; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2014 |
[Metastasized renal cell carcinoma - research subjects needed!].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Drug Administration Schedule; Humans; Indazoles; Kidney Neoplasms; Multicenter Studies as Topic; Neoplasm Metastasis; Niacinamide; Patient Selection; Phenylurea Compounds; Pyrimidines; Randomized Controlled Trials as Topic; Sorafenib; Sulfonamides | 2014 |
Impact of surgery on the prognosis of metastatic renal cell carcinoma with IVC thrombus received TKI therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplastic Cells, Circulating; Nephrectomy; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis; Thrombectomy; Treatment Outcome; Vena Cava, Inferior; Venous Thrombosis | 2014 |
Sequential Tyrosine Kinase Inhibitors (TKIs) in metastatic renal cell carcinoma: results from a large cohort of patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cohort Studies; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome | 2014 |
Sequential targeted therapy after pazopanib therapy in patients with metastatic renal cell cancer: efficacy and toxicity.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Everolimus; Female; Follow-Up Studies; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Pyrimidines; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Survival Rate; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2014 |
Efficacy of targeted therapy for metastatic renal cell carcinoma in the elderly patient population.
Topics: Age Factors; Aged; Aged, 80 and over; Aging; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Databases, Factual; Female; Humans; Indoles; Kidney Neoplasms; Male; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2014 |
Metastatic involvement of the maxillary antrum from an uncommon source.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Chemoradiotherapy, Adjuvant; Embolization, Therapeutic; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Male; Maxillary Sinus Neoplasms; Nephrectomy; Niacinamide; Palatal Neoplasms; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib | 2014 |
Sarcomatoid dedifferentiation in metastatic clear cell renal cell carcinoma and outcome on treatment with anti-vascular endothelial growth factor receptor tyrosine kinase inhibitors: a retrospective analysis.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Cell Differentiation; Disease-Free Survival; Female; Humans; Imidazoles; Indazoles; Indoles; Kidney; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib; Treatment Outcome | 2014 |
Prognostic value of hematologic parameters in patients with metastatic renal cell carcinoma using tyrosine kinase inhibitors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Cohort Studies; Disease-Free Survival; Eosinophils; Female; Hemoglobins; Humans; Indazoles; Indoles; Kidney Neoplasms; Leukocyte Count; Lymphocyte Count; Male; Middle Aged; Multivariate Analysis; Neutrophils; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib | 2014 |
Hyponatremia as a powerful prognostic predictor for Japanese patients with clear cell renal cell carcinoma treated with a tyrosine kinase inhibitor.
Topics: Aged; Antineoplastic Agents; C-Reactive Protein; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Hyponatremia; Indoles; Japan; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Retrospective Studies; Risk Factors; Serum Albumin; Sodium; Sorafenib; Sunitinib; Survival Rate | 2015 |
[Prognostic value of toxicities induced by targeted therapies in patients treated for a metastatic renal cell carcinoma].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Everolimus; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Prognosis; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Survival Rate | 2014 |
Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib | 2015 |
Delayed onset perforating folliculitis associated with sorafenib.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Drug Eruptions; Folliculitis; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Time Factors | 2014 |
Survival trends among patients with advanced renal cell carcinoma in the United States.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; SEER Program; Sorafenib; Survival Analysis; Survival Rate; Time Factors; Treatment Outcome; United States; Young Adult | 2015 |
MiR-200c sensitizes clear-cell renal cell carcinoma cells to sorafenib and imatinib by targeting heme oxygenase-1.
Topics: Antineoplastic Agents; Benzamides; Carcinoma, Renal Cell; Cell Line, Tumor; DNA Methylation; Heme Oxygenase-1; Humans; Imatinib Mesylate; Kidney Neoplasms; MicroRNAs; Niacinamide; Phenylurea Compounds; Piperazines; Promoter Regions, Genetic; Pyrimidines; Sorafenib | 2014 |
Prognostic factors in renal cell carcinoma patients treated with sorafenib: results from the Czech registry.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Czech Republic; Databases, Factual; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Registries; Retrospective Studies; Sorafenib; Treatment Outcome; Young Adult | 2015 |
Molecular analysis of sunitinib resistant renal cell carcinoma cells after sequential treatment with RAD001 (everolimus) or sorafenib.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Cell Line, Tumor; Everolimus; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyrroles; Sirolimus; Sorafenib; Sunitinib | 2015 |
Sorafenib treatment of advanced renal cell carcinoma patients in daily practice: the large international PREDICT study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care Facilities; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prospective Studies; Sorafenib; Treatment Outcome; Young Adult | 2015 |
Hypoxia promotes 786-O cells invasiveness and resistance to sorafenib via HIF-2α/COX-2.
Topics: Animals; Antineoplastic Agents; Basic Helix-Loop-Helix Transcription Factors; Cadherins; Cyclooxygenase 2; Drug Resistance, Neoplasm; Humans; Hypoxia; Kidney Neoplasms; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Snail Family Transcription Factors; Sorafenib; Transcription Factors; Tumor Cells, Cultured | 2015 |
Health economic changes as a result of implementation of targeted therapy for metastatic renal cell carcinoma: national results from DARENCA study 2.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Angiogenesis Inhibitors; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Costs and Cost Analysis; Denmark; Drug Costs; Efficiency; Employment; Everolimus; Female; Fluorouracil; Health Care Costs; Hospitalization; Humans; Immunologic Factors; Indoles; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Radiography; Radiotherapy; Registries; Sirolimus; Sorafenib; Sunitinib | 2015 |
Comparison of sorafenib-loaded poly (lactic/glycolic) acid and DPPC liposome nanoparticles in the in vitro treatment of renal cell carcinoma.
Topics: 1,2-Dipalmitoylphosphatidylcholine; Antineoplastic Agents; Carcinoma, Renal Cell; Cell Line, Tumor; Chemistry, Pharmaceutical; Chitosan; Dose-Response Relationship, Drug; Drug Carriers; Humans; Hydrophobic and Hydrophilic Interactions; Kidney Neoplasms; Kinetics; Lactic Acid; Liposomes; Nanoparticles; Nanotechnology; Niacinamide; Phenylurea Compounds; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Solubility; Sorafenib; Technology, Pharmaceutical | 2015 |
Cyclophilin D-mediated apoptosis attributes to sorafenib-induced cytotoxicity in clear cell-renal cell carcinoma.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Renal Cell; Cell Line; Cell Line, Tumor; Cell Survival; Cyclophilins; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Kidney Neoplasms; Male; Membrane Potential, Mitochondrial; Middle Aged; Niacinamide; Peptidyl-Prolyl Isomerase F; Phenylurea Compounds; Sorafenib | 2015 |
[Five-year therapeutic experience of sorafenib for patients with advanced renal cell carcinoma].
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Diarrhea; Fatigue; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Niacinamide; Phenylurea Compounds; Sorafenib | 2014 |
Sorafenib neoadjuvant therapy in the treatment of high risk renal cell carcinoma.
Topics: Adult; Aged; Carcinoma, Renal Cell; Female; Follow-Up Studies; Humans; Kidney Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Niacinamide; Phenylurea Compounds; Preoperative Period; Risk; Sorafenib; Treatment Outcome | 2015 |
miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cytochrome P-450 CYP1B1; Drug Resistance, Neoplasm; Hep G2 Cells; Humans; Inactivation, Metabolic; Kidney Neoplasms; Liver Neoplasms; Mice; MicroRNAs; Niacinamide; Phenylurea Compounds; RNA, Messenger; Sorafenib; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2015 |
Education and imaging. Hepatology: Complete regression of locally advanced hepatocellular carcinoma following Sorafenib monotherapy.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Remission Induction; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
MiRNA-30a-mediated autophagy inhibition sensitizes renal cell carcinoma cells to sorafenib.
Topics: Aged; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Autophagy-Related Protein 5; Beclin-1; Carcinoma, Renal Cell; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Female; Gene Knockdown Techniques; Humans; Kidney Neoplasms; Male; Membrane Proteins; MicroRNAs; Microtubule-Associated Proteins; Middle Aged; Niacinamide; Phenylurea Compounds; RNA, Neoplasm; RNA, Small Interfering; Signal Transduction; Sorafenib; Up-Regulation | 2015 |
Relationship of pathologic factors to efficacy of sorafenib treatment in patients with metastatic clear cell renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease Progression; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Necrosis; Neoplasm Grading; Neoplasm Staging; Nephrectomy; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Prognosis; Sorafenib | 2015 |
Professor Shukui Qin: patient reported outcomes in study of axitinib or sorafenib in Asian patients with metastatic renal cell carcinoma.
Topics: Asia; Asian People; Axitinib; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Time Factors; Treatment Outcome | 2015 |
Sorafenib enhances the antitumor effects of anti-CTLA-4 antibody in a murine cancer model by inhibiting myeloid-derived suppressor cells.
Topics: Animals; Antibodies, Anti-Idiotypic; CD8-Positive T-Lymphocytes; CTLA-4 Antigen; Humans; Kidney Neoplasms; Lymphocyte Activation; Mice; Myeloid Cells; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Sorafenib | 2015 |
Enhanced sensitivity to sorafenib by inhibition of Akt1 expression in human renal cell carcinoma ACHN cells both in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Renal Cell; Cell Proliferation; Dose-Response Relationship, Drug; Gene Expression; Gene Silencing; Humans; Kidney Neoplasms; Male; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-akt; Sorafenib; Tumor Cells, Cultured | 2015 |
Cost-effectiveness analysis of axitinib through a probabilistic decision model.
Topics: Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Cost-Benefit Analysis; Disease Progression; Disease-Free Survival; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Markov Chains; Models, Economic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Quality-Adjusted Life Years; Sorafenib; Uncertainty | 2015 |
Results of the first trial assessing adjuvant tyrosine kinase inhibitors in renal cell carcinoma do not reASSURE.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Disease-Free Survival; Early Termination of Clinical Trials; Humans; Indoles; Kidney Neoplasms; Nephrectomy; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrroles; Randomized Controlled Trials as Topic; Sorafenib; Sunitinib; Treatment Outcome | 2015 |
Baseline chronic kidney disease is associated with toxicity and survival in patients treated with targeted therapies for metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Chronic Disease; Female; Glomerular Filtration Rate; Humans; Indoles; Kidney Diseases; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Survival Rate | 2015 |
Effects of Cancer Therapy Targeting Vascular Endothelial Growth Factor Receptor on Central Blood Pressure and Cardiovascular System.
Topics: Aged; Antineoplastic Agents; Arteries; Blood Pressure; Carcinoma, Renal Cell; Female; Heart; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pulse Wave Analysis; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thyroid Neoplasms; Vascular Stiffness | 2016 |
Prolonging survival in metastatic renal cell carcinoma patients treated with targeted anticancer agents: a single-center experience of treatment strategy modifications.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Carcinoma, Renal Cell; Disease-Free Survival; Female; Hand-Foot Syndrome; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Life Style; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Patient Education as Topic; Phenylurea Compounds; Pyrroles; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Sorafenib; Sunitinib; Survival Rate | 2015 |
Novel Cancer Therapeutics with Allosteric Modulation of the Mitochondrial C-Raf-DAPK Complex by Raf Inhibitor Combination Therapy.
Topics: Aged; Animals; Apoptosis; Cell Line, Tumor; Death-Associated Protein Kinases; Disease-Free Survival; Drug Synergism; Female; Gene Knockout Techniques; Humans; Indoles; Kidney Neoplasms; Male; Mice; Middle Aged; Mitochondria; Niacinamide; Phenols; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Proteins c-raf; Reactive Oxygen Species; Signal Transduction; Sorafenib; Xenograft Model Antitumor Assays | 2015 |
Assessment of early therapeutic response to sorafenib in renal cell carcinoma xenografts by dynamic contrast-enhanced and diffusion-weighted MR imaging.
Topics: Animals; Biomarkers, Tumor; Carcinoma, Renal Cell; Contrast Media; Diffusion Magnetic Resonance Imaging; Disease Models, Animal; Feasibility Studies; Kidney Neoplasms; Magnetic Resonance Imaging; Male; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Reproducibility of Results; Sensitivity and Specificity; Sorafenib; Treatment Outcome | 2015 |
Efficacy and safety of sorafenib for treatment of Japanese metastatic renal cell carcinoma patients undergoing hemodialysis.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease Progression; Disease-Free Survival; Female; Humans; Japan; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Niacinamide; Phenylurea Compounds; Renal Dialysis; Retrospective Studies; Risk Assessment; Sorafenib; Survival Rate; Treatment Outcome | 2016 |
Sorafenib-Sunitinib Sequence: The Jury Is Out.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib | 2015 |
A large-scale prospective registration study of the safety and efficacy of sorafenib tosylate in unresectable or metastatic renal cell carcinoma in Japan: results of over 3200 consecutive cases in post-marketing all-patient surveillance.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Japan; Kidney Neoplasms; Male; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Prospective Studies; Protein Kinase Inhibitors; Sorafenib; Survival Analysis; Treatment Outcome | 2015 |
Retrospective Analysis of the Efficacy and Safety of Sorafenib in Chinese Patients With Metastatic Renal Cell Carcinoma and Prognostic Factors Related to Overall Survival.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; China; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Monitoring; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; raf Kinases; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sorafenib; Treatment Outcome | 2015 |
Clinical Trial Participants With Metastatic Renal Cell Carcinoma Differ From Patients Treated in Real-World Practice.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials as Topic; Female; Humans; Indazoles; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Patients; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Severity of Illness Index; Sirolimus; Sorafenib; Sulfonamides; Sunitinib | 2015 |
Early Tumor Shrinkage Under Treatment with First-line Tyrosine Kinase Inhibitors as a Predictor of Overall Survival in Patients with Metastatic Renal Cell Carcinoma: a Retrospective Multi-Institutional Study in Japan.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Japan; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Protein Kinase Inhibitors; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome | 2016 |
Absence of Significant Correlation of Adverse Events Between First- and Second-Line Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib | 2016 |
Initial Experience of Sorafenib Neoadjuvant Therapy Combined with Retroperitoneoscopy in Treating T2 Large Renal Carcinoma.
Topics: Aged; Carcinoma, Renal Cell; Female; Humans; Kidney Neoplasms; Laparoscopy; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Niacinamide; Perioperative Care; Peritoneum; Phenylurea Compounds; Sorafenib; Tomography, X-Ray Computed | 2015 |
Cardiovascular toxicity after antiangiogenic therapy in persons older than 65 years with advanced renal cell carcinoma.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cardiovascular Diseases; Female; Humans; Incidence; Indoles; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Pyrroles; Risk Factors; SEER Program; Sorafenib; Sunitinib; Survival Analysis; United States | 2016 |
[Prognostic factors for metastatic renal cell carcinoma treated with second-line targeted therapies].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Everolimus; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Prognosis; Pyrroles; Retrospective Studies; Risk Factors; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome | 2016 |
Clinicopathological and prognostic factors for long-term survival in Chinese patients with metastatic renal cell carcinoma treated with sorafenib: a single-center retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Retrospective Studies; Sorafenib; Survival Analysis; Treatment Outcome; Young Adult | 2015 |
Growth inhibitory effect of an injectable hyaluronic acid-tyramine hydrogels incorporating human natural interferon-α and sorafenib on renal cell carcinoma cells.
Topics: Animals; Carcinoma, Renal Cell; Cell Line, Tumor; Humans; Hyaluronic Acid; Hydrogels; Interferon-alpha; Kidney Neoplasms; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Sorafenib; Tyramine; Xenograft Model Antitumor Assays | 2016 |
[Three Patients with Acute Myocardial Infarction Associated with Targeted Therapy of Sorafenib for Metastatic Renal Cell Carcinoma : Case Report].
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Myocardial Infarction; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib | 2015 |
Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell Carcin
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Databases, Factual; Diarrhea; Drug Administration Schedule; Fatigue; Female; Hand-Foot Syndrome; Humans; Imidazoles; Indazoles; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Models, Statistical; Molecular Targeted Therapy; Mucositis; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Pyrimidines; Pyrroles; Retrospective Studies; Risk Assessment; Risk Factors; Sorafenib; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A | 2016 |
Efficacy of sorafenib correlates with Memorial Sloan-Kettering Cancer Center (MSKCC) risk classification and bone metastasis in Chinese patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Asian People; Bone Neoplasms; Carcinoma, Renal Cell; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Risk Factors; Sorafenib; Survival Analysis; Treatment Outcome; Young Adult | 2016 |
Real-world dosing and drug costs with everolimus or axitinib as second targeted therapies for advanced renal cell carcinoma: a retrospective chart review in the US.
Topics: Aged; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Comorbidity; Disease-Free Survival; Dose-Response Relationship, Drug; Everolimus; Fees, Pharmaceutical; Female; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib | 2016 |
The Relationship Between the Adverse Events and Efficacy of Sorafenib in Patients With Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Study from Northwest China.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; China; Disease Progression; Female; Humans; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Young Adult | 2015 |
Long-term outcomes of tyrosine kinase inhibitor discontinuation in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease Progression; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib; Time Factors; Withholding Treatment | 2016 |
[Efficacy and safety of sorafenib in patients with advanced renal cell carcinoma].
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Diarrhea; Disease-Free Survival; Fatigue; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Treatment Outcome | 2015 |
A Case of Pancreatic Side Effects Resulting from Sorafenib and Axitinib Treatment of Stage IV Renal Cell Carcinoma.
Topics: Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Pancreatitis; Phenylurea Compounds; Sorafenib | 2015 |
Comparative effectiveness of everolimus and axitinib as second targeted therapies for metastatic renal cell carcinoma in the US: a retrospective chart review.
Topics: Aged; Animals; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Comparative Effectiveness Research; Disease-Free Survival; Everolimus; Female; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Treatment Outcome; United States | 2016 |
Outcomes for Patients with Metastatic Renal Cell Carcinoma Achieving a Complete Response on Targeted Therapy: A Registry-based Analysis.
Topics: Aged; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Registries; Response Evaluation Criteria in Solid Tumors; Sorafenib; Sulfonamides; Sunitinib; Survival Rate; Treatment Outcome; Withholding Treatment | 2016 |
Singapore Cancer Network (SCAN) Guidelines for Systemic Therapy of Metastatic Renal Cell Carcinoma (mRCC).
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Nephrectomy; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Singapore; Sirolimus; Sorafenib; Sulfonamides; Sunitinib | 2015 |
Hypothyroidism Side Effect in Patients Treated with Sunitinib or Sorafenib: Clinical and Structural Analyses.
Topics: Carcinoma, Renal Cell; Female; Humans; Hypothyroidism; Indoles; Kidney Neoplasms; Male; Models, Molecular; Molecular Docking Simulation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Receptors, Retinoic Acid; Retinoic Acid Receptor gamma; Retinoid X Receptor alpha; Sorafenib; Sunitinib | 2016 |
Posterior Reversible Encephalopathy Syndrome Associated with Sorafenib and Successful Retreatment.
Topics: Aged; Blood Pressure; Brain; Carcinoma, Renal Cell; Female; Humans; Hypertension; Immunosuppressive Agents; Kidney Neoplasms; Magnetic Resonance Imaging; Neoplasm Metastasis; Neoplasm Recurrence, Local; Posterior Leukoencephalopathy Syndrome; Sorafenib; Thrombosis; Vascular Endothelial Growth Factor A | 2018 |
Combined Treatment of Tyrosine Kinase Inhibitor-Labeled Gold Nanorod Encapsulated Albumin With Laser Thermal Ablation in a Renal Cell Carcinoma Model.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Survival; Coumarins; Drug Compounding; Gold; Humans; Kidney Neoplasms; Lasers; Nanotubes; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Serum Albumin; Solubility; Sorafenib | 2016 |
Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Diarrhea; Disease-Free Survival; Fatigue; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome | 2016 |
Adverse reactions in mRCC patients documented in routine practice by German office-based oncologists and uro-oncologists.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Diarrhea; Documentation; Fatigue; Female; Germany; Humans; Indoles; Interferons; Kidney Neoplasms; Male; Medical Oncology; Middle Aged; Nausea; Niacinamide; Phenylurea Compounds; Prospective Studies; Pyrroles; Registries; Sirolimus; Sorafenib; Stomatitis; Sunitinib | 2017 |
Resveratrol attenuates constitutive STAT3 and STAT5 activation through induction of PTPε and SHP-2 tyrosine phosphatases and potentiates sorafenib-induced apoptosis in renal cell carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Movement; Cell Survival; Humans; Kidney Neoplasms; Membrane Potential, Mitochondrial; Niacinamide; Phenylurea Compounds; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Receptor-Like Protein Tyrosine Phosphatases, Class 4; Resveratrol; S Phase Cell Cycle Checkpoints; Signal Transduction; Sorafenib; STAT3 Transcription Factor; STAT5 Transcription Factor; Stilbenes | 2016 |
Fuhrman Grade and Neutrophil-To-Lymphocyte Ratio Influence on Survival in Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Tyrosine Kinase Inhibitors.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Leukocyte Count; Lymphocyte Count; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis; Treatment Outcome; Young Adult | 2016 |
Kidney cancer: No advantage of adjuvant sunitinib or sorafenib.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2016 |
Prognostic value of pathological features of primary lesion in metastatic renal cell carcinoma treated with sorafenib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Sorafenib | 2016 |
Little Impact on Renal Function in Advanced Renal Cell Carcinoma Patients Treated with Sorafenib--Analyses of Postmarketing Surveillance in Japan in over 3,200 Consecutive Cases.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Glomerular Filtration Rate; Humans; Kidney; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Bone Neoplasms; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; Humans; Imidazoles; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Pyrroles; Remission Induction; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Survival Rate; Treatment Outcome; Tumor Burden | 2016 |
Prognostic Value of SETD2 Expression in Patients with Metastatic Renal Cell Carcinoma Treated with Tyrosine Kinase Inhibitors.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Gene Expression Regulation, Neoplastic; Histone-Lysine N-Methyltransferase; Humans; Indoles; Kidney Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Young Adult | 2016 |
Long-term response of over ten years with sorafenib monotherapy in metastatic renal cell carcinoma: a case report.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Sorafenib; Time; Treatment Outcome | 2016 |
Occurrence of hepatotoxicity with pazopanib and other anti-VEGF treatments for renal cell carcinoma: an observational study utilizing a distributed database network.
Topics: Aged; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Chemical and Drug Induced Liver Injury; Cohort Studies; Computer Communication Networks; Female; Follow-Up Studies; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A | 2016 |
Sunitinib in metastatic renal cell carcinoma (mRCC): a developing country experience. Do our patients behave differently than the Western patients?
Topics: Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Agents; Carcinoma, Renal Cell; Developing Countries; Disease-Free Survival; Fatigue; Female; Follow-Up Studies; Hand-Foot Syndrome; Humans; India; Indoles; Kidney Neoplasms; Male; Middle Aged; Mucositis; Niacinamide; Phenylurea Compounds; Pigmentation Disorders; Prospective Studies; Pyrroles; Response Evaluation Criteria in Solid Tumors; Sirolimus; Sorafenib; Sunitinib; Survival Rate; White People; Young Adult | 2016 |
Model-based prediction of progression-free survival in patients with first-line renal cell carcinoma using week 8 tumor size change from baseline.
Topics: Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; Humans; Imidazoles; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; Logistic Models; Multivariate Analysis; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyrroles; Randomized Controlled Trials as Topic; Sorafenib; Sunitinib; Time Factors | 2016 |
A retrospective study of predictive factors for unexpectedly prolonged or shortened progression-free survival and overall survival among patients with metastatic renal cell carcinoma who received first-line targeted therapy.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Pyrimidines; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis; Treatment Outcome | 2016 |
Predictive Immunohistochemical Markers Related to Drug Selection for Patients Treated with Sunitinib or Sorafenib for Metastatic Renal Cell Cancer.
Topics: Adult; Antineoplastic Agents; Basic Helix-Loop-Helix Transcription Factors; Biomarkers, Tumor; Carbonic Anhydrase IX; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Niacinamide; Phenylurea Compounds; Platelet Endothelial Cell Adhesion Molecule-1; Prognosis; Prospective Studies; Pyrroles; Receptor, Platelet-Derived Growth Factor beta; Sorafenib; Sunitinib; Tissue Array Analysis; Vascular Endothelial Growth Factor Receptor-1 | 2016 |
Overall prognostic impact of C-reactive protein level in patients with metastatic renal cell carcinoma treated with sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Cohort Studies; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Retrospective Studies; Sorafenib; Survival Rate | 2016 |
Effect of the timing of best tumor shrinkage on survival of patients with metastatic renal cell carcinoma who received first-line tyrosine kinase inhibitor therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Response Evaluation Criteria in Solid Tumors; Sorafenib; Sulfonamides; Sunitinib; Survival Rate; Time Factors | 2017 |
Eosinophil percentage elevation as a prognostic factor for overall survival in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitor.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Enzyme Inhibitors; Eosinophils; Female; Humans; Kaplan-Meier Estimate; Kidney Neoplasms; Leukocyte Count; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Protein-Tyrosine Kinases; Sorafenib; Young Adult | 2016 |
Clinical significance of sunitinib-associated macrocytosis in metastatic renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Erythrocyte Indices; Erythrocytes, Abnormal; Female; Hematologic Diseases; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2016 |
Ubenimex attenuates acquired sorafenib resistance in renal cell carcinoma by inhibiting Akt signaling in a lipophagy associated mechanism.
Topics: Adenine; Animals; Autophagy; Carcinoma, Renal Cell; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Kidney Neoplasms; Leucine; Lipid Metabolism; Mice; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-akt; Signal Transduction; Sorafenib; Xenograft Model Antitumor Assays | 2016 |
Potential biomarkers for the therapeutic efficacy of sorafenib, sunitinib and everolimus.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; Cell Cycle Proteins; Cell Line, Tumor; Disease-Free Survival; Everolimus; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Phosphoproteins; Protein Kinase Inhibitors; Pyrroles; Ribosomal Protein S6 Kinases, 70-kDa; Sorafenib; Sunitinib; Treatment Outcome | 2017 |
Long noncoding RNA-SRLR elicits intrinsic sorafenib resistance via evoking IL-6/STAT3 axis in renal cell carcinoma.
Topics: Biomarkers, Tumor; Carcinoma, Renal Cell; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Profiling; Humans; Interleukin-6; Kidney Neoplasms; Microarray Analysis; Niacinamide; Phenylurea Compounds; RNA, Long Noncoding; Signal Transduction; Sorafenib; STAT3 Transcription Factor | 2017 |
Pituitary Metastasis from Renal Cell Carcinoma: Description of a Case Report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Axitinib; Carcinoma, Renal Cell; Disease Progression; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Neurosurgical Procedures; Niacinamide; Phenylurea Compounds; Pituitary Neoplasms; Pyrroles; Radiotherapy, Adjuvant; Sorafenib; Sunitinib; Treatment Outcome | 2017 |
Sorafenib versus sunitinib as first-line treatment agents in Chinese patients with metastatic renal cell carcinoma: the largest multicenter retrospective analysis of survival and prognostic factors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome | 2017 |
Adjuvant Treatment of High-risk Renal Cell Carcinoma: Leaving the Desert?
Topics: Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Disease-Free Survival; Humans; Indoles; Kidney Neoplasms; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Risk; Risk Assessment; Sorafenib; Sunitinib; Survival Rate; Treatment Outcome | 2017 |
Combination of Everolimus with Sorafenib for Solid Renal Tumors in Tsc2
Topics: Animals; ATP-Binding Cassette Transporters; Cell Death; Cell Line, Tumor; Disease Models, Animal; Drug Synergism; Everolimus; GTPase-Activating Proteins; Kidney Neoplasms; Mice; Mice, Knockout; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Sorafenib; Tuberous Sclerosis | 2017 |
Prognostic role of N-Acetylgalactosaminyltransferase 10 in metastatic renal cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Renal Cell; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; N-Acetylgalactosaminyltransferases; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Polypeptide N-acetylgalactosaminyltransferase; Prognosis; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Survival Rate | 2017 |
Assessment of response to anti-angiogenic targeted therapy in pulmonary metastatic renal cell carcinoma: R2* value as a predictive biomarker.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Niacinamide; Observer Variation; Phenylurea Compounds; Pyrroles; Reproducibility of Results; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; ROC Curve; Sorafenib; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome | 2017 |
Real-World Survival Outcomes and Prognostic Factors Among Patients Receiving First Targeted Therapy for Advanced Renal Cell Carcinoma: A SEER-Medicare Database Analysis.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Grading; Nephrectomy; Niacinamide; Phenylurea Compounds; Prognosis; Pyrimidines; Pyrroles; SEER Program; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis; Treatment Outcome | 2017 |
Bax/Bak-independent mitochondrial depolarization and reactive oxygen species induction by sorafenib overcome resistance to apoptosis in renal cell carcinoma.
Topics: Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Carcinoma, Renal Cell; Caspase 8; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Activation; Flow Cytometry; Humans; Kidney Neoplasms; Membrane Potential, Mitochondrial; Mitochondria; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Protein Conformation; Reactive Oxygen Species; RNA, Small Interfering; Signal Transduction; Sorafenib; TNF-Related Apoptosis-Inducing Ligand | 2017 |
Pretreatment Serum Prealbumin as an Independent Prognostic Indicator in Patients With Metastatic Renal Cell Carcinoma Using Tyrosine Kinase Inhibitors as First-Line Target Therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prealbumin; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrroles; Retrospective Studies; Serum Albumin, Human; Sorafenib; Sunitinib; Treatment Outcome | 2017 |
MUC13 overexpression in renal cell carcinoma plays a central role in tumor progression and drug resistance.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Blotting, Western; Carcinoma, Renal Cell; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Humans; Immunoenzyme Techniques; Indoles; Kidney Neoplasms; Mucins; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Pyrroles; Sorafenib; Sunitinib; Survival Rate; Tumor Cells, Cultured | 2017 |
Tumoral cubilin is a predictive marker for treatment of renal cancer patients with sunitinib and sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Pharmacological; Biomarkers, Tumor; Carcinoma, Renal Cell; Disease-Free Survival; Drug Monitoring; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Pyrroles; Receptors, Cell Surface; Sorafenib; Sunitinib; Treatment Outcome | 2017 |
Primary Tumor Characteristics Are Important Prognostic Factors for Sorafenib-Treated Patients with Metastatic Renal Cell Carcinoma: A Retrospective Multicenter Study.
Topics: Bone Neoplasms; Carcinoma, Renal Cell; Demography; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Prognosis; Retrospective Studies; Sorafenib | 2017 |
Prognostic Value of Pretreatment Metabolic Tumor Volume and Total Lesion Glycolysis Using 18F-FDG PET/CT in Patients With Metastatic Renal Cell Carcinoma Treated With Anti-Vascular Endothelial Growth Factor-Targeted Agents.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Female; Fluorodeoxyglucose F18; Glycolysis; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Positron Emission Tomography Computed Tomography; Pyrimidines; Pyrroles; Radiopharmaceuticals; Sorafenib; Sulfonamides; Sunitinib | 2017 |
Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib.
Topics: Administration, Topical; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Female; Fluorouracil; Foot Dermatoses; Hand Dermatoses; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Male; Middle Aged; Niacinamide; Nicotinic Acids; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Urea | 2008 |
Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Biopsy; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Diagnosis, Differential; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Quinolones; Receptors, Vascular Endothelial Growth Factor; Skin Neoplasms; Sorafenib | 2008 |
Sorafenib-induced eruptive melanocytic lesions.
Topics: Administration, Oral; Antineoplastic Agents; Benzenesulfonates; Biopsy; Carcinoma, Renal Cell; Diagnosis, Differential; Drug Eruptions; Female; Follow-Up Studies; Humans; Kidney Neoplasms; Male; Middle Aged; Nevus, Pigmented; Niacinamide; Phenylurea Compounds; Pyridines; Receptors, Vascular Endothelial Growth Factor; Skin; Skin Neoplasms; Sorafenib | 2008 |
Sorafenib-induced palmoplantar hyperkeratosis.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Keratoderma, Palmoplantar; Kidney Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2008 |
Neoadjuvant therapy with sorafenib in advanced renal cell carcinoma with vena cava extension submitted to radical nephrectomy.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Follow-Up Studies; Humans; Kidney Neoplasms; Male; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Neoplastic Cells, Circulating; Nephrectomy; Niacinamide; Phenylurea Compounds; Pyridines; Risk Assessment; Sorafenib; Treatment Outcome; Vena Cava, Inferior | 2008 |
Comment on Di Silverio et al.: Neodajuvant therapy with sorafenib in advanced renal cell carcinoma with vena cava extension submitted to radical nephrectomy. Urol Int 2008;80:451-453.
Topics: Aged; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Male; Neoadjuvant Therapy; Neoplastic Cells, Circulating; Nephrectomy; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Sorafenib; Treatment Outcome; Vena Cava, Inferior | 2008 |
Pre-treatment global quality of health predicts progression free survival in metastatic kidney cancer patients treated with sorafenib or sunitinib.
Topics: Adolescent; Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Female; Health Surveys; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Niacinamide; Palliative Care; Phenylurea Compounds; Prognosis; Prospective Studies; Pyridines; Pyrroles; Quality of Life; Salvage Therapy; Sorafenib; Sunitinib; Surveys and Questionnaires; Treatment Outcome; Young Adult | 2009 |
[Regression of vena cava tumour thrombus in response to sorafenib].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Follow-Up Studies; Humans; Kidney; Kidney Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Receptors, Vascular Endothelial Growth Factor; Renal Veins; Sorafenib; Time Factors; Treatment Outcome; Venae Cavae; Venous Thrombosis | 2008 |
Efficacy of sunitinib and sorafenib in non-clear cell renal cell carcinoma: results from expanded access studies.
Topics: Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Indoles; Kidney Neoplasms; Male; Maximum Tolerated Dose; Multicenter Studies as Topic; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Risk Assessment; Sorafenib; Sunitinib; Survival Analysis; Treatment Outcome | 2008 |
A distinct cutaneous reaction to sorafenib and a multikinase inhibitor.
Topics: Administration, Oral; Benzenesulfonates; Biopsy, Needle; Drug Therapy, Combination; Follow-Up Studies; Head; Humans; Immunohistochemistry; Kidney Neoplasms; Male; Middle Aged; Neck; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Risk Assessment; Severity of Illness Index; Skin Diseases, Papulosquamous; Sorafenib; Treatment Outcome | 2008 |
Sunitinib-induced macrocytosis in patients with metastatic renal cell carcinoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anemia, Macrocytic; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Erythrocyte Indices; Female; Hematologic Tests; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Retrospective Studies; Risk Assessment; Sorafenib; Sunitinib | 2008 |
von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Chi-Square Distribution; DNA Primers; Female; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Logistic Models; Male; Middle Aged; Mutation; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Sorafenib; Sunitinib; Survival Rate; Treatment Outcome; Vascular Endothelial Growth Factor A; von Hippel-Lindau Disease | 2008 |
A Kaposi's sarcoma complete clinical response after sorafenib administration.
Topics: Benzenesulfonates; Carcinoma, Renal Cell; Drug Administration Schedule; Follow-Up Studies; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sarcoma, Kaposi; Skin Neoplasms; Sorafenib; Treatment Outcome | 2008 |
[Targeted therapy - point blank or single shot].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Delivery Systems; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib | 2008 |
Preoperative tyrosine kinase inhibition as an adjunct to debulking nephrectomy.
Topics: Aged; Benzenesulfonates; Carcinoma, Renal Cell; Combined Modality Therapy; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Niacinamide; Phenylurea Compounds; Preoperative Care; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2008 |
Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Therapy, Combination; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Time Factors; Treatment Outcome; Young Adult | 2008 |
Watchdog set to reject four drugs for kidney cancer on the NHS.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Drug Approval; Drug Costs; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; State Medicine; Sunitinib; United Kingdom | 2008 |
[New therapeutic regimes in metastasic renal-cell carcinoma].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2008 |
[Antiangiogenics: new therapeutic standards in metastatic kidney cancer].
Topics: Angiogenesis Inhibitors; Benzenesulfonates; Humans; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2008 |
Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib.
Topics: Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Melanoma; Middle Aged; Niacinamide; Phenylurea Compounds; Polycythemia; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2008 |
Long-lasting successful cerebral response with sorafenib in advanced renal cell carcinoma.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Brain Neoplasms; Carcinoma, Renal Cell; Cerebral Cortex; Female; Humans; Kidney Neoplasms; Magnetic Resonance Imaging; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2009 |
Prospective comparison of sorafenib and sunitinib for second-line treatment of cytokine-refractory kidney cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Prospective Studies; Pyridines; Pyrroles; Sample Size; Sorafenib; Sunitinib; Survival Rate; Treatment Outcome | 2008 |
Sorafenib: tolerance in patients on chronic hemodialysis: a single-center experience.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Lung Neoplasms; Male; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Receptors, Vascular Endothelial Growth Factor; Renal Dialysis; Sorafenib | 2008 |
Acute exacerbation of hemorrhagic rectocolitis during antiangiogenic therapy with sunitinib and sorafenib.
Topics: Angiogenesis Inhibitors; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proctocolitis; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2008 |
Major treatment improvements encourage kidney cancer researchers to seek further gains.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Disease-Free Survival; Everolimus; Humans; Immunosuppressive Agents; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2008 |
[Systemic therapy of metastasizing renal cell carcinoma].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Clinical Trials as Topic; Disease Progression; Drug Therapy, Combination; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Tomography, X-Ray Computed | 2008 |
[Anti-angiogenic treatment in the management of metastatic renal cell carcinoma].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Brain Neoplasms; Carcinoma, Renal Cell; Drug Administration Schedule; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib | 2008 |
Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma.
Topics: Aged; Aged, 80 and over; Benzenesulfonates; Biomarkers; Carcinoma, Renal Cell; Cardiovascular Diseases; Echocardiography; Electrocardiography; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prospective Studies; Protein Kinase Inhibitors; Pyridines; Pyrroles; Risk Factors; Sorafenib; Sunitinib; Time Factors; Treatment Outcome | 2008 |
Editorial comment on: Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Male; Neoplasm Metastasis; Neoplasm Staging; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Retrospective Studies; Risk Assessment; Sorafenib; Sunitinib; Survival Analysis; Withholding Treatment | 2009 |
Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Retrospective Studies; Risk Assessment; Sorafenib; Sunitinib; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome; Withholding Treatment | 2009 |
Localized palmar-plantar epidermal hyperplasia associated with use of sorafenib.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Eruptions; Erythema; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2008 |
Successful sorafenib treatment for metastatic renal cell carcinoma in a case with chronic renal failure.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Kidney Failure, Chronic; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2009 |
Sequential therapy with sorafenib and sunitinib in renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Survival Analysis | 2009 |
Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Drug Delivery Systems; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2009 |
Generalised erythematous skin eruptions induced by sorafenib: cutaneous toxicity and treatment outcome.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Dermatitis, Exfoliative; Drug Eruptions; Female; Humans; Kidney Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Skin; Sorafenib; Treatment Outcome | 2008 |
Antitumor effects of a combination of interferon-alpha and sorafenib on human renal carcinoma cell lines.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Extracellular Signal-Regulated MAP Kinases; Humans; Interferon-alpha; Kidney Neoplasms; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase Kinases; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Vascular Endothelial Growth Factor A | 2008 |
[Medical treatment of metastatic renal cell carcinoma after the approval and market entry of multitargeted tyrosine kinase inhibitors in Germany].
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Cohort Studies; Data Interpretation, Statistical; Female; Germany; Humans; Indoles; Kidney Neoplasms; Male; Medical Oncology; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sorafenib; Sunitinib; Surveys and Questionnaires; Time Factors; Urology | 2009 |
[Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Indoles; Kidney; Kidney Neoplasms; Neoadjuvant Therapy; Neoplasm Metastasis; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Risk Assessment; Risk Factors; Sirolimus; Sorafenib; Sunitinib; Time Factors | 2009 |
Brain magnetic resonance imaging changes after sorafenib and sunitinib chemotherapy in patients with advanced renal cell and breast carcinoma.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Brain; Brain Edema; Brain Neoplasms; Breast Neoplasms; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prospective Studies; Pyridines; Pyrroles; Seizures; Sorafenib; Sunitinib | 2009 |
Sorafenib induces therapeutic response in a patient with metastatic collecting duct carcinoma of kidney.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Lymphatic Metastasis; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome | 2009 |
Tyrosine kinase inhibitors in advanced renal cell carcinoma: the evolving treatment paradigm.
Topics: Benzenesulfonates; Carcinoma, Renal Cell; Drug Eruptions; Foot Diseases; Hand Dermatoses; Humans; Indoles; Kidney Neoplasms; Niacinamide; Paresthesia; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2009 |
Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib.
Topics: Aged; Benzenesulfonates; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Drug Eruptions; Female; Humans; Inflammation; Keratoacanthoma; Keratosis, Actinic; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Skin Neoplasms; Sorafenib | 2009 |
[Hand-foot syndrome and sorafenib].
Topics: Benzenesulfonates; Dermatology; Drug Eruptions; Foot Dermatoses; Hand Dermatoses; Humans; Kidney Neoplasms; Liver Neoplasms; Medical Oncology; Niacinamide; Pharmacy; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Skin; Sorafenib; Syndrome | 2009 |
Recommendations from the Spanish Oncology Genitourinary Group for the treatment of metastatic renal cancer.
Topics: Algorithms; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Everolimus; Humans; Indoles; Kidney Neoplasms; Linear Models; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Kinases; Pyridines; Pyrroles; Receptor Protein-Tyrosine Kinases; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factors | 2009 |
Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Cell Differentiation; Cell Line, Tumor; Dendritic Cells; Humans; Indoles; Interleukin-12; Kidney Neoplasms; Lymphocyte Activation; Lymphocyte Culture Test, Mixed; Monocytes; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; T-Lymphocytes; Vascular Endothelial Growth Factor A | 2009 |
Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Bone Neoplasms; Brain Neoplasms; Carcinoma, Renal Cell; Disease Progression; Female; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Prospective Studies; Pyridines; Pyrroles; Salvage Therapy; Sorafenib; Sunitinib; Survival Rate; Treatment Outcome | 2009 |
Antitumor efficacy of recombinant human interleukin-2 combined with sorafenib against mouse renal cell carcinoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Cell Line, Tumor; Disease Models, Animal; Female; Flow Cytometry; Immunohistochemistry; Interleukin-2; Kidney Neoplasms; Lung Neoplasms; Mice; Mice, Inbred BALB C; Niacinamide; Phenylurea Compounds; Pyridines; Recombinant Proteins; Sorafenib | 2009 |
[Toxicity of radiation therapy and antiangiogenics combination: a case report].
Topics: Adenocarcinoma; Benzenesulfonates; Humans; Kidney Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Muscle Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Radiodermatitis; Receptors, Vascular Endothelial Growth Factor; Sorafenib | 2009 |
Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models.
Topics: Animals; Atorvastatin; Benzenesulfonates; Cystadenoma; Disease Models, Animal; Doxycycline; Drug Evaluation, Preclinical; Drug Therapy, Combination; Female; Heptanoic Acids; Immunosuppressive Agents; Interferon-gamma; Kidney Neoplasms; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Nude; Neoplasms, Experimental; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sirolimus; Sorafenib; Survival Analysis; Treatment Outcome; Tuberous Sclerosis; Tuberous Sclerosis Complex 2 Protein; Tumor Burden; Tumor Suppressor Proteins | 2009 |
A cross-over response to sequential use of sunitinib after sorafenib in a patient with metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2009 |
Nephrotic-range proteinuria in a patient with a renal allograft treated with sorafenib for metastatic renal-cell carcinoma.
Topics: Angiogenesis Inhibitors; Antihypertensive Agents; Benzenesulfonates; Biopsy; Carcinoma, Renal Cell; Disease Progression; Glomerulonephritis, IGA; Humans; Hypertension; Kidney Neoplasms; Kidney Transplantation; Male; Middle Aged; Nephrotic Syndrome; Niacinamide; Phenylurea Compounds; Proteinuria; Pyridines; Sorafenib; Transplantation, Homologous | 2009 |
Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Blood Pressure; Carcinoma, Renal Cell; Humans; Hypertension; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Prospective Studies; Pyridines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2009 |
Evidence and values: requirements for public reimbursement of drugs for rare diseases--a case study in oncology.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Cost-Benefit Analysis; Drug Costs; Evidence-Based Medicine; Government Regulation; Health Policy; Health Priorities; Health Services Accessibility; Health Services Needs and Demand; Humans; Insurance, Health, Reimbursement; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Research Support as Topic; Social Values; Sorafenib; Survival Analysis; Treatment Outcome | 2009 |
Sequential sorafenib and sunitinib for renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Cohort Studies; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Female; Follow-Up Studies; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Probability; Pyridines; Pyrroles; Retrospective Studies; Risk Assessment; Sorafenib; Sunitinib; Survival Analysis; Treatment Outcome | 2009 |
Targeting renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Disease-Free Survival; Humans; Kaplan-Meier Estimate; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Randomized Controlled Trials as Topic; Sorafenib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2009 |
The reverse side of the victory: flare up of symptoms after discontinuation of sunitinib or sorafenib in renal cell cancer patients. A report of three cases.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Nephrectomy; Niacinamide; Phenylurea Compounds; Pleural Neoplasms; Pyridines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2009 |
Does arterial spin-labeling MR imaging-measured tumor perfusion correlate with renal cell cancer response to antiangiogenic therapy in a mouse model?
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Image Processing, Computer-Assisted; Kidney Neoplasms; Linear Models; Magnetic Resonance Imaging; Mice; Mice, Nude; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Spin Labels | 2009 |
Erythema multiforme induced by sorafenib.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Eruptions; Erythema Multiforme; Female; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2009 |
A case of acute haemolysis with 2 different multi target thyrosine kinase inhibitors in a patient with renal cancer.
Topics: Aged; Anemia, Hemolytic; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Hemoglobins; Hemolysis; Humans; Indoles; Kidney Neoplasms; L-Lactate Dehydrogenase; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2009 |
Sorafenib-induced erythema multiforme in metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Erythema Multiforme; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome | 2009 |
Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Drug Eruptions; Female; Foot Dermatoses; Gastrointestinal Stromal Tumors; Hand Dermatoses; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Retrospective Studies; Skin Diseases; Sorafenib; Stomatitis; Sunitinib; Young Adult | 2009 |
Surgical resection of renal cell carcinoma after targeted therapy.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Combined Modality Therapy; Female; Humans; Indoles; Interleukin-2; Kidney Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Nephrectomy; Niacinamide; Phenylurea Compounds; Postoperative Complications; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib | 2009 |
Efficacy of sorafenib on metastatic renal cell carcinoma in Asian patients: results from a multicenter study.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; China; Female; Follow-Up Studies; Humans; Kidney Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Nephrectomy; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome | 2009 |
Rlip76 transports sunitinib and sorafenib and mediates drug resistance in kidney cancer.
Topics: Animals; Antineoplastic Agents; ATP-Binding Cassette Transporters; Benzenesulfonates; Biological Transport; Blotting, Western; Cell Line, Tumor; Cell Survival; Cells, Cultured; DNA, Antisense; Doxorubicin; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; GTPase-Activating Proteins; Humans; Indoles; Kidney Neoplasms; Kinetics; Mice; Mice, Knockout; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Pyridines; Pyrroles; RNA, Small Interfering; Sorafenib; Sunitinib; Transfection; Tumor Burden | 2010 |
Long-term response in primary renal cancer to sequential antiangiogenic therapy.
Topics: Angiogenesis Inhibitors; Benzenesulfonates; Female; Humans; Indoles; Kidney Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Phosphorylcholine; Pyridines; Pyrroles; Sorafenib; Sunitinib; Time Factors | 2009 |
Safety and efficacy of sorafenib therapy in patients with metastatic kidney cancer with impaired renal function.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Female; Humans; Kidney; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2009 |
Effect of the UK postcode lottery on survival of patients with metastatic renal cancer: an audit of outcomes in patients with metastatic renal cancer suitable for treatment with tyrosine kinase inhibitors.
Topics: Angiogenesis Inhibitors; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney; Kidney Neoplasms; Male; Medical Audit; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Survival Analysis; United Kingdom | 2009 |
The histologic spectrum of epithelial neoplasms induced by sorafenib.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Biopsy; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Epithelium; Humans; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Skin Neoplasms; Sorafenib | 2009 |
Efficacy of targeted therapy in patients with renal cell carcinoma with pre-existing or new bone metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bone Neoplasms; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Compassionate Use Trials; Disease Progression; Drug Delivery Systems; Female; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Placebos; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome | 2010 |
Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease Progression; Drug Administration Schedule; Drug Eruptions; Female; Humans; Hypertension; Hypothyroidism; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib | 2010 |
Spontaneous pyopneumothorax in patients treated with mTOR inhibitors for subpleural pulmonary metastases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Calcitonin; Carcinoma, Renal Cell; Combined Modality Therapy; Disease Susceptibility; Everolimus; Fatal Outcome; Female; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Necrosis; Neoplasm Proteins; Nephrectomy; Niacinamide; Phenylurea Compounds; Pneumonia, Bacterial; Pneumothorax; Protein Precursors; Pyridines; Pyrroles; Rupture, Spontaneous; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases | 2010 |
Everolimus: in advanced renal cell carcinoma.
Topics: Benzenesulfonates; Carcinoma, Renal Cell; Cell Proliferation; Clinical Trials, Phase III as Topic; Disease-Free Survival; Double-Blind Method; Everolimus; Humans; Immunosuppressive Agents; Indoles; Kidney Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Placebos; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome | 2009 |
Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Sorafenib; Sunitinib; Survival Rate; Vascular Endothelial Growth Factor A | 2009 |
Multidisciplinary treatment including sorafenib stabilized the bone metastases of renal cell carcinoma in an immunosuppressed renal transplant recipient.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Renal Cell; Diphosphonates; Humans; Imidazoles; Immunosuppressive Agents; Incidental Findings; Interferon-alpha; Kidney Neoplasms; Kidney Transplantation; Male; Middle Aged; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Radiotherapy, Adjuvant; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome; Zoledronic Acid | 2009 |
Acute aortic dissection during sorafenib-containing therapy.
Topics: Aged; Antihypertensive Agents; Antineoplastic Combined Chemotherapy Protocols; Aortic Aneurysm; Aortic Dissection; Benzenesulfonates; Capecitabine; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Hypertension; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2010 |
Nephrotic syndrome caused by the angiogenesis inhibitor sorafenib.
Topics: Angiogenesis Inhibitors; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Nephrotic Syndrome; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2010 |
Therapy for metastatic RCC--questions remain.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2009 |
Where does the combination of sorafenib and interferon in renal cell carcinoma stand?
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Drug Delivery Systems; Humans; Interferons; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Receptors, Vascular Endothelial Growth Factor; Sorafenib | 2010 |
Sorafenib-induced hand-foot skin reaction: a Koebner phenomenon?
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Foot Dermatoses; Hand Dermatoses; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyridines; Skin Diseases; Skin Tests; Sorafenib | 2009 |
Interstitial pneumonia probably associated with sorafenib treatment: An alert of an adverse event.
Topics: Antineoplastic Agents; Asian People; Benzenesulfonates; Bone Neoplasms; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2010 |
Successful treatment of a brain-metastasized renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Brain Neoplasms; Carcinoma, Renal Cell; Follow-Up Studies; Humans; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Niacinamide; Parietal Lobe; Phenylurea Compounds; Pyridines; Radiotherapy, Adjuvant; Receptors, Vascular Endothelial Growth Factor; Sorafenib | 2009 |
Evidence-based urology in practice: when to believe a subgroup analysis?
Topics: Age Factors; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Evidence-Based Medicine; Humans; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Randomized Controlled Trials as Topic; Sorafenib | 2010 |
Salvage therapy with sorafenib plus vinblastine and fluorouracil for metastatic renal cell carcinoma.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Fluorouracil; Humans; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Salvage Therapy; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome; Vinblastine | 2009 |
The loss of radiographic enhancement in primary renal cell carcinoma tumors following multitargeted receptor tyrosine kinase therapy is an additional indicator of response.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Radiographic Image Enhancement; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome | 2010 |
[Impact of immunotherapy in metastatic kidney cancer in Germany after introduction of new target therapy--results of a telephone survey of the German Society of Immuno- and Targeted Therapy (DGFIT)].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Attitude of Health Personnel; Benzenesulfonates; Carcinoma, Renal Cell; Cooperative Behavior; Data Collection; Drug Delivery Systems; Drug Utilization; Germany; Humans; Immunotherapy; Indoles; Interdisciplinary Communication; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Medical Oncology; Niacinamide; Patient Care Team; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Urology | 2010 |
Sorafenib-induced acute myocardial infarction due to coronary artery spasm.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Coronary Vasospasm; Humans; Kidney Neoplasms; Male; Myocardial Infarction; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; rho-Associated Kinases; rhoA GTP-Binding Protein; Signal Transduction; Sorafenib | 2009 |
VEGFR TKI 'resistance' or transient clinical insensitivity to VEGFR TKI in metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Time Factors | 2010 |
Radiation recall dermatitis triggered by multi-targeted tyrosine kinase inhibitors: sunitinib and sorafenib.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyridines; Pyrroles; Radiodermatitis; Sorafenib; Sunitinib; Treatment Outcome | 2010 |
Health policy: The UK 'postcode lottery' in renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Health Care Rationing; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Regional Health Planning; Sorafenib; Sunitinib; Survival Rate; United Kingdom | 2009 |
[Sorafenib-induced multiple eruptive keratoacanthomas].
Topics: Adenocarcinoma; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Immunosuppressive Agents; Keratoacanthoma; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Skin Diseases; Sorafenib; Sunlight | 2009 |
[Clinical observation of 21 cases of metastatic renal cell carcinoma treated with sorafenib].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Diarrhea; Female; Follow-Up Studies; Humans; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Remission Induction; Sorafenib | 2009 |
Re: Sequential sorafenib and sunitinib for renal cell carcinoma M. P. Sablin, S. Negrier, A. Ravaud, S. Oudard, C. Balleyguier, J. Gautier, C. Celier, J. Medioni and B. Escudier J Urol 2009; 182: 29-34.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2010 |
Evaluation of response in malignant tumors treated with the multitargeted tyrosine kinase inhibitor sorafenib: a multitechnique imaging assessment.
Topics: Adrenal Gland Neoplasms; Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Contrast Media; Female; Humans; Kidney Neoplasms; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pheochromocytoma; Protein Kinase Inhibitors; Pyridines; Sensitivity and Specificity; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome; Ultrasonography | 2010 |
Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT.
Topics: Adult; Aged; Analysis of Variance; Benzenesulfonates; Carcinoma, Renal Cell; Contrast Media; Disease Progression; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Retrospective Studies; Sensitivity and Specificity; Sorafenib; Sunitinib; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
Experience with sorafenib and the elderly patient.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Female; Humans; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Quality of Life; Randomized Controlled Trials as Topic; Sorafenib; Survival Rate | 2010 |
Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Compassionate Use Trials; Disease-Free Survival; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; North America; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2010 |
Sunitinib and sorafenib in metastatic renal cell carcinoma patients with renal insufficiency.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Renal Insufficiency; Sorafenib; Sunitinib | 2010 |
Combination therapy of interleukin-2 and sorafenib improves survival benefits and prevents spontaneous pulmonary metastasis in murine renal cell carcinoma models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Cell Line, Tumor; Female; Interleukin-2; Kidney Neoplasms; Lung Neoplasms; Mice; Mice, Inbred BALB C; Nephrectomy; Niacinamide; Phenylurea Compounds; Pyridines; Recombinant Proteins; Sorafenib; Survival Rate | 2010 |
[Renal cell carcinoma].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2010 |
Choroidal metastasis of renal cell carcinoma: a case report.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Choroid Neoplasms; Eye Enucleation; Humans; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Nephrectomy; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2010 |
Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network.
Topics: Adolescent; Adult; Antineoplastic Agents; Antiviral Agents; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Benzenesulfonates; Carcinoma, Renal Cell; Child; Child, Preschool; Chromosomes, Human, Pair 11; Chromosomes, Human, X; Everolimus; Female; Gene Fusion; Humans; Immunosuppressive Agents; Indoles; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Research Report; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Survival Rate; TOR Serine-Threonine Kinases; Translocation, Genetic; Treatment Outcome; Vascular Endothelial Growth Factor A; Young Adult | 2010 |
Sorafenib-associated remission of psoriasis in hypernephroma: case report.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Psoriasis; Pyridines; Pyrroles; Retreatment; Sorafenib; Sunitinib; Treatment Outcome | 2010 |
Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy.
Topics: Aged; Antigens, Neoplasm; Antineoplastic Agents; Benzenesulfonates; Carbonic Anhydrase IX; Carbonic Anhydrases; Carcinoma, Renal Cell; Epidemiologic Methods; Female; Humans; Immunohistochemistry; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2010 |
Painless acute pancreatitis associated with sorafenib treatment: a case report.
Topics: Adrenal Gland Neoplasms; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Immunologic Factors; Interferon-alpha; Kidney Neoplasms; Male; Niacinamide; Pancreatitis; Phenylurea Compounds; Pyridines; Sorafenib | 2011 |
Highlights from the Eigth International Kidney Cancer Symposium.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Renal Cell; Cell Line, Tumor; Disease Models, Animal; Humans; Kidney Neoplasms; Multigene Family; Niacinamide; Phenylurea Compounds; Pyridines; Receptors, Vascular Endothelial Growth Factor; Sorafenib | 2009 |
Tolerable sorafenib therapy for a renal cell carcinoma patient with hemodialysis: a case study.
Topics: Antineoplastic Agents; Benzenesulfonates; Biotransformation; Carcinoma, Renal Cell; Drug Administration Schedule; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Renal Dialysis; Sorafenib; Treatment Outcome | 2010 |
Association of percentage of tumour burden removed with debulking nephrectomy and progression-free survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Combined Modality Therapy; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Nephrectomy; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome; Tumor Burden; Vascular Endothelial Growth Factor A | 2010 |
Effect of tyrosine kinase inhibitor treatment of renal cell carcinoma on the accumulation of carbonic anhydrase IX-specific chimeric monoclonal antibody cG250.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Benzenesulfonates; Carbonic Anhydrases; Carcinoma, Renal Cell; Drug Synergism; Female; Humans; Immunohistochemistry; Indoles; Kidney Neoplasms; Mice; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib | 2011 |
Metronomic chemotherapy for renal cancer in the landscape of targeted therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Drug Administration Schedule; Fluorouracil; Gemcitabine; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2010 |
Prognostic factors in patients treated with VEGF-targeted therapies.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Humans; Indazoles; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factors | 2010 |
Preoperative induction with sorafenib pathologically downstaged advanced renal cell carcinoma: a case report.
Topics: Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Combined Modality Therapy; Female; Humans; Kidney Neoplasms; Nephrectomy; Niacinamide; Phenylurea Compounds; Preoperative Care; Pyridines; Severity of Illness Index; Sorafenib; Tomography, X-Ray Computed | 2010 |
[Renal cell carcinoma management and therapies in 2010].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Combined Modality Therapy; Everolimus; Humans; Indoles; Interferons; Interleukin-2; Intracellular Signaling Peptides and Proteins; Kidney Neoplasms; Metabolic Networks and Pathways; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Serine-Threonine Kinases; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2010 |
[Targeted therapies: sequential and combined treatments].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Combined Modality Therapy; Cytokines; ErbB Receptors; Humans; Indoles; Interferon-alpha; Intracellular Signaling Peptides and Proteins; Kidney Neoplasms; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2010 |
[Management of side effects associated with antiangiogenic treatment in renal cell carcinoma].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Digestive System; Heart; Humans; Hypothyroidism; Indoles; Kidney Neoplasms; Lung Injury; Mucous Membrane; Muscle Fatigue; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib | 2010 |
[Advanced renal carcinomas with special situations. How to treat them?].
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Brain Neoplasms; Carcinoma, Renal Cell; Everolimus; Humans; Indoles; Intracellular Signaling Peptides and Proteins; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Serine-Threonine Kinases; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2010 |
Sorafenib with doxorubicin augments cytotoxicity to renal cell cancer through PERK inhibition.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Blotting, Western; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Nucleus; Cell Separation; Doxorubicin; eIF-2 Kinase; Eukaryotic Initiation Factor-2; Flow Cytometry; Gene Knockdown Techniques; Humans; Hydrogen Peroxide; Kidney Neoplasms; NF-E2-Related Factor 2; Niacinamide; Oxidants; Oxidative Stress; Phenylurea Compounds; Phosphorylation; Pyridines; RNA, Small Interfering; Sorafenib | 2010 |
Editorial comment.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Radiography; Sorafenib; Sunitinib; Treatment Outcome | 2010 |
Editorial comment.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Radiography; Sorafenib; Sunitinib; Treatment Outcome | 2010 |
Combined anticancer effects of sphingosine kinase inhibitors and sorafenib.
Topics: Adamantane; Adenocarcinoma; Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Caspase 3; Caspase 7; Catechols; Cell Line, Tumor; DNA Fragmentation; Drug Synergism; Female; Humans; Kidney Neoplasms; Mice; Mice, SCID; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Phosphotransferases (Alcohol Group Acceptor); Pyridines; Sorafenib; Xenograft Model Antitumor Assays | 2011 |
[Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].
Topics: Algorithms; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Disease Progression; Drug Delivery Systems; Everolimus; Humans; Indoles; Kidney Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib | 2010 |
Morphology, Attenuation, Size, and Structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy.
Topics: Adult; Aged; Angiogenesis Inhibitors; Benzenesulfonates; Carcinoma, Renal Cell; Contrast Media; Disease Progression; Female; Humans; Indoles; Iohexol; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Retrospective Studies; Sensitivity and Specificity; Sorafenib; Sunitinib; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
[Diagnosis and treatment of bone metastasis of renal cancer: an expert consensus statement (2008 version)].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bone Neoplasms; Carcinoma, Renal Cell; Humans; Interleukin-2; Kidney Neoplasms; Neoplasm Staging; Niacinamide; Pain; Phenylurea Compounds; Pyridines; Recombinant Proteins; Sorafenib | 2010 |
Non-pigmenting fixed drug eruption induced by sorafenib.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Biopsy; Carcinoma, Renal Cell; Drug Eruptions; Erythema; Humans; Kidney Neoplasms; Male; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Skin; Sorafenib | 2010 |
Sustained response following sorafenib therapy in an older adult patient with advanced renal cancer on hemodialysis: a case report.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Male; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Renal Dialysis; Sorafenib | 2011 |
Impact of sorafenib on health-related quality of life in Japanese patients with metastatic renal cell carcinoma: a prospective evaluation.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Epidemiologic Methods; Female; Health Status; Humans; Japan; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Quality of Life; Sorafenib; Treatment Outcome | 2010 |
Sorafenib-induced erythema multiforme for metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Erythema Multiforme; Female; Humans; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome | 2010 |
Long-term stable disease in metastatic renal cell carcinoma: sorafenib sequenced to sunitinib and everolimus: a case study.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Everolimus; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Sirolimus; Sorafenib; Sunitinib | 2011 |
Response to sorafenib in a patient with metastatic xp11 translocation renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Chromosomes, Human, X; Disease-Free Survival; Humans; Kidney Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Niacinamide; Phenylurea Compounds; Pleural Neoplasms; Protein Kinase Inhibitors; Pyridines; Sorafenib; Time Factors; Tomography, X-Ray Computed; Translocation, Genetic; Treatment Outcome; Young Adult | 2010 |
Treatment outcomes of sorafenib for first line or cytokinerefractory advanced renal cell carcinoma in Japanese patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Cytokines; Disease Progression; Female; Humans; Japan; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Sorafenib; Treatment Outcome | 2010 |
Sorafenib in metastatic renal cell carcinoma with sarcomatoid differentiation.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Sarcoma; Sorafenib | 2010 |
Presurgical targeted therapy with tyrosine kinase inhibitors for advanced renal cell carcinoma: clinical results and histopathological therapeutic effects.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome | 2010 |
Impact of the incorporation of tyrosine kinase inhibitor agents on the treatment of patients with a diagnosis of advanced renal cell carcinoma: study based on experience at the Hospital Universitario Central de Asturias.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Disease-Free Survival; Drug Therapy, Combination; Female; Humans; Immunologic Factors; Indoles; Interferon-alpha; Interleukin-2; Kaplan-Meier Estimate; Kidney Neoplasms; Lapatinib; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome | 2010 |
Editorial comment to Treatment outcomes of sorafenib for first line or cytokine-refractory advanced renal cell carcinoma in Japanese patients.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Cytokines; Disease Progression; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome | 2010 |
Safety and efficacy of sorafenib in elderly patients treated in the North American advanced renal cell carcinoma sorafenib expanded access program.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Ethnicity; Female; Humans; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Safety; Sorafenib; Survival Analysis | 2010 |
[Nexavar clinical registry].
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Registries; Sorafenib | 2010 |
Primitive neuroectodermal tumor of the kidney with inferior vena cava tumor thrombus during pregnancy response to sorafenib.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Female; Humans; Kidney Neoplasms; Neuroectodermal Tumors, Primitive; Niacinamide; Phenylurea Compounds; Pregnancy; Pyridines; Radiography; Sorafenib; Thrombosis; Vena Cava, Inferior | 2010 |
Safety and efficacy of the combination of erlotinib and sirolimus for the treatment of metastatic renal cell carcinoma after failure of sunitinib or sorafenib.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Chromatography, Liquid; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sunitinib; Tandem Mass Spectrometry | 2010 |
Sorafenib reduces the percentage of tumour infiltrating regulatory T cells in renal cell carcinoma patients.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Lymphocytes, Tumor-Infiltrating; Neoadjuvant Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; T-Lymphocytes, Regulatory; Treatment Outcome | 2011 |
Combination therapy with sorafenib and S-1 for renal cell carcinoma producing granulocyte colony-stimulating factor.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Drug Combinations; Granulocyte Colony-Stimulating Factor; Humans; Kidney Neoplasms; Leukocytosis; Male; Medical Futility; Niacinamide; Oxonic Acid; Phenylurea Compounds; Pyridines; Sorafenib; Tegafur | 2011 |
Hypothyroidism in patients with renal cell carcinoma: blessing or curse?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Hypothyroidism; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Sorafenib; Sunitinib; Thyrotropin; Treatment Outcome | 2011 |
Transient perforating folliculitis induced by sorafenib.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Folliculitis; Humans; Kidney Neoplasms; Male; Neutrophil Infiltration; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Remission, Spontaneous; Sorafenib | 2010 |
Hyperkeratotic eruption, hand-foot skin reaction, facial erythema, and stomatitis secondary to multi-targeted kinase inhibitor sorafenib.
Topics: Benzenesulfonates; Carcinoma, Renal Cell; Erythema; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Skin Diseases, Papulosquamous; Sorafenib; Stomatitis | 2010 |
Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Everolimus; Feasibility Studies; Female; Humans; Indoles; Italy; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Survival Rate; Time Factors; TOR Serine-Threonine Kinases; Treatment Outcome | 2010 |
High-performance liquid chromatographic method for the determination of sorafenib in human serum and peritoneal fluid.
Topics: Antineoplastic Agents; Ascitic Fluid; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Chromatography, High Pressure Liquid; Drug Monitoring; Humans; Kidney Neoplasms; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sensitivity and Specificity; Sorafenib | 2011 |
Toxic effects of sorafenib when given early after allogeneic hematopoietic stem cell transplantation.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Cell Line, Tumor; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Kidney Neoplasms; Mice; Mice, Inbred BALB C; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Transplantation, Homologous | 2010 |
[Tegafur-uracil markedly reduced pulmonary metastasis from renal cell carcinoma refractory to sorafenib, interferon and interleukin 2].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Drug Resistance, Neoplasm; Humans; Interferons; Interleukin-2; Kidney Neoplasms; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Tegafur; Tomography, X-Ray Computed; Uracil | 2010 |
Enhancing mda-7/IL-24 therapy in renal carcinoma cells by inhibiting multiple protective signaling pathways using sorafenib and by Ad.5/3 gene delivery.
Topics: Adenoviridae; Animals; Apoptosis; bcl-X Protein; Benzenesulfonates; Blotting, Western; Carcinoma, Renal Cell; Cell Line, Tumor; Culture Media, Conditioned; fas Receptor; Gene Knockdown Techniques; Gene Transfer Techniques; Genetic Therapy; Humans; Interleukins; Kidney Neoplasms; Mice; Mitochondria; Mitogen-Activated Protein Kinase Kinases; Niacinamide; Phenylurea Compounds; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyridines; Signal Transduction; Sorafenib; TOR Serine-Threonine Kinases | 2010 |
Bevacizumab for metastatic renal cell carcinoma: a monoclonal antibody in a sea of small molecules.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Disease-Free Survival; Humans; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; Multicenter Studies as Topic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis | 2010 |
111In-bevacizumab imaging of renal cell cancer and evaluation of neoadjuvant treatment with the vascular endothelial growth factor receptor inhibitor sorafenib.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Female; Humans; Immunohistochemistry; Indium Radioisotopes; Kidney Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Nephrectomy; Niacinamide; Phenylurea Compounds; Pyridines; Radionuclide Imaging; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sorafenib; Time Factors; Vascular Endothelial Growth Factor A | 2010 |
Mechanism of synergistic antitumor effect of sorafenib and interferon-α on treatment of renal cell carcinoma.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Cell Line, Tumor; Drug Synergism; Drug Therapy, Combination; Female; Humans; Immunologic Factors; Interferon-alpha; Kidney Neoplasms; Mice; Mice, Inbred BALB C; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2010 |
The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Nephrectomy; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Survival Rate; Vascular Endothelial Growth Factors | 2011 |
Kidney cancer: Does hypothyroidism predict clinical outcome?
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Hypothyroidism; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2011 |
Systemic immune tuning in renal cell carcinoma: favorable prognostic impact of TGF-β1 mRNA expression in peripheral blood mononuclear cells.
Topics: Adult; Aged; Benzenesulfonates; Carcinoma, Renal Cell; CD4-Positive T-Lymphocytes; Disease-Free Survival; Flow Cytometry; Forkhead Transcription Factors; Gene Expression; Humans; Immune Tolerance; Interleukin-10; Interleukin-2 Receptor alpha Subunit; Kidney Neoplasms; Leukocytes, Mononuclear; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; RNA, Messenger; Sorafenib; T-Lymphocytes, Regulatory; Transforming Growth Factor beta1; Treatment Outcome | 2011 |
Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Hypothyroidism; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Survival Rate; Thyrotropin; Thyroxine; Treatment Outcome; Triiodothyronine | 2011 |
Prolonged survival in renal transplant recipient with advanced renal cell carcinoma by everolimus and sorafenib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Everolimus; Female; Humans; Kidney Neoplasms; Kidney Transplantation; Lung Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sirolimus; Sorafenib | 2011 |
More than 4 years of progression-free survival in a patient with metastatic renal cell carcinoma treated sequentially with sunitinib, everolimus, sorafenib, and temsirolimus.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Drug Administration Schedule; Everolimus; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib | 2010 |
Immunomodulatory effects of sorafenib on peripheral immune effector cells in metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Cytokines; Female; Humans; Immunologic Factors; Interleukin-10; Kidney Neoplasms; Leukocytes, Mononuclear; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; RNA, Messenger; Sorafenib; T-Lymphocytes; Transforming Growth Factor beta1 | 2011 |
Initial patterns of care with oral targeted therapies for patients with renal cell carcinoma.
Topics: Administration, Oral; Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Young Adult | 2011 |
Economic evaluation of new targeted therapies for the first-line treatment of patients with metastatic renal cell carcinoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Cost-Benefit Analysis; Disease Progression; Drug Costs; Female; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Male; Markov Chains; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quality-Adjusted Life Years; Sorafenib; Sunitinib; Sweden; United States | 2011 |
Biomarkers in renal cell carcinoma: what next?
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Renal Cell; Cohort Studies; Humans; Kidney Neoplasms; Multicenter Studies as Topic; Niacinamide; Phenylurea Compounds; Pyridines; Randomized Controlled Trials as Topic; Sorafenib; Treatment Outcome | 2011 |
Temsirolimus in metastatic chromophobe renal cell carcinoma after interferon and sorafenib therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Interferons; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Salvage Therapy; Sirolimus; Sorafenib; Treatment Outcome | 2011 |
Sequential treatment with sorafenib and sunitinib in metastatic renal cell carcinoma: clinical outcomes from a retrospective clinical study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Disease Progression; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Survival Rate; Time Factors | 2012 |
Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell ca
Topics: Academic Medical Centers; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Boston; Carcinoma, Renal Cell; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Niacinamide; Observer Variation; Phenylurea Compounds; Predictive Value of Tests; Pyridines; Pyrroles; Reproducibility of Results; Retrospective Studies; ROC Curve; Sorafenib; Sunitinib; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden; Vascular Endothelial Growth Factor A | 2011 |
Tumor size is a potential predictor of response to tyrosine kinase inhibitors in renal cell cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Combined Modality Therapy; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome | 2011 |
Sorafenib may induce hypophosphatemia through a fibroblast growth factor-23 (FGF23)-independent mechanism.
Topics: Antineoplastic Agents; Benzenesulfonates; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hypophosphatemia; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2011 |
[Management of hypothyroidism secondary to tyrosine kinase inhibitors: description of treatment in three distinct clinical settings].
Topics: Adult; Benzamides; Benzenesulfonates; Carcinoma, Renal Cell; Choristoma; Female; Gastrointestinal Stromal Tumors; Humans; Hypothyroidism; Imatinib Mesylate; Indoles; Kidney Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Piperazines; Pleural Diseases; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sunitinib; Thymus Gland; Thyroxine | 2011 |
[Squamous cell carcinoma in a patient receiving sorafenib].
Topics: Antineoplastic Agents; Benzenesulfonates; Biopsy; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Cooperative Behavior; Follow-Up Studies; Humans; Interdisciplinary Communication; Kidney Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Skin; Skin Neoplasms; Sorafenib; Vascular Endothelial Growth Factor A | 2011 |
Serum interferon alpha receptor 2 mRNA may predict efficacy of interferon alpha with/without low-dose sorafenib for metastatic clear cell renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Receptor, Interferon alpha-beta; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sorafenib | 2011 |
[Economic evaluation of targeted biologic therapy in metastatic renal cell carcinoma].
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Cost-Benefit Analysis; Drug Costs; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2010 |
Surgical outcomes and complications associated with presurgical tyrosine kinase inhibition for advanced renal cell carcinoma (RCC).
Topics: Aged; Carcinoma, Renal Cell; Cohort Studies; Combined Modality Therapy; Female; Humans; Indoles; Kidney Neoplasms; Logistic Models; Male; Middle Aged; Multivariate Analysis; Nephrectomy; Niacinamide; Phenylurea Compounds; Postoperative Complications; Preoperative Care; Protein Kinase Inhibitors; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome; Urinary Bladder | 2013 |
Clinical results and pharmacokinetics of sorafenib in chronic hemodialysis patients with metastatic renal cell carcinoma in a single center.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Drug Administration Schedule; Erythropoietin; Feasibility Studies; Hematinics; Hemoglobins; Humans; Kaplan-Meier Estimate; Kidney Failure, Chronic; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Renal Dialysis; Sample Size; Sorafenib; Treatment Outcome | 2011 |
Multidrug resistance protein 2 implicates anticancer drug-resistance to sorafenib.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP-Binding Cassette Sub-Family B Member 4; Benzenesulfonates; Carcinoma, Renal Cell; Cell Cycle; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sorafenib; Substrate Specificity; Sunitinib; Swine; Transfection | 2011 |
Prognostic prediction in patients with metastatic renal cell carcinoma treated with sorafenib based on expression levels of potential molecular markers in radical nephrectomy specimens.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Bone Neoplasms; Carcinoma, Renal Cell; Combined Modality Therapy; Disease Progression; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Kidney Neoplasms; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Nephrectomy; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib; Survival Rate | 2013 |
Inhibition of angiogenic and non-angiogenic targets by sorafenib in renal cell carcinoma (RCC) in a RCC xenograft model.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Down-Regulation; Humans; Kidney Neoplasms; Male; Mice; Mice, SCID; Molecular Targeted Therapy; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2011 |
Safety and treatment patterns of multikinase inhibitors in patients with metastatic renal cell carcinoma at a tertiary oncology center in Italy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma; Fatigue; Female; Humans; Indoles; Italy; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Oncology Service, Hospital; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2011 |
Sequential therapies with sorafenib and sunitinib in advanced or metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease Progression; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Longitudinal Studies; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome | 2011 |
Safety and treatment patterns of angiogenesis inhibitors in patients with metastatic renal cell carcinoma: evidence from US community oncology clinics.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Benzenesulfonates; Cancer Care Facilities; Carcinoma, Renal Cell; Community Health Services; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Male; Medical Records; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Outcome Assessment, Health Care; Phenylurea Compounds; Practice Patterns, Physicians'; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; United States | 2012 |
Erythrocyte sedimentation rate kinetics as a marker of treatment response and predictor of prognosis in Chinese metastatic renal cell carcinoma patients treated with sorafenib.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Biomarkers; Blood Sedimentation; Carcinoma, Renal Cell; Disease Progression; Disease-Free Survival; Female; Humans; Kidney Neoplasms; Kinetics; Male; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Prognosis; Prospective Studies; Pyridines; Sorafenib | 2011 |
Impact of tyrosine kinase inhibitors on the incidence of brain metastasis in metastatic renal cell carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Brain Neoplasms; Carcinoma, Renal Cell; Female; Humans; Incidence; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2011 |
Sequential mTOR inhibitor treatment with temsirolimus in metastatic renal cell carcinoma following failure of VEGF receptor tyrosine kinase inhibitors.
Topics: Adult; Aged; Carcinoma, Renal Cell; Disease Progression; Female; Follow-Up Studies; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Survival Rate; TOR Serine-Threonine Kinases; Treatment Failure; Treatment Outcome | 2013 |
Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma--data from the Czech registry.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Drug Administration Schedule; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Registries; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome | 2012 |
Sorafenib augments cytotoxic effect of S-1 in vitro and in vivo through TS suppression.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Cell Line, Tumor; Drug Combinations; Drug Synergism; E2F1 Transcription Factor; Female; Fluorouracil; Humans; Kidney Neoplasms; Mice; Mice, Inbred BALB C; Niacinamide; Oxonic Acid; Phenylurea Compounds; Pyridines; RNA, Messenger; Sorafenib; Tegafur; Thymidylate Synthase | 2011 |
One-month relative dose intensity of not less than 50% predicts favourable progression-free survival in sorafenib therapy for advanced renal cell carcinoma in Japanese patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Japan; Kidney Neoplasms; Male; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Sorafenib; Treatment Outcome | 2011 |
Continuing response to subsequent treatment lines with tyrosine kinase inhibitors in an adolescent with metastatic renal cell carcinoma.
Topics: Adolescent; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Combined Modality Therapy; Everolimus; Fatal Outcome; Female; Humans; Kidney Neoplasms; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sirolimus; Sorafenib | 2011 |
Resistance of renal cell carcinoma to sorafenib is mediated by potentially reversible gene expression.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Kidney Neoplasms; Mice; Mice, Nude; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2011 |
[Metastatic renal cell cancer in Germany in 2010. Impact of different target therapies].
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Data Collection; Disease Progression; Drug Delivery Systems; Everolimus; Female; Germany; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Practice Patterns, Physicians'; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases | 2011 |
Editorial comment to erythrocyte sedimentation rate kinetics as a marker of treatment response and predictor of prognosis in Chinese metastatic renal cell carcinoma patients treated with sorafenib.
Topics: Antineoplastic Agents; Benzenesulfonates; Blood Sedimentation; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Sorafenib | 2011 |
Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Drug Therapy, Combination; Female; Humans; Indoles; Italy; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib | 2011 |
Efficacy of temsirolimus after previous treatment with sunitinib, sorafenib or everolimus in advanced renal cell cancer.
Topics: Aged; Aged, 80 and over; Anemia; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Diarrhea; Disease-Free Survival; Everolimus; Female; Humans; Indoles; Karnofsky Performance Status; Kidney Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Nausea; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Thrombocytopenia | 2011 |
cAMP-dependent cytosolic mislocalization of p27(kip)-cyclin D1 during quinol-thioether-induced tuberous sclerosis renal cell carcinoma.
Topics: Animals; Benzenesulfonates; Bucladesine; Carcinoma, Renal Cell; Cell Line; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p27; Cytosol; Down-Regulation; Female; Gene Expression Regulation, Neoplastic; Glutathione; Humans; Hydroquinones; Kidney Neoplasms; Male; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Niacinamide; Pentoxifylline; Phenylurea Compounds; Phosphodiesterase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-raf; Pyridines; Rats; RNA, Small Interfering; Signal Transduction; Sorafenib; Theophylline; Tuberous Sclerosis; Tuberous Sclerosis Complex 2 Protein; Tumor Suppressor Proteins | 2011 |
[Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Cooperative Behavior; Cytokines; Disease Progression; Everolimus; Evidence-Based Medicine; Humans; Indazoles; Indoles; Interdisciplinary Communication; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Patient Care Team; Phenylurea Compounds; Platelet-Derived Growth Factor; Pyridines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Signal Transduction; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Survival Rate; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2011 |
Intrinsic resistance to tyrosine kinase inhibitors is associated with poor clinical outcome in metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Resistance, Neoplasm; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Time Factors; Treatment Outcome | 2011 |
Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Cell Line, Tumor; Female; Humans; Imidazoles; Kidney Neoplasms; Mice; Mice, Nude; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Pyridines; Quinolines; Sorafenib; TOR Serine-Threonine Kinases; Treatment Outcome; Xenograft Model Antitumor Assays | 2011 |
Sequence therapy in patients with metastatic renal cell carcinoma: comparison of common targeted treatment options following failure of receptor tyrosine kinase inhibitors.
Topics: Academic Medical Centers; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Chi-Square Distribution; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Everolimus; Female; Germany; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Pyridines; Pyrroles; Receptor Protein-Tyrosine Kinases; Retrospective Studies; Risk Assessment; Risk Factors; Sirolimus; Sorafenib; Sunitinib; Survival Rate; Time Factors; Treatment Failure | 2011 |
Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the international kidney cancer working group.
Topics: Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Databases, Factual; Female; Humans; Indoles; International Cooperation; Kidney Neoplasms; Logistic Models; Male; Models, Biological; Multivariate Analysis; Neoplasm Metastasis; Niacinamide; Outcome Assessment, Health Care; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyridines; Pyrroles; Reproducibility of Results; Sorafenib; Sunitinib; Survival Analysis; Time Factors | 2011 |
Sequential use of sorafenib and sunitinib in advanced renal cell carcinoma: does the order of sequencing matter?
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib | 2012 |
Course of size and density of metastatic renal cell carcinoma lesions in the early follow-up of molecular targeted therapy.
Topics: Aged; Aged, 80 and over; Carcinoma, Renal Cell; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Kidney; Kidney Neoplasms; Liver; Lung; Lymph Nodes; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Niacinamide; Outcome Assessment, Health Care; Phenylurea Compounds; Protein Kinase Inhibitors; raf Kinases; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sorafenib; Time Factors; Tomography, X-Ray Computed | 2012 |
Sorafenib attenuates p21 in kidney cancer cells and augments cell death in combination with DNA-damaging chemotherapy.
Topics: Antineoplastic Agents; Benzenesulfonates; Cell Death; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; DNA Damage; Doxorubicin; Drug Synergism; Hep G2 Cells; Humans; Kidney Neoplasms; MAP Kinase Signaling System; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2011 |
Clinical efficacy and prognostic factors for overall survival in Japanese patients with metastatic renal cell cancer treated with sunitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antiviral Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Female; Follow-Up Studies; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome | 2012 |
Utilizing pre-therapy clinical schema and initial CT changes to predict progression-free survival in patients with metastatic renal cell carcinoma on VEGF-targeted therapy: a preliminary analysis.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Niacinamide; Outcome Assessment, Health Care; Phenylurea Compounds; Prognosis; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Risk Assessment; Risk Factors; Sorafenib; Sunitinib; Tomography, X-Ray Computed; Vascular Endothelial Growth Factor A | 2013 |
Clinical outcome and prognostic factors of sorafenib in Japanese patients with advanced renal cell carcinoma in general clinical practice.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Benzenesulfonates; Carcinoma, Renal Cell; Cohort Studies; Female; Follow-Up Studies; Humans; Kidney Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Practice Patterns, Physicians'; Prognosis; Pyridines; Retrospective Studies; Sorafenib; Survival Rate | 2011 |
Nutlin-3 enhances sorafenib efficacy in renal cell carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; bcl-2-Associated X Protein; Benzenesulfonates; Carcinoma, Renal Cell; Caspase 3; Cell Line, Tumor; Cell Movement; Humans; Imidazoles; Kidney Neoplasms; MAP Kinase Signaling System; Niacinamide; Phenylurea Compounds; Phosphorylation; Piperazines; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-mdm2; Pyridines; Sorafenib; Tumor Suppressor Protein p53; Vascular Endothelial Growth Factor Receptor-2 | 2013 |
Better effect of sorafenib on the rhabdoid component of a clear cell renal cell carcinoma owing to its higher level of vascular endothelial growth factor-A production.
Topics: Antineoplastic Agents; Arthritis, Rheumatoid; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Depression; Female; Humans; Hypertension; Kidney Neoplasms; Middle Aged; Neoadjuvant Therapy; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Vascular Endothelial Growth Factor A | 2011 |
Role of sorafenib in renal cell carcinoma: focus on elderly patients.
Topics: Age Factors; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2011 |
Chloracne-like drug eruption associated with sorafenib.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Chloracne; Drug Eruptions; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2011 |
Tilting the AXIS towards therapeutic limits in renal cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2011 |
Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Disease-Free Survival; Drug Resistance, Neoplasm; Everolimus; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Logistic Models; Male; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Risk Factors; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome | 2012 |
Severe clinical toxicities are correlated with survival in patients with advanced renal cell carcinoma treated with sunitinib and sorafenib.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Survival Rate | 2011 |
Third-line sunitinib following sequential use of cytokine therapy and sorafenib in Japanese patients with metastatic renal cell carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Indoles; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome | 2013 |
Cost-effectiveness evaluation of sunitinib as first-line targeted therapy for metastatic renal cell carcinoma in Spain.
Topics: Angiogenesis Inhibitors; Antiviral Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Cost-Benefit Analysis; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Markov Chains; Models, Economic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quality-Adjusted Life Years; Sorafenib; Sunitinib | 2011 |
Downsizing a thrombus of advanced renal cell carcinoma in a presurgical setting with sorafenib.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Humans; Kidney Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome; Vena Cava, Inferior; Venous Thrombosis | 2012 |
High dose intermittent sorafenib shows improved efficacy over conventional continuous dose in renal cell carcinoma.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Kidney Neoplasms; Mice; Mice, Nude; Microvessels; Niacinamide; Perfusion; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome; Xenograft Model Antitumor Assays | 2011 |
Complete response after sequential sunitinib-sorafenib treatment in a patient with renal cell carcinoma: a case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Radiography; Sorafenib; Sunitinib; Treatment Outcome; Tumor Burden | 2012 |
Complete remission with tyrosine kinase inhibitors in renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Feasibility Studies; Female; Humans; Indoles; Kidney Neoplasms; Male; Medical Records; Middle Aged; Molecular Targeted Therapy; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Remission Induction; Retrospective Studies; Sorafenib; Sunitinib; Surveys and Questionnaires; Treatment Outcome | 2012 |
Efficacy and safety of vascular endothelial growth factor receptor tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma and poor risk features.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Drug Administration Schedule; Fatigue; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis; Thrombocytopenia; Treatment Outcome; Young Adult | 2012 |
Is there a role for targeted therapies in the collecting ducts of Bellini carcinoma? Efficacy data from a retrospective analysis of 7 cases.
Topics: Adult; Aged; Benzenesulfonates; Carcinoma, Renal Cell; Female; Hand-Foot Syndrome; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib | 2012 |
Resampling phase III data to assess phase II trial designs and endpoints.
Topics: Benzenesulfonates; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; Female; Humans; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Randomized Controlled Trials as Topic; Research Design; Sorafenib; Treatment Outcome | 2012 |
Metastatic renal cell carcinoma treated sequentially with multiple VEGF receptor-targeted inhibitors--a case report.
Topics: Angiogenesis Inhibitors; Axitinib; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib | 2012 |
Combination of Temsirolimus and tyrosine kinase inhibitors in renal carcinoma and endothelial cell lines.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Drug Therapy, Combination; Human Umbilical Vein Endothelial Cells; Humans; Indoles; Kidney Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib | 2012 |
Sorafenib rechallenge in patients with metastatic renal cell carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Retreatment; Retrospective Studies; Sorafenib | 2012 |
Sorafenib rechalenge in metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2012 |
Use of tyrosine kinase inhibitors in patients with metastatic kidney cancer receiving haemodialysis: a retrospective Italian survey.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Contraindications; Female; Humans; Indoles; Kidney Failure, Chronic; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Renal Dialysis; Retrospective Studies; Sorafenib; Sunitinib | 2012 |
Incidence of thyroid hormone therapy in patients treated with sunitinib or sorafenib: a cohort study.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Cohort Studies; Databases as Topic; Female; Humans; Hypothyroidism; Indoles; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Thyroid Hormones | 2012 |
Choosing phase II endpoints and designs: evaluating the possibilities.
Topics: Benzenesulfonates; Clinical Trials, Phase III as Topic; Female; Humans; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Randomized Controlled Trials as Topic; Research Design; Sorafenib | 2012 |
Comparative efficacy of vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) and mammalian target of rapamycin (mTOR) inhibitor as second-line therapy in patients with metastatic renal cell carcinoma after the failure of first-line VE
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Enzyme Inhibitors; ErbB Receptors; Everolimus; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein-Tyrosine Kinases; Pyrroles; Salvage Therapy; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Treatment Outcome | 2012 |
Hyperthyroidism and thyroid autoimmunity induced by sorafenib in metastatic renal cell cancer.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Hyperthyroidism; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Radionuclide Imaging; Sorafenib; Thyroid Function Tests; Thyroid Gland; Thyroiditis, Autoimmune | 2012 |
Painful leg mass.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Hospice Care; Humans; Kidney Neoplasms; Leg; Liver Neoplasms; Lung Neoplasms; Male; Medication Adherence; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Pain; Palliative Care; Phenylurea Compounds; Prognosis; Pyridines; Skin Neoplasms; Sorafenib; Tomography, X-Ray Computed | 2012 |
Clusterin inhibition using OGX-011 synergistically enhances antitumour activity of sorafenib in a human renal cell carcinoma model.
Topics: Animals; Apoptosis; Benzenesulfonates; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Clusterin; Disease Models, Animal; Gene Knockdown Techniques; Humans; Kidney Neoplasms; Mice; Mice, Nude; Niacinamide; Oligonucleotides, Antisense; Phenylurea Compounds; Pyridines; Sorafenib; Thionucleotides; Up-Regulation; Xenograft Model Antitumor Assays | 2012 |
Second-line therapy after VEGF targeted therapy in metastatic renal cancer: a law of diminishing returns.
Topics: Angiogenesis Inhibitors; Axitinib; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Disease-Free Survival; Drug Resistance, Neoplasm; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Vascular Endothelial Growth Factor A | 2012 |
Thyroid dysfunction in patients treated with tyrosine kinase inhibitors, sunitinib, sorafenib and axitinib, for metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Axitinib; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sorafenib; Sunitinib; Thyroid Diseases; Thyroid Gland; Thyrotoxicosis | 2012 |
Combination of the ERK inhibitor AZD6244 and low-dose sorafenib in a xenograft model of human renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Benzimidazoles; Carcinoma, Renal Cell; Cell Proliferation; Humans; Kidney Neoplasms; Mice; Mitogen-Activated Protein Kinase 3; Niacinamide; Phenylurea Compounds; Phosphorylation; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Protein Processing, Post-Translational; Pyridines; Receptor, Platelet-Derived Growth Factor beta; Sorafenib; Tumor Burden; Tumor Cells, Cultured; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2012 |
Appropriate management of cutaneous adverse events maximizes compliance with sorafenib treatment: a single-center experience.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Female; Humans; Kidney Neoplasms; Liver Neoplasms; Male; Medication Adherence; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Skin Diseases; Sorafenib | 2012 |
A pooled analysis of sequential therapies with sorafenib and sunitinib in metastatic renal cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Drug Administration Schedule; Humans; Indoles; Kidney Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome | 2012 |
Second-line treatment outcomes after first-line sunitinib therapy in metastatic renal cell carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Everolimus; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome | 2012 |
GSK-3 inhibition in vitro and in vivo enhances antitumor effect of sorafenib in renal cell carcinoma (RCC).
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Cell Proliferation; Glycogen Synthase Kinase 3; Humans; Kidney Neoplasms; Mice; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Xenograft Model Antitumor Assays | 2012 |
Cardiovascular comorbidities for prediction of progression-free survival in patients with metastatic renal cell carcinoma treated with sorafenib.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Cardiovascular Diseases; Comorbidity; Disease-Free Survival; Female; Humans; Hypertension; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Sorafenib; Treatment Outcome | 2012 |
Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: a national registry-based study.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Exanthema; Female; Hand-Foot Syndrome; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Registries; Retrospective Studies; Skin; Sorafenib; Sunitinib; Treatment Outcome | 2012 |
Objective response and time to progression on sequential treatment with sunitinib and sorafenib in metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Disease Progression; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib | 2012 |
Erythema multiforme induced by sorafenib for metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Disease-Free Survival; Erythema Multiforme; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Retrospective Studies; Sample Size; Sorafenib; Treatment Outcome | 2012 |
Pneumatosis intestinalis and hepatic portal venous gas in a patient receiving sorafenib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Diagnosis, Differential; Female; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pneumatosis Cystoides Intestinalis; Portal Vein; Sorafenib | 2012 |
Heme oxygenase-1 promotes survival of renal cancer cells through modulation of apoptosis- and autophagy-regulating molecules.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Autophagy-Related Proteins; Beclin-1; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Heme Oxygenase-1; Humans; Intracellular Signaling Peptides and Proteins; Kidney Neoplasms; Membrane Proteins; Microtubule-Associated Proteins; Niacinamide; Phenylurea Compounds; Protoporphyrins; Pyridines; Sirolimus; Sorafenib | 2012 |
HDAC inhibitors synergize antiproliferative effect of sorafenib in renal cell carcinoma cells.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Sulfonamides; Von Hippel-Lindau Tumor Suppressor Protein; Vorinostat | 2012 |
Impact of hyponatremia on survival of patients with metastatic renal cell carcinoma treated with molecular targeted therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; C-Reactive Protein; Carcinoma, Renal Cell; Confidence Intervals; Female; Humans; Hyponatremia; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Leukocytosis; Male; Middle Aged; Molecular Targeted Therapy; Multivariate Analysis; Neutrophils; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Pyrroles; Retrospective Studies; Severity of Illness Index; Sodium; Sorafenib; Sunitinib | 2012 |
The effect of sorafenib treatment on the diabetic status of patients with renal cell or hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Comorbidity; Diabetes Mellitus; Humans; Kidney Neoplasms; Liver Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome | 2012 |
Two cases of gastrointestinal perforation after radiotherapy in patients receiving tyrosine kinase inhibitor for advanced renal cell carcinoma.
Topics: Carcinoma, Renal Cell; Combined Modality Therapy; Female; Humans; Intestinal Perforation; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Sigmoid Diseases; Sorafenib | 2012 |
Editorial comment from Dr Saito to impact of hyponatremia on survival of patients with metastatic renal cell carcinoma treated with molecular targeted therapy.
Topics: Bone Neoplasms; Carcinoma, Renal Cell; Female; Humans; Hyponatremia; Indoles; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib | 2012 |
Evaluation of changes in the tumor microenvironment after sorafenib therapy by sequential histology and 18F-fluoromisonidazole hypoxia imaging in renal cell carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Humans; Hypoxia; Kidney Neoplasms; Mice; Mice, Nude; Misonidazole; Niacinamide; Phenylurea Compounds; Platelet Endothelial Cell Adhesion Molecule-1; Radiopharmaceuticals; Sorafenib; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2012 |
Editorial comment from Dr Vázquez-Alonso and Dr Puche-Sanz to impact of hyponatremia on survival of patients with metastatic renal cell carcinoma treated with molecular targeted therapy.
Topics: Bone Neoplasms; Carcinoma, Renal Cell; Female; Humans; Hyponatremia; Indoles; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib | 2012 |
Sorafenib-induced tuberculosis reactivation.
Topics: Aged; Antineoplastic Agents; Antitubercular Agents; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Latent Tuberculosis; Male; Niacinamide; Phenylurea Compounds; Secondary Prevention; Sorafenib; Treatment Outcome | 2012 |
Thyroid dysfunction in patients treated with sunitinib or sorafenib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Hypothyroidism; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Thyroid Gland; Thyroid Hormones | 2012 |
Tyrosine kinase inhibitor induced pancreatitis.
Topics: Aged; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Middle Aged; Niacinamide; Pancreatitis; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Sorafenib; Sunitinib | 2013 |
[A case of fatal clinical course with reversible acute cardiac failure and glucose intolerance during sorafenib therapy for metastatic renal cell carcinoma].
Topics: Acute Disease; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Glucose Intolerance; Heart Failure; Humans; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Sorafenib | 2012 |
c-KIT: potential predictive factor for the efficacy of sorafenib in metastatic renal cell carcinoma with sarcomatoid feature.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Sorafenib; Survival Rate; Treatment Outcome | 2013 |
Effects of antiangiogenic therapy.
Topics: Aged; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Cystoscopy; Embolization, Therapeutic; Female; Humans; Kidney Neoplasms; Magnetic Resonance Imaging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Stents; Time Factors; Treatment Outcome | 2012 |
Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Renal Cell; Diphosphonates; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Osteonecrosis; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome | 2012 |
Carbonic anhydrase IX as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma patients receiving sorafenib or placebo: analysis from the treatment approaches in renal cancer global evaluation trial (TARGET).
Topics: Adult; Aged; Aged, 80 and over; Antigens, Neoplasm; Biomarkers, Tumor; Carbonic Anhydrase IX; Carbonic Anhydrases; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Disease-Free Survival; Female; Humans; Immunohistochemistry; Interleukin-2; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Prognosis; Randomized Controlled Trials as Topic; Retrospective Studies; Sorafenib; Treatment Outcome | 2013 |
Durable spontaneous regression of lung metastases from renal cell carcinoma after incomplete use of multiple kinase inhibitor sorafenib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Kidney Neoplasms; Lung; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Remission Induction; Sorafenib | 2013 |
Do anti-angiogenic therapies prevent brain metastases in advanced renal cell carcinoma?
Topics: Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Brain Neoplasms; Cancer Care Facilities; Carcinoma, Renal Cell; Everolimus; Female; France; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Pyridines; Pyrroles; Retrospective Studies; Risk Factors; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome | 2012 |
Dietary supplement hymecromone and sorafenib: a novel combination for the control of renal cell carcinoma.
Topics: Animals; Apoptosis; Carcinoma, Renal Cell; Cell Proliferation; Dietary Supplements; Disease Models, Animal; Drug Therapy, Combination; Human Umbilical Vein Endothelial Cells; Hymecromone; Immunoblotting; Kidney Neoplasms; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Random Allocation; Sensitivity and Specificity; Sorafenib; Treatment Outcome; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2013 |
Fatal case of sorafenib-associated idiosyncratic hepatotoxicity in the adjuvant treatment of a patient with renal cell carcinoma.
Topics: Acute Kidney Injury; Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Fatal Outcome; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic; Sorafenib | 2012 |
Pituitary metastasis from a renal cell carcinoma progressed after sorafenib treatment.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pituitary Neoplasms; Radiotherapy, Conformal; Sorafenib | 2013 |
[Side effects of sorafenib and countermeasures].
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Sorafenib | 2012 |
Treatment with sorafenib and sunitinib in renal cell cancer: a Swedish register-based study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Administration Schedule; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Sweden; Young Adult | 2013 |
Brain metastases from renal cell carcinoma in the era of tyrosine kinase inhibitors.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Blood-Brain Barrier; Brain; Brain Neoplasms; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Mice; Mice, Knockout; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome | 2013 |
Spontaneous regression of metastatic papillary renal cell cancer after cessation of treatment with sorafenib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Male; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Remission, Spontaneous; Sorafenib | 2013 |
Treatment patterns: targeted therapies indicated for first-line management of metastatic renal cell carcinoma in a real-world setting.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Cohort Studies; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; United States | 2013 |
A "game of thrones" in metastatic renal cell carcinoma: vascular endothelial growth factor-tyrosine kinase inhibitors and mammalian target of rapamycin inhibitors battling for position.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Disease-Free Survival; Everolimus; Humans; Indazoles; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Treatment Outcome | 2013 |
A contemporary update on rates and management of toxicities of targeted therapies for metastatic renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sulfonamides; Sunitinib | 2013 |
Sorafenib tolerability in elderly patients with advanced renal cell carcinoma: results from a large pooled analysis.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Treatment Outcome | 2013 |
Quantification of plasma cell-free DNA in predicting therapeutic efficacy of sorafenib on metastatic clear cell renal cell carcinoma.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; DNA; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Real-Time Polymerase Chain Reaction; Sorafenib; Treatment Outcome | 2013 |
[Two cases of bowel perforation in patients with metastatic renal cancer treated with a molecularly targeted drug].
Topics: Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Intestinal Perforation; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib | 2012 |
Expression of angiogenesis-related gene profiles and development of resistance to tyrosine-kinase inhibitor in advanced renal cell carcinoma: characterization of sorafenib-resistant cells derived from a cutaneous metastasis.
Topics: Aneuploidy; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Kidney Neoplasms; Male; Middle Aged; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Primary Cell Culture; Protein Kinase Inhibitors; Skin Neoplasms; Sorafenib; Transcriptome; Tumor Cells, Cultured | 2013 |
Cancer. Encouraging results for second-generation antiangiogenesis drugs.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Clinical Trials as Topic; Gastrointestinal Stromal Tumors; Humans; Kidney Neoplasms; Neoplasms; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Sorafenib; United States; United States Food and Drug Administration; Vascular Endothelial Growth Factor A | 2005 |
Multi-kinase inhibitors create buzz at ASCO.
Topics: Antineoplastic Agents; Benzenesulfonates; Biotechnology; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Phosphotransferases; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2005 |
Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant.
Topics: Benzamides; Benzenesulfonates; Carcinoma; Cell Proliferation; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; K562 Cells; Kidney Neoplasms; mRNA Cleavage and Polyadenylation Factors; Mutation; Niacinamide; Oncogene Proteins, Fusion; Phenylurea Compounds; Piperazines; Point Mutation; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Sorafenib | 2006 |
Targeted therapy for cytokine-refractory metastatic renal cell carcinoma, and treatment in the community.
Topics: Antineoplastic Agents; Benzenesulfonates; Biomarkers; Carcinoma, Renal Cell; Community Health Services; Cytokines; Disease Progression; Drug Delivery Systems; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Failure | 2006 |
Trials probe new agents for kidney cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Indoles; Kidney Neoplasms; Lapatinib; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sunitinib | 2006 |
Clinical activity of sorafenib and sunitinib in renal cell carcinoma refractory to previous vascular endothelial growth factor-targeted therapy: two case reports.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib | 2006 |
Renal cell carcinoma: today's targeted therapies improving tomorrow's outcomes.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Drug Delivery Systems; Humans; Indoles; Interleukin-2; Karnofsky Performance Status; Kidney Neoplasms; Neoplasm Staging; Nephrectomy; Niacinamide; Nurse's Role; Oncology Nursing; Patient Education as Topic; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Risk Assessment; Safety Management; Sorafenib; Sunitinib; Survival Analysis | 2006 |
To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: pilot study using dynamic contrast-enhanced Doppler ultrasound.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Contrast Media; Disease Progression; Disease-Free Survival; Double-Blind Method; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Phospholipids; Pilot Projects; Pyridines; Randomized Controlled Trials as Topic; Sorafenib; Sulfur Hexafluoride; Survival Analysis; Treatment Outcome; Ultrasonography, Doppler | 2006 |
New therapeutic options for renal cell carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Disease Progression; Humans; Indoles; Interferons; Interleukin-2; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2006 |
Problems with the randomized discontinuation design.
Topics: Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Data Interpretation, Statistical; Drug Administration Schedule; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Randomized Controlled Trials as Topic; Research Design; Sorafenib; Survival Analysis; Treatment Outcome | 2006 |
Speeding up cancer-drug development.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Humans; Kidney Neoplasms; Liver Neoplasms; Multiple Myeloma; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Treatment Outcome | 2006 |
Inhibition of tumor endothelial ERK activation, angiogenesis, and tumor growth by sorafenib (BAY43-9006).
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Carcinoma, Renal Cell; Cell Proliferation; Collagen; Drug Combinations; Endothelial Cells; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Fibroblast Growth Factor 2; Humans; Kidney Neoplasms; Laminin; Melanoma; Mice; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phosphorylation; Proteoglycans; Proto-Oncogene Proteins c-akt; Pyridines; Sorafenib | 2006 |
Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models.
Topics: Actins; Adenocarcinoma, Clear Cell; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzenesulfonates; Capillaries; Cell Line, Tumor; Female; Humans; Hypoxia; Immunohistochemistry; In Situ Nick-End Labeling; Kidney Neoplasms; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Platelet Endothelial Cell Adhesion Molecule-1; Pyridines; Regional Blood Flow; Sorafenib; Vascular Endothelial Growth Factor A | 2007 |
Renal-cell carcinoma--molecular pathways and therapies.
Topics: Angiogenesis Inhibitors; Benzenesulfonates; Carcinoma, Renal Cell; Gene Silencing; Humans; Hypoxia-Inducible Factor 1; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Protein Kinases; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Von Hippel-Lindau Tumor Suppressor Protein | 2007 |
Hand-foot and stump syndrome to sorafenib.
Topics: Amputation Stumps; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Eruptions; Foot; Hand; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Syndrome | 2007 |
[Therapy sequence for renal cell carcinoma--new aspects!].
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Combined Modality Therapy; Drug Approval; Humans; Interleukin-2; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pilot Projects; Pyridines; Randomized Controlled Trials as Topic; Sorafenib; Thalidomide | 2007 |
Two new drugs for renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Costs; Drug Interactions; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2007 |
Newly approved therapies for RCC and their effect on the standard of care.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Indoles; Interferons; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Von Hippel-Lindau Tumor Suppressor Protein | 2007 |
ASCO 2006 highlights: targeted therapy for renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2007 |
Yellow skin discoloration associated with sorafenib use for treatment of metastatic renal cell carcinoma.
Topics: Acrodermatitis; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Erythema; Humans; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pigmentation Disorders; Protein Kinase Inhibitors; Pyridines; raf Kinases; Sorafenib; Spinal Neoplasms | 2007 |
Pulmonary blastoma with renal metastasis responds to sorafenib.
Topics: Administration, Oral; Adult; Benzenesulfonates; Biopsy, Needle; Chemotherapy, Adjuvant; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Immunohistochemistry; Kidney Neoplasms; Lung Neoplasms; Neoplasm Staging; Nephrectomy; Niacinamide; Phenylurea Compounds; Pneumonectomy; Pulmonary Blastoma; Pyridines; Risk Assessment; Sorafenib; Treatment Outcome | 2007 |
Sorafenib-induced pancreatitis.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Kidney Neoplasms; Middle Aged; Neoplasm Metastasis; Niacinamide; Pancreatitis; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2007 |
Adjuvant therapy with sorafenib in bone metastases bilateral renal carcinoma: a case report.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Bone Neoplasms; Carcinoma, Renal Cell; Combined Modality Therapy; Humans; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2007 |
Do the results of the new trials change the standard treatment of metastatic renal cell cancer?
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Cytokines; Drug Costs; Humans; Indoles; Kidney Neoplasms; Long-Term Care; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Survival Rate | 2007 |
Interstitial nephritis in a patient taking sorafenib.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Biopsy; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Inflammation; Kidney; Kidney Neoplasms; Leukocytes; Male; Nephritis, Interstitial; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2007 |
[Chronic lymphocytic leukemia and loss of strength in the right arm--not a typical combination].
Topics: Administration, Oral; Aged; Antineoplastic Agents; Arm; Benzenesulfonates; Bone Neoplasms; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Disease Progression; Humans; Hypesthesia; Indoles; Kidney Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Liver Neoplasms; Lung Neoplasms; Magnetic Resonance Imaging; Male; Muscle Weakness; Neoplasms, Second Primary; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Radiography, Abdominal; Radiography, Thoracic; Risk; Risk Factors; Sex Factors; Sorafenib; Splenic Neoplasms; Sunitinib; Time Factors; Tomography, X-Ray Computed | 2007 |
Radiation therapy and sorafenib: clinical data and rationale for the combination in metastatic renal cell carcinoma.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Combined Modality Therapy; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Sorafenib; Treatment Outcome | 2007 |
Re: Börje Ljungberg, Damian C. Hanbury, Marcus A. Kuczyk, Axel S. Merseburger, Peter F.A. Mulders, Jean-Jaques Patard and Ioanel C. Sinescu. Renal cell cacinoma guideline. Eur Urol 2007;51:1502-10.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Immunologic Factors; Indoles; Interferon-alpha; Kidney Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Practice Guidelines as Topic; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Survival Rate | 2007 |
Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Female; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Prognosis; Prospective Studies; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Sorafenib; Sunitinib; Survival Rate; Vascular Endothelial Growth Factor A | 2007 |
Sorafenib [corrected] in kidney cancer.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Humans; Interferons; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Randomized Controlled Trials as Topic; Sorafenib; Treatment Outcome | 2007 |
Combination of radiofrequency ablation with antiangiogenic therapy for tumor ablation efficacy: study in mice.
Topics: Analysis of Variance; Animals; Benzenesulfonates; Carcinoma, Renal Cell; Catheter Ablation; Combined Modality Therapy; Kidney Neoplasms; Mice; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Prospective Studies; Protein Kinase Inhibitors; Pyridines; Sorafenib; Statistics, Nonparametric | 2007 |
[Interdisciplinary recommendations on targeted therapy in the treatment of renal cell carcinoma].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Controlled Clinical Trials as Topic; Humans; Immunologic Factors; Immunotherapy; Indoles; Interferon-alpha; Kidney; Kidney Neoplasms; Meta-Analysis as Topic; Neoplasm Metastasis; Nephrectomy; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Time Factors | 2007 |
[Application monitoring of the use of sorafenib in papillary renal cell carcinoma].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Signal Transduction; Sorafenib; T-Lymphocytes, Regulatory; Tumor Escape | 2007 |
Characterization of tumor specimens for a targeted therapy in metastatic renal cell carcinoma patients.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Vascular Endothelial Growth Factor A | 2007 |
ASCO 2007: plenary top 5.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Carcinoma, Small Cell; Colorectal Neoplasms; Humans; Kidney Neoplasms; Leukemia, Promyelocytic, Acute; Liver Neoplasms; Lung Neoplasms; Medical Oncology; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Societies, Medical; Sorafenib; United States | 2007 |
High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor.
Topics: Adult; Aged; Benzenesulfonates; Brain Neoplasms; Carcinoma, Renal Cell; Cerebral Hemorrhage; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib | 2008 |
Renal cell cancer presented with leptomeningeal carcinomatosis effectively treated with sorafenib.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Male; Meningeal Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2007 |
Acute pancreatitis associated with sorafenib.
Topics: Acute Disease; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Enzyme Inhibitors; Follow-Up Studies; Humans; Kidney Neoplasms; Male; Niacinamide; Pancreatitis; Phenylurea Compounds; Pyridines; raf Kinases; Sorafenib; Tomography, X-Ray Computed | 2007 |
Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Benzenesulfonates; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Hypothyroidism; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Risk Assessment; Sorafenib; Thyroid Function Tests | 2008 |
Localized palmar-plantar epidermal hyperplasia: a previously undefined dermatologic toxicity to sorafenib.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Eruptions; Erythema; Humans; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Receptors, Vascular Endothelial Growth Factor; Skin Diseases; Sorafenib | 2007 |
Sorafenib and surgical complications: a case report of adverse reaction to sorafenib during treatment for renal cell carcinoma.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Colonic Diseases; Colonoscopy; Diagnosis, Differential; Follow-Up Studies; Humans; Intestinal Perforation; Kidney Neoplasms; Male; Nephrectomy; Niacinamide; Phenylurea Compounds; Postoperative Complications; Pyridines; Receptors, Vascular Endothelial Growth Factor; Rupture, Spontaneous; Sorafenib; Tomography, X-Ray Computed | 2009 |
Increased cardiotoxicity of sorafenib in sunitinib-pretreated patients with metastatic renal cell carcinoma.
Topics: Aged; Atrial Fibrillation; Benzenesulfonates; Carcinoma, Renal Cell; Cardiovascular Diseases; Chest Pain; Drug Interactions; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Middle Aged; Myocardial Ischemia; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Risk Assessment; Sampling Studies; Severity of Illness Index; Sorafenib; Sunitinib | 2007 |
Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Feasibility Studies; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib | 2008 |
Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy.
Topics: Aged; Aged, 80 and over; Benzenesulfonates; Blister; Carcinoma, Renal Cell; Drug Eruptions; Female; Foot Dermatoses; Hand Dermatoses; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Treatment Outcome | 2008 |
Re: damien pouessel, stéphane culine. High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor. Eur urol 2008;
Topics: Benzenesulfonates; Brain Neoplasms; Carcinoma, Renal Cell; Cerebral Hemorrhage; France; Humans; Incidence; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Receptors, Vascular Endothelial Growth Factor; Risk Factors; Sorafenib; Treatment Outcome | 2008 |
Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Papillary; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Sorafenib; Sunitinib; Survival Rate; Treatment Outcome | 2008 |
[New drugs; sunitinib and sorafenib].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Treatment Outcome | 2007 |
Complete response in a cutaneous facial metastatic nodule from renal cell carcinoma after hypofractionated radiotherapy.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Facial Neoplasms; Humans; Interleukin-2; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Palliative Care; Phenylurea Compounds; Pyridines; Remission Induction; Skin Neoplasms; Sorafenib | 2007 |
Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Nephrectomy; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2008 |
Safety and activity of sorafenib in different histotypes of advanced renal cell carcinoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bone Neoplasms; Carcinoma, Papillary; Carcinoma, Renal Cell; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Remission Induction; Salvage Therapy; Sorafenib; Survival Rate | 2007 |
Bowel perforation after radiotherapy in a patient receiving sorafenib.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Combined Modality Therapy; Female; Humans; Intestinal Perforation; Kidney Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Radiation Injuries; Skin Neoplasms; Sorafenib | 2008 |
Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Nephrectomy; Niacinamide; Phenylurea Compounds; Postoperative Complications; Preoperative Care; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2008 |